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Evolution of developmental toxicity testing
T eratology as a modern science has its origins in the early 1930s, when Fred Hale discovered that vitamin A deprivation in food of pregnant pig 
sows resulted in offspring with developmental defects, including ocular defects 
(anophthalmia) and cleft palate [1]. Subsequent studies on vitamin A deprivation 
during pregnancy in other species confirmed the importance of vitamin A as a 
morphogen during embryogenesis [2]. In addition, a few years later, it was 
demonstrated that excess vitamin A consumption by pregnant rats as well 
induced malformations in offspring, indicating the balance of vitamin A intake 
is critical during development [3]. In the following two decades, the importance 
of disease and chemical induced developmental defects in humans became 
evident, including the correlation between maternal rubella infection and 
children born with birth defects  and environmental methylmercury (MeHg) 
poisoning inducing (neuro-)developmental defects, a syndrome at present 
characterized as congenital Minamata disease [4, 5]. It was not until the late 
1950s and early 1960s, when the thalidomide tragedy was laid bare, that the 
importance of developmental toxicity testing of pharmaceuticals and chemicals 
became evident [6]. The presumed safe drug thalidomide was prescribed to 
pregnant women as a mild sedative, however unexpectedly, exposure during 
pregnancy caused severe congenital malformations to the developing embryo 
in more than 10.000 women [6]. Concurrently, in 1959 Wilson proposed the 
six general principles of teratology, which today still are valid largely unchanged 
and important aspects in current advancement of teratological studies [7]. 
These principles included topics such as genotype and adverse environmental 
factors interactions, varying susceptibility for developing malformations to a 
compound over developmental stages, multiple mechanisms of action between 
compounds resulting in comparable morphological endpoints, dose-response 
relationships and different manifestations of deviant development (death, 
malformation, growth retardation and functional defect). Due to the 
thalidomide incident, the United States Food and Drug Administration (U.S. 
FDA) issued extensive in vivo animal testing protocols for reproductive and 
developmental toxicity, based on the Wilson’s principles of teratology [8]. 
These protocols were eventually incorporated in worldwide guidelines for 
developmental toxicity testing of chemicals in the 1980s by the Organization 
for Economic Co-operation and Development (OECD) and for pharmaceuti-
cals in the International Conference of Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
[9-11]. These guidelines were designed to cover all critical stages during 
reproduction and development, from mating and conception to gestation, 
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and form a plaque of heterogeneous cell types, including contracting cardio-
myocytes, which can be observed through the microscope. Compound inhibition 
of ESC differentiation into cardiomyocytes in this system is regarded as a 
measure for developmental toxicity.
Intermezzo - a short history of stem cell research
The term ‘stem cell’ was first proposed by the Russian histologist Alexander 
Maximow in 1909 for cell types present during development and postnatal in 
bone marrow, currently defined as haemapoietic stem cells [22]. More than 
fifty years later, McCullough and Till demonstrated the presence of 
self-renewing cells in mouse bone-marrow, which they later defined as stem 
cells [23, 24]. In 1964, the pluripotency of single cells derived from an embryo-
carcinoma was shown, ultimately resulting in the first established embryo-
carcinoma cell (ECC) lines in the early 1970s [25, 26]. Due to their pluripotent 
nature, ECC could be differentiated into a wide variety of cell types, providing 
insight in early differentiation in the vertebrate embryo [27, 28]. Subsequently, 
ECC systems were used to study perturbation of differentiation by 
developmental toxic compounds [29]. However, due to the nature of ECC as 
cancer cells, they have many limitations and imperfections, including 
chromosomal aberrations, a chance to lose the ability to differentiate and the 
need of addition of chemical inducers to initiate differentiation in vitro [30].  In 
1981, two research groups separately isolated the first murine ESC derived 
from the inner cell mass of the blastocyst, followed by isolation of human 
ESCs in 1998 [31-33]. ESC, being more close to cell differentiation in vivo 
compared to ECC, exhibit less of the problems associated with ECC culture 
and differentiation, and over time, have become the default cells for studying 
cell differentiation in vitro and currently form the basis for studying compound 
effects on differentiation in the EST.  
Validation of the (cardiac) EST
In order to optimize the EST test protocol, a pre-validation study was performed 
in which ten compounds inducing developmental toxicity in vivo with diverse 
potencies were tested by two laboratories [34]. In this study, the prediction 
model described earlier by Spielmann et al. [18] misclassified four out of ten 
compounds. An improved statistical prediction model was then introduced, 
which resulted in an accuracy of 93% for the same test compounds [34]. 
Following the pre-validation study, a larger validation study, funded by the 
European Centre for Validation of Alternative Methods (ECVAM), was 
performed  following the ECVAM approach for validation of alternative 
methods [17, 35]. This validation study was set up as an inter-laboratory blind 
prenatal development and postnatal development. In 2009, the new European 
legislation for Registration, Evaluation, Authorization and Restriction of 
Chemicals (REACH) came into force, which required all compounds produced 
and used in the European Union to be tested for toxicity, including reproductive 
and developmental toxicity [11, 12]. Testing protocols required within REACH 
are mainly based on animal testing strategies, with relatively few allowed in 
vitro alternatives. However, development of in vitro alternatives for toxicity 
testing was greatly supported in the REACH legislation. Early calculations on 
the amount of experimental animals needed within REACH predicted that 
approximately 65% of the animals used will be accounted for reproductive 
and developmental toxicity testing, with a predicted cost between 1.3 and 9.6 
billion euro [12, 13]. Due to the high costs of the time consuming animal test 
protocols and the increasing public ethical awareness to reduce animal testing, 
it became highly desirable to develop high-throughput alternative screening 
methods for toxicity testing, especially in the field of reproductive and 
developmental toxicology. 
In vitro developmental toxicity testing
In order to reduce the number of animals needed for developmental toxicity 
testing and screening,  a range of in vitro test systems have been developed over 
the past decades, of which the most promising test systems include the rat 
whole embryo culture (WEC), the zebrafish embryotoxicity test (ZET) and the 
murine embryonic stem cell test (EST) [14-17]. In the WEC and the ZET 
systems compound developmental toxic properties are assessed on live whole 
embryos derived from pregnant rats or fertilized zebrafish eggs, and are 
therefore not completely animal free alternative test systems, although the 
number of animals used for these test systems is predicted to be 10-100 fold 
lower. A potential high-throughput in vitro screening assay for developmental 
toxicity free of animal use is the EST, first described in 1997 by Spielmann et 
al. [18]. This test system is based on the ability of blastocyst-derived pluripotent 
murine embryonic stem cells (ESC) to differentiate into virtually any cell type 
present in the vertebrate organism, such as cardiomyocytes, neurons and 
osteoblasts [19]. In the original EST, differentiation of the ESC towards 
cardiomyocytes is induced through the hanging drop culture technique [20], in 
which the ESC form aggregates called embryoid bodies (EB) [21]. EBs resemble 
the anterior pre-streak embryo, with the epiblast-like core able to generate 
derivatives of all three primary germ layers; mesoderm, ectoderm and 
endoderm [19]. In the EST, cardiomyocyte differentiation is further induced by 
growing the EB in suspension culture for two days after which EB are plated 
on plastic tissue culture dishes. Cells of the EB further migrate and differentiate 
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6)  a metabolic activation system should be incorporated, 
7)  the stability of the test compounds should be assessed. 
As a response to the recommendations in this workshop, a selection procedure 
was performed by ECVAM and international experts, resulting in a group of 
thirty-one compounds which were selected to be included in a second screening 
study. Thirteen of these compounds, strong, moderate or non-developmental 
toxic in vivo, were tested by two laboratories in the European ReProTect 
Consortium [37]. The analysis for these compounds demonstrated only 2 out 
of 13 compounds were classified correctly, indicating the improved prediction 
model was not capable of predicting developmental toxicity for this compound 
set. In a workshop organized by the EU 6th framework programme ReProTect 
project and ECVAM, the unexpected results were discussed, and recommen-
dations to modify the test system were advised [37]. These again included 
modifications to the EST protocol, addition of a metabolic system and new 
differentiation endpoints to be studied using molecular markers. 
In recent years, as an answer to the recommended improvements to the EST, 
many proposals have been published to optimize, shorten and enhance the 
cardiac EST regarding predictivity, objective molecular endpoint parameters 
and technical improvements [37-40]. In addition, novel differentiation endpoints 
have been proposed [36, 37, 41, 42]. In the following sections, in vitro neural 
differentiation and the use of molecular endpoints will be further addressed as 
improvements for the EST.
Neural differentiation models in neurodevelopmental toxicity testing
Although compounds are known which induce subtle neurodevelopmental and 
behavioral effects to offspring at lower doses than in the adult, until recently 
at the regulatory level, compound and pharmaceutical induced effects on neu-
rodevelopment and behavior were relatively under-investigated [43-45]. For 
example, under OECD testing guidelines, compound induced effects on neural 
development were only assessed at the histological and malformation level in 
the fetus (OECD guidelines 414, 416 and 421) [46]. Recently, OECD introduced 
new guidelines to predict neurodevelopmental toxicity: the developmental 
neurotoxicity study (OECD 426) and the extended one generation study, 
including a developmental neurotoxicity cohort (OECD 443). Following these 
guidelines, both central nervous system histology as well as behavior are to be 
assessed. In order to screen for potential compound induced effects on neuro-
development, in vitro screening assays are required to reduce animal testing, 
cost and time and to gain mechanistic insight in compound induced neurode-
velopmental toxicity.
trial in which four laboratories of different international institutes tested 20 
compounds, each with a different in vivo developmental toxicity potency, 
without the need of metabolization (non-developmental toxic, weakly developmental 
toxic and 7 strongly developmental toxic). The improved prediction model 
predicted the developmental toxicity of the compounds with an overall 
accuracy of 78%. For the strong developmental toxicants, prediction was very 
good (100%) with a precision of 86%. Prediction was defined as the likelihood 
that a positive prediction in EST correctly identifies a strongly developmental 
toxic compounds. Precision was defined as the proportion of compounds 
which are strongly developmental toxic in vivo and correctly classified as such 
in the EST. The only strong developmental toxic compound not correctly predicted 
by the prediction model was the neurodevelopmental toxicant MeHg, which 
was classified as non-developmental toxic in 4 out of 8 experiments. Predictivity 
of the weak- and non-developmental toxic compounds was much lower (69% 
and 73%, respectively) producing a relatively high rate of false positive classi-
fications. The test system was therefore deemed good in determining strong 
developmental toxicants, but the tests limitation lied in discriminating between 
weak and non-developmental toxicants [17]. The first validation test was very 
promising for the implementation of the EST as a test system to screen for 
developmental toxicants, however, it was based on a limited set of compounds, 
and further characterization with additional compounds and optimization of 
the model on the basis of results was deemed necessary. 
In 2003, ECVAM organized an expert workshop to determine the applicability 
domain of the EST [36]. Furthermore, it was evaluated if the validated EST 
could be used as a screening test for lead compounds in the pharmaceutical 
industry and to detect the developmental toxicity of compounds in the chemical 
industry under REACH. Due to a number of limitations in the test system [36], 
the EST in its current form was not deemed fit to be accepted in regulatory 
context, but could be used to add supportive information. Furthermore, it was 
recommended that, to optimize the predictability and increase knowledge on 
the applicability domain of the EST, a number of improvements should be 
added to the EST, including: 
1)  the existing chemicals database should be expanded with known in vivo 
embryotoxicants, 
2)  differentiation of additional specific lineages should be incorporated in the 
testing paradigm (e.g. neural differentiation, osteoblast differentiation, etc.), 
3)  objective quantitative endpoints should be established,
4)  in vitro / in vivo concentration correlations should be considered,
5)  additional (statistical) prediction models should be developed, 
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test systems, each describing a sub-process in neural development is needed. 
This complexity has resulted in a range of diverse test systems published, 
studying compound perturbation on different aspects of neural development 
[60]. The main focus currently rests on morphological endpoints, such as 
effects on axonal outgrowth and determining molecular endpoints predicting 
perturbation of neural differentiation [61]. Due to the complexity of neural 
differentiation, it is advisable to first characterize the culture systems and then 
study the mechanisms behind neurodevelopmental toxicity in these models in 
order to define the applicability domain of these neural differentiation assays. 
For example, with the aim of gaining insight in  neural differentiation systems, 
Kuegler et al. [62] investigated critical processes mediating mouse ESC differ-
entiation into cells of the nervous system. A list of in total 197 mRNA markers 
was compiled from literature defining undifferentiated mouse ESC, neural 
stem cells, astrocytes and the pattern of different neuronal and non-neuronal 
cells generated. These mRNA markers could be supportive in determining 
neurodevelopmental toxicity in neural differentiation cultures. However, to 
fully understand mechanisms of neurodevelopmental toxicity, further 
molecular characterization for each developed model should be performed. A 
relatively new tool to do this is genomics.
Transcriptomics as a tool for predictive toxicology
Recent technological advancements in molecular biology introduced new tools 
to investigate thousands of molecular endpoints in a single assay.  This 
technology, called genomics, has its origins in the discovery of the DNA 
structure by Watson and Crick in 1953 nearly 60 years ago [63]. In the 
following 60 years, translation of the DNA code to function in the cell has 
substantially progressed, revealing molecular information on signaling and 
functional processes within the cells of an organism. Together with our 
increasing knowledge of these molecular processes, detection methods have 
developed from single gene or molecule detection to rapid and high throughput 
on-chip systems with which expression of thousands different genes or 
molecules can be assessed [64]. This technology in combination with the 
unraveling of the genome sequence of multiple species, including the human, 
made it possible to study compound effects genome-wide in one experiment 
[65]. Currently available state-of-the-art techniques can be used to study the 
whole transcriptome (RNA transcripts of DNA), proteome, epigenome, 
metabolome or other ‘-omes’. Transcriptomics approaches can be used to 
increase knowledge on biological processes in the fields of physiology, 
pathology and toxicology. The application of genomics technologies in 
toxicology provided the new research field toxicogenomics [66]. Toxicogenomic 
One of the first in vitro systems ever developed was based on differentiation of 
neuroblastoma cells. In 1907, the embryologist Ross G. Harrison for the first 
time successfully cultured neuroblasts from Xenopus laevis to study nerve 
ending growth, taking the first step into current in vitro precursor cell and 
stem cell research [47, 48]. Furthermore, in 1967, Joseph Altman observed 
neurogenesis due to stem cell differentiation in the adult brain, contradicting 
the then believed paradigm of a non-growing, fixed brain structure [49]. 
However, his research was not widely accepted and forgotten over time, only 
to be ‘re-discovered’ in the early 1990’s leading into exceptionally increased 
research in the field of neural differentiation and brain plasticity. Due to this 
increased interest, over the last few decades many in vitro neural cell lines have 
been developed to study neural development and neuron differentiation, 
including PC12 cells, embryonal precursor cells derived from a tumor which 
can be differentiated to form neurites, neuroblastoma cells, cells derived from 
a neuroblastoma cancer, neurospheres, derived from embryonic neural 
progenitor cells, and most recently both mouse and human ESC neural differ-
entiation systems  [50-55]. The first mouse ESC based neural differentiation 
protocols were described in the early-1990’s and many different protocols for 
neuron and glia cell differentiation have been published since [52, 56]. In order 
to differentiate mouse ESC into neural cells, most neural differentiation 
protocols depend on EB formation, addition of the morphogen all-trans 
retinoic acid (RA), serum deprivation and/or addition of neural growth factors 
[56]. Although these protocols are relatively laborious, the advantage compared 
to other available in vitro models is that all stages of neural development can 
be studied: from ESC to neural stem cells to precursor cells to ultimately 
mature neurons and glia [19]. Furthermore, ESC obtained from the inner cell 
mass of the blastocyst are not immortalized or derived from a tumor, retaining 
the in vivo quality of these cell types. However, in order to make an ESC-based 
neural differentiation protocol suitable for neurodevelopmental toxicity 
testing, it has to be standardized, characterized, validated and the applicability 
domain should be assessed [57].  
In vivo, development of the nervous system is an intricate dynamic process, 
requiring coordinated expression of a range of complicated cellular and 
molecular events in a temporal- and region dependent process [44, 58]. Cell 
types and key processes important in neural development are proliferation, 
differentiation of precursor cells into neurons and glia cells, migration, growth 
of axons and dendrites, synapse formation, myelination and programmed cell 
death [59]. To incorporate all these endpoints in one in vitro system in order to 
study neurodevelopmental toxicity is highly complicated, therefore a battery of 
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discovery rate (FDR) [85]. Furthermore, as an additional cutoff the fold change 
(FC) can be used, which takes into account the level of difference in gene 
expression between the exposed sample and the control. Genes differentially 
expressed can then be visualized for further interpretation using cluster 
analysis, such as hierarchical clustering or principal component analysis (PCA) 
[86, 87]. These tools can be used to visualize similar or dissimilar gene 
expression patterns for single genes or groups of similarly behaving genes [88]. 
When studying single genes, biological function and other information can be 
manually assessed using databases collecting scientific literature on single 
genes, such as National Center for Biotechnology Information (NCBI), 
GeneCards (the human genome compendium), Gene Ontology (GO) and the 
Comparative Toxicogenomics Database (CTD) [89-91]. 
When interested in a shared biological function of a set of genes, overrepresen-
tation of these genes annotated to biological processes, molecular function 
(GO) or pathways (KEGG- or Wiki-pathway) can be assessed using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) or 
GO-Quant, which additionally provides a quantitative average ratio of the 
genes expressed within the biological process or molecular function [92-95]. 
These analyses will provide additional information on gene set shared biology, 
function or cellular location, but will not provide information on gene 
interaction within the set. In order to study the interconnection of the genes 
within a set, pathway analysis can be performed using the publicly available 
STRING, STITCH, Wiki pathways, GenMAPP and KEGG, or the commercial 
available MetaCore and Ingenuity Pathway Analysis Tool [96-98].  However, 
due to the limited knowledge on development related pathways, use of these 
program is of less additional value in research for developmental toxicity.
Previous described tools all make use of a predefined set of genes. Another way 
to analyze data is by making use of all the available data and determine average 
gene changes of genes in biological processes or molecular function terms, by 
using Tox-profiler or Gene Set Enrichment Analysis (GSEA) [99, 100]. This 
approach can provide additional information on gene set involvement in 
processes by detecting subtle and coordinated expression changes over the 
whole set. Although this approach does not provide additional information on 
biological function, it does allow detection of regulated genes in predefined 
processes of which individual genes may not meet significance threshold 
criteria. 
profiling has been applied to identify molecular mechanisms behind toxicity, 
to search for biomarkers to identify toxicity and may be used to identify 
compound-class specific induced toxicity effects. The first toxicogenomic 
studies were performed in the field of carcinogenesis, where in vivo effects of 
known genotoxic and non-genotoxic carcinogens on transcription in the liver 
was assessed and later could be discriminated between the two classes [67, 68]. 
Next to prediction of genotoxic-carcinogenicity, toxicogenomics has been 
used to predict other toxic responses, including immunotoxicity, developmental 
toxicity, reproductive toxicity and endocrine disruption, among others, and is 
occasionally used in drug discovery and development to study adverse drug 
effects [69-72]. In vivo developmental and reproductive toxicity studies using 
toxicogenomics as a readout have improved knowledge on understanding 
processes involved with specific compound perturbed developmental toxicity, 
including endocrine disruptors, metals, anti-fungicides (triazoles), vitamin A 
and anticonvulsants [73-77]. In order to predict developmental toxicity in a 
high throughput fashion, more recent studies used in vitro methods for 
prediction of known and possible developmental toxicants, including the 
WEC, ZET and the cardiac EST (ESTc) [78-82]. In one of the first of these 
studies, gene expression profiling in the WEC showed distinct and relevant 
alterations in gene expression after compound exposure at a time point 
preceding morphologically detectable developmental toxic responses, 
indicating a transcriptomics-based method can be used to predict developmental 
toxicity earlier in time [82]. Transcriptomics techniques have additionally been 
used to further characterize and validate the ESTc. By studying multiple 
compound effects at an earlier time point, van Dartel et al. were able to develop 
gene sets specific for early cardiomyocyte related mesoderm differentiation 
and ultimately introduce a biomarker gene set to predict developmental toxicity 
effects on cardiomyocyte differentiation [83, 84].
Analysis of transcriptomics data
Transcriptomics experiments generate massive amounts of data, providing a 
challenge for data analysis. For instance, the mouse whole genome Affymetrix 
array chips used for experiments in this thesis consist of 39.000+ transcripts, 
which after a correction for non-annotated genes, ultimately represent more 
than 16.000 genes as data points per sample. In order to analyze and interpret 
differences between control samples and treated samples analysis strategies 
and tools have been developed. 
A standard first approach is to identify the differentially expressed genes, 
being the genes regulated by exposure compared to control. Selection of these 
genes is defined by a significance cutoff value, which can be a p-value or a false 
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Objective and outline of this thesis
Objective of the thesis
The classic EST was developed as a response to the high need of in vitro 
alternatives in developmental toxicity testing. After validation of the EST, in 
order to increase predictivity of the assay, it was proposed to build in 
modifications to the test system. These included incorporation of additional 
differentiation routes to the testing paradigm to reduce the number of 
misclassified compounds and implementation of molecular techniques as 
objective endpoints. Incorporation of a neural embryonic stem cell test (ESTn) 
in the EST testing paradigm is assumed to provide additional information to 
specific neurodevelopmental toxicants which were misclassified in the EST, 
such as MeHg [17]. In addition, due to increased knowledge in the field of 
neurodevelopmental toxicity, there is a growing demand for in vitro alternatives 
in this field. 
Use of genomic technologies in toxicology can provide mechanistic insight in 
toxicity and test system applicability domain. Furthermore genomic technologies 
may ultimately provide gene set biomarkers for prediction of specific modes of 
toxicity. Implementation of genomics technologies in a neural variant of the 
EST may therefore enhance knowledge of the mechanisms behind neural 
development and compound perturbation of development. 
The aim of this research is to develop a high-throughput alternative in vitro  assay 
for prediction of neurodevelopmental toxicity, of which the method is similar 
to the EST for easy inter-model comparisons. In addition, transcriptomics 
techniques will be used to optimize and characterize the culture system and to 
assess compound induced mechanistic effects on early neural development. 
Ultimately, combined analysis of multiple compound exposure studies should 
lead to discovery of a biomarker gene set which is able to predict developmental 
toxicity in the ESTn.
A schematic overview of the experiments described in each chapter of this 
thesis is provided in Figure 1. Incorporation of the ESTn with molecular 
endpoints in the EST testing paradigm may contribute to increase mechanistic 
insight in compound induced (neuro)developmental toxicity and reduction of 
animal testing in this field.
Figure 1  Schematic overview of the experiments described in this thesis
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gene set for neurodevelopmental toxicity prediction in the ESTn. The PCA 
based differentiation track algorithm was used to sample random gene sets for 
identification of the best performing prediction.
The ESTn was designed as a companion test system to the cardiac EST (ESTc), 
to improve prediction and mechanistic insight in compound (neuro)
developmental toxicity. To confirm this, it was needed to investigate similar 
and dissimilar characteristics of both methods at the transcriptome level. In 
Chapter 7 time-induced gene expression changes in ESTn and ESTc are 
compared over days 3, 4 and 5 in both models. Furthermore, compound 
induced changes after 24h exposure of seven compounds are compared 
between the two models. 
In order to be able to perform correct extrapolation in risk assessment for in 
vitro models, it is mandatory to know the similarities and differences between 
in vitro and in vivo models. In chapter 8 toxicogenomic comparisons are made 
between in vitro and in vivo models for developmental toxicity and general 
toxicity after exposure to MeHg. Developmental toxicity models used in this 
assessment are the in vitro ESTn, ESTc and WEC and two in vivo rat 
embryotoxicity tests. General toxicity models used are mouse embryonic 
fibroblasts in vitro and transcriptomics on adult rat brain and liver in vivo.
Chapter 9 summarizes the results of all previous chapters and provides a 
general discussion on the development and implementation of transcriptomics 
techniques in the ESTn. Furthermore, possible implementation of the ESTn in 
the current testing paradigms will be discussed.  
Outline of the thesis
In order to increase prediction of the classical EST, additional differentiation 
end points have been proposed. In chapter 2 the development of a murine ESC 
neural differentiation test system for assessment of neurodevelopmental 
toxicity is described. Three protocol lengths (13, 17 and 21 days) are 
characterized over time and compared, leading into a shortened EST-resembling 
neural differentiation protocol, called the neural embryonic stem cell test 
(ESTn). As a proof-of-principle, the effects of the model neurodevelopmental 
toxicant methylmercury (MeHg) are assessed in the ESTn by microscopic 
morphological scoring of neural outgrowth. Three exposure designs were 
performed to determine the most optimal exposure conditions. The developed 
morphological scoring system during these experiments was used to determine 
compound induced effects on neural outgrowth in following studies.
A transcriptomics approach was used in chapter 3 to further mechanistically 
characterize neural differentiation over time in the ESTn. Samples were taken 
at the start of the protocol (day 0) and at consecutive days 3, 4, 5, 6 and 7 and 
specific time-dependent changes following neural differentiation could be 
described. Furthermore, as proof-of-concept MeHg induced changes on gene 
expression were assessed over time after 24, 48, 72 and 96h exposure starting 
from day 3 onwards. Based on these data an exposure of 24h was chosen for 
future experiments.
Next to time, concentration is also an essential variable for determining 
compound toxicity [101]. In chapter 4 compound induced concentration- 
dependent effects on neural differentiation after 24h exposure are assessed at 
four concentrations for three known developmental toxic compounds; the 
triazoles cyproconazole and hexaconazole and the anticonvulsant valproic 
acid. Differences and similarities in gene expression profiles and process 
enrichment between compounds and compound classes are described.
To further determine the applicability domain of the ESTn, in chapter 5 a 
 transcriptomics study was performed in the ESTn to determine the effects of 
six mechanistically diverse compounds at two concentrations, one morpho-
logically non-toxic and one ‘developmental’ toxic but not cytotoxic. Five of the 
studied compounds were known developmental toxicants (acetaldehyde, 
carbamazepine, flusilazole, monoethylhexyl phthalate and phenytoin) and one 
was a negative control (penicillin G). In addition, assessment of compound 
induced gene expression at the low non-toxic concentration and the high toxic 
concentration was assessed to study adaptive and adverse gene expression 
responses to compounds.
In chapter 6 data from chapters 3, 4 and 5 is used to perform a de novo analysis 
on combined raw data (10 compounds, 19 exposures) to identify an optimized 
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Introduction
C hemical risk assessment is currently still highly dependent on globally harmonized experimental animal studies. Reproductive toxicity testing 
proposed within the European chemical safety legislation (REACH) has been 
estimated to require approximately 60% of the total animals needed for 
toxicity testing [12, 102]. Therefore, this area of toxicity testing is a high 
priority area for designing alternative assays to reduce experimental animal 
use. An established in vitro test system for developmental toxicity is the 
embryonic stem cell test (EST) [17], in which the developmental toxic effect of 
compounds on stem cell differentiation towards beating cardiomyocytes is 
assessed. Despite the promise of this in vitro developmental methodology,  a 
recent validation study suggests  a number of in vivo developmental toxic 
compounds are  misclassified as negative in the EST, one of which being 
methylmercury chloride [17]. Misclassifications may be partly due to the 
prediction model used, in which both proliferation and differentiation 
parameters play a role.  However, these compounds may have been misclassified, 
because they may not affect mesodermal-derived cardiomyocyte differentia-
tion in vivo, but primarily affect alternative differentiation routes, such as the 
ectodermal or the endodermal routes [17]. Additional alternative in vitro 
embryonic stem cell differentiation assays complementary to the EST may 
improve the prediction for such compounds. 
Several neural differentiation protocols for murine embryonic stem cells (ESC) 
have been described since the mid 1990s, most of which were developed for 
mechanistic studies of embryonic cell differentiation [52, 54]. These methods 
use a variety of factors to reach a similar extent of neural differentiation. They 
include retinoic acid (RA) [54, 103], serum deprivation [52], hormones and 
growth factors and supporting matrices for a range of different neural end 
points [104]. Most methods make use of three-dimensional embryoid body 
(EB) formation [52, 54], while some methods use a two-dimensional monolayer 
culture [105, 106], or a combination of these two [103]. For the rapid prediction 
of neurodevelopmental toxicity, it is urgently needed to develop a short 
duration, high-throughput model, which sufficiently mimics the in vivo dif-
ferentiation of ESC towards neuronal-type cells. In the present study we have 
designed a testing model based on methods described by Okabe et al. (1996)
[52] and Bibel et al. (2004) [103] using EB formation and stimulation of neural 
differentiation using RA and serum deprivation. These models appear to 
approach the in vivo situation in terms of their neural differentiation pattern. 
However, we have reduced the length of a combination of these two protocols 
to enable increased throughput of compound testing. Furthermore, multi- 
Abstract
A lternative assays are highly desirable to reduce the extensive experimental animal use in developmental toxicity testing. In the present study, we 
developed an improved test system for assessing neurodevelopmental toxicity 
using differentiating mouse embryonic stem cells. We advanced previously 
established methods by merging, modifying and abbreviating the original 
20-day protocol into a more efficient 13-day neural differentiation protocol. 
Using morphological observation, immunocytochemistry, gene expression and 
flow cytometry, it was shown predominantly multiple lineages of neuro-ecto-
dermal cells were formed in our protocol, and to a lower extent endodermal 
and mesodermal differentiated cell types. This abbreviated protocol should 
lead to an advanced screening method using morphology in combination with 
selected differentiation markers aimed at predicting neurodevelopmental 
toxicity. Finally, the assay was shown to express differential sensitivity to a 
model developmental neurotoxicant, methylmercury. 
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Materials and Methods
Culture Media
Complete medium (CM) contained Dulbecco’s modified eagle’s medium 
(DMEM) medium (Gibco BRL, Gaithersburg, MD, USA) supplemented with 
20% fetal bovine serum (Hyclone, Logan, UT, USA), 1% nonessential amino 
acids (Gibco BRL, Gaithersburg, MD, USA), 1% penicillin/streptomycin 
(Gibco BRL, Gaithersburg, MD, USA), 2 mM L-glutamine (Gibco BRL, 
Gaithersburg, MD, USA) and 0.1 mM β-mercapto-ethanol (Sigma–Aldrich, 
Zwijndrecht, The Netherlands). Low serum medium (LS), had the same 
composition as CM except that the serum percentage is 10%. Insulin-transfer-
rin-selenite-fibronectin medium (ITS) contained DMEM/Ham’s nutrient 
mixture F12 (DMEM/F12) medium (Gibco, BRL, Gaithersburg, MD, USA) 
supplemented with 0.2 µg/ml bovine insulin (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), 1% Penicillin/streptomycin  (Gibco BRL, Gaithersburg, MD, 
USA), 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD, USA), 30 nM 
sodium selenite (Sigma-Aldrich, Zwijndrecht, The Netherlands), 50 µg/ml 
apo-transferrin (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 2.5 µg/ml 
fibronectin (Invitrogen, Carlsbad, CA, USA). N2 medium contained DMEM/
F12 medium (Gibco, BRL, Gaithersburg, MD, USA) supplemented with 0.2 
µg/ml bovine insulin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1% 
Penicillin/streptomycin  (Gibco BRL, Gaithersburg, MD, USA), 30 nM sodium 
selenite (Sigma-Aldrich, Zwijndrecht, The Netherlands), 50 µg/ml apo-trans-
ferrin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 20 nM progesteron 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) and 100 µM putrescine 
(Sigma-Aldrich, Zwijndrecht, The Netherlands).
Embryonic Stem Cell Culture
Murine embryonic stem cells (ESC) (ES-D3, ATCC, Rockville, MD, USA) 
were routinely sub-cultured every 2–3 days and grown as a monolayer in CM 
supplemented with leukemia inhibiting factor (LIF) (Chemicon, Temecula, 
CA, USA) at a final concentration of 1000 units/ml. The cells were maintained 
in a humidified atmosphere at 37°C and 5% CO2.
Neural Differentiation Protocol
Differentiation of ESC into the neural lineage was carried out in hanging drop 
culture, based on methods described by Okabe et al. [52] and Bibel et al. [103]. 
In brief, stem cell suspensions (3.75×104 cells/ml) were placed on ice before the 
initiation of the culture. Drops (20µl) containing 750 cells in CM were placed 
onto the inner side of the lid of a 90 cm Petri dish filled with phosphate-buff-
lineage (ectodermal, mesodermal and endodermal) differentiation of the combined 
protocols was studied. 
In vivo studies have shown that the development of the brain is a process 
sensitive towards developmental toxic challenges [45, 107, 108]. During neural 
system development of the embryo, stem cells differentiate into many types of 
neurons, glial cells and neuronal epithelial cells [30]. In this highly tuned 
process, interaction between specific cell types is essential for proper differen-
tiation and the establishment of optimal ratios of cell types in the brain in time 
and space. It is known from in vivo studies that neurodevelopmental toxicants, 
such as methylmercury (MeHg) [109] and ethanol [110], can influence these 
ratios and disrupt the developing brain. Therefore, improvement of assessing 
the putative effects of neurodevelopmental toxicants is expected by monitoring 
over time the varying quantities of specific neural cell types using a battery of 
differentiation markers. 
In this study, we used MeHg to evaluate the responsiveness of our assay. Two 
well known incidents of MeHg poisoning occurred in the early 1950s at the 
Minamata Bay in Japan and 1970s in Iraq. In Japan, due to environmental 
poisoning more than 21.000 individuals claimed to be affected by MeHg 
poisoning [109]. Pregnant women who manifested mild or no symptoms were 
reported to give birth to infants with severe developmental disabilities, 
including cerebral palsy, mental retardation, and seizures [109]. In Iraq, 
pregnant women were exposed to MeHg by dietary intake and a total of 83 
women participated in a developmental assessment of their offspring. Results 
suggested a dose–response relationship associated with delayed neurodevelop-
mental milestones [111]. Today, MeHg is widely used as a model neurodevel-
opmental toxic compound.
In the present study we have successfully designed a 13-day differentiation 
protocol, in which multiple lineages of neural and other brain-associated cells 
are formed. In addition, we developed a screening method using a group of 
differentiation markers, which may be used to predict neurodevelopmental 
toxicity. Finally, the model was shown to have differential sensitivity to a 
developmental neurotoxicant, MeHg. This work represents the first steps 
towards an assay for assessing developmental neurotoxicity in vitro.  
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ered saline (PBS) (Gibco BRL, Gaithersburg, MD) and incubated at 37 °C, 
90% relative humidity and 5% CO2. After 3 days of hanging drop culture 
embryoid bodies (EB) had formed and were subsequently transferred to 
bacterial Petri dishes (Greiner Bio-one, Frickenhausen, Germany) containing 
CM supplemented with 0.5 µM retinoic acid (RA) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). On day 5, EB were plated on laminin (Roche, Basel, 
Switzerland) coated dishes (Corning Incorporated, Corning, NY, USA) in LS 
medium supplemented with 2.5 µg/ml fibronectin (Invitrogen, Carlsbad, CA, 
USA). One day later, on day 6, the LS medium was replaced by ITS medium. 
In the short protocol, on day 7, EB were washed with phosphate buffered saline 
(PBS) (Gibco BRL, Gaithersburg, MD, USA) and incubated in cell dissociation 
buffer (Gibco BRL, Gaithersburg, MD, USA) for 3 minutes. Then EB were 
carefully detached from the Petri dish and replated on poly-L-ornithine (Sigma-
Aldrich, Zwijndrecht, The Netherlands) and laminin coated dishes in N2 
medium. After 6 hours incubation, basic fibroblast growth factor (bFGF) 
(Strathmann-Biotec AG, Englewood, CO, USA) was added to the medium at a 
concentration of 10 ng/ml. Concerning the medium and long protocols, ITS 
medium was replaced every other day until replating of the EB was performed 
on day 10 or day 13 for the medium or long protocol, respectively. After 
replating the EB, the N2 medium supplemented with bFGF was replaced every 
other day for 7 days in all three protocols (Figure 1).
Antibodies
The following primary antibodies were used: rabbit anti βIII-tubulin (1:2000) 
(Sigma-Aldrich, Zwijndrecht, The Netherlands), mouse anti nestin (1:50) 
(Millipore, Billerica, MA, USA), rabbit anti Glial Fibrilary Acidic Protein 
(GFAP) (Dako, Glostrup, Denmark), mouse anti Stage specific protein 
antigen-1 (1:400) (SSEA1) (1:400) (Millipore, Billerica, MA, USA), myelin-
associated oligodendrocyte basic protein (1:50) (MOBP) (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA), Oligodendrocyte marker O4 (1:50) 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Secondary antibodies were 
polyclonal swine anti rabbit FITC (Dako, Glostrup, Denmark), rat anti mouse 
IgG1-PE (BD Biosciences, Franklin Lakes, NJ, USA), rat anti mouse IgG1-FITC 
(BD Biosciences, Franklin Lakes, NJ, USA), APC anti mouse IgM1 (Biolegend, 
San Diego, CA, USA), donkey anti rabbit IgG Cy3 (Jackson ImmunoResearch 
Europe Ltd, Suffolk, UK). In addition, TO-PRO-3 (1:1500) (Invitrogen, 
Carlsbad, CA, USA) was used as nucleus staining.
Figure 1  Neural differentiation short protocol. After a 3 day formation of embryoid 
bodies (EB) in hanging drops in 20% serum containing medium (CM), EB were 
cultured in bacteriological dishes in CM with retinoic acid (RA) for 2 days. At day 5 
EB were plated on laminin coated dishes in 10% serum containing medium (LS). At 
day 6 the medium was refreshed with serum free medium (ITS). At day 7 EB were 
replated on poly-L-ornithin/laminin coated dishes and serum free N2 medium 
supplemented with bFGF. Morphological scoring was performed on day 11 and flow 
cytometric analysis was performed on day 13, the end stage of the protocol. In the 
medium and long protocol, the ITS phase had a duration of 4 and 7 days, respectively.
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antibody section). After a triple wash with wash buffer, cells were incubated 
with the secondary fluorescent labeled (FITC, PE and APC) antibodies diluted 
in wash buffer for 30 minutes at RT in the dark. Cells were washed three times 
with wash buffer and resuspended in FACS buffer. Cells were analyzed using a 
FACSCalibur flowcytometer (BD Biosciences, Franklin Lakes, NJ, USA) and 
CellQuest Pro software (BD Biosciences, Franklin Lakes, NJ, USA).
RNA isolation and Real Time Polymerase Chain Reaction 
(RT-PCR)
Total RNA was isolated from differentiated ESC at days 5, 6 and 7 and at the 
end stage of the short (day 13), medium (day 17) and long (day 20) protocols 
using the Qiagen RNEasy Mini Kit (Qiagen Benelux, Venlo, The Netherlands) 
following manufacturer’s instructions. RNA concentration and integrity  was 
determined using the Nanodrop (Isogen Lifescience, de Meern, The 
Netherlands) and the 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), 
respectively. For conversion to cDNA 50 ng total RNA was reversed transcribed 
using reverse transcriptase, primers and probes, obtained from Applied 
Biosystems (High capacity cDNA reverse transcriptase kit) (Applied Biosystems 
Inc, Foster City, CA, USA). RT-PCR was performed using Taqman® fast 
universal PCR (Applied Biosystems Inc, Foster City, CA, USA) and specific 
TaqMan® Gene Expression Assays (Applied Biosystems Inc, Foster City, CA, 
USA) for each gene studied: Ectodermal genes studied were Sox1, an early 
marker for neural cell fate [112], paired box gene 6 (Pax6) a marker for early 
neural differentiation and radial glia cells [113] and nestin a neural precursor 
marker [114] [115]. Endodermal genes studied were Gata4, a transcription 
factor which activates endoderm specific gene products [116], alpha fetal 
protein (AFP), a serum protein secreted by visceral endoderm [117, 118] and 
hepatocyte nuclear factor 4 alpha (HNF4α), a transcription factor which 
regulates expression of several hepatic genes [119]. Mesodermal genes studied 
were T, involved in formation of posterior mesoderm, an early peaking 
mesodermal marker [120], Nkx2-5, an early mesodermal marker [121] and 
myosin heavy chain 6 (Myh6), a marker for myosin [122]. 
For mature neural cells the following markers were used: markers for 
glutamatergic neurons, vesicular glutamate transporter 1 and 2  (VGluT1 and 
VGluT2) [123], for GABA-ergic neurons, vesicular GABA transporter (VGAT) 
[124] and glutamate decarboxylase 65 (GAD65) [125], tyrosine hydroxylase 
(TH) for dopaminergic neurons [126],  Brn3 for sensory neurons [127], HB9 
for motor neurons [128] and GFAP as a marker for astrocytes [129]. 
RT-PCR was performed using the 7500 Fast Real-Time PCR System (Applied 
Biosystems Inc, Foster City, CA, USA). All gene expression assays were 
Immunocytochemistry
Cells were washed with ice-cold PBS, fixed with cold 2% paraformaldehyde 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) in PBS for 5 minutes and 
washed once with PBS. Then the cells were incubated for 5 minutes in HEPES 
buffered saline solution (HBSS) (Lonza, Walkersville, MD, USA) supplemented 
with 0.1% saponin (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 
incubated for 10 minutes in glycine (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) in PBS. Cells were washed three times 5 minutes in PBS with 1% 
albumin from bovine serum (BSA) (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and 0.1% saponin after which the sample was exposed to the 
primary antibody diluted in HBSS with 0.1% saponin for 30 minutes at room 
temperature (RT). Then the cells were washed three times 5 minutes in PBS 
with 1% BSA and 0.1% saponin, after which the cells were exposed to the 
secondary antibody diluted in 1% BSA and 0.1% saponin for 30 minutes at 
RT. The cells were washed two times 5 minutes with HBSS with 0.1% saponin 
in PBS and were treated with TO-PRO3 in PBS for 15 minutes at RT in the 
dark and afterwards washed once with PBS. Cells were closed in Vectashield 
(Vector Laboratories Inc, Burlingame, CA, USA) and the glass slide was closed 
using nailpolish. Samples were examined under a BX51 fluorescence 
microscope (Olympus, Zoeterwoude, The Netherlands) with CellF software 
for analysis (Olympus, Zoeterwoude, The Netherlands). Observations were 
performed under the fluorescence microscope. With negative ( - ) scoring, 
there were no positive cells present. With (++) scoring, the highest number of 
cells positive for the marker was observed in the cultures. With (+) scoring, 
only smaller groups of the cell type were present. At least 3 samples per 
experiment were examined. For each differentiation protocol studied, at least 
3 experiments were performed.
Flow Cytometry
Cell types present at the end stage of the three protocols with varying culture 
times were counted by using fluorescent activated cell sorting (FACS). EB and 
cells in culture were dissociated for 30 minutes using cell dissociation buffer 
and resuspended into a single cell suspension. Cells were then washed with PBS 
and permeabilised with 4% paraformaldehyde for 30 minutes at RT. Cells were 
subsequently washed with FACS buffer (0.5% BSA, 5mM ethylenediaminetet-
raacetic acid (EDTA) (Sigma-Aldrich, Zwijndrecht, The Netherlands) in PBS), 
permeabilised with permeabilization buffer (0.15% saponin in PBS) for 30 
minutes at RT and again washed three times with wash buffer (1% BSA, 0.15% 
saponin in PBS) and incubated with the primary antibodies (anti-βIII-tubulin, 
anti-nestin and anti-SSEA1) diluted in wash buffer for 30 minutes at RT (see 
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Results
Abbreviation of the neural differentiation protocol
In order to enhance throughput of the neural differentiation assay, shorter 
versions of the original combined 20 days neural differentiation protocol (long 
protocol) were designed and tested. Initial morphological observations showed 
that neural differentiation was present from day 7 onwards. Therefore the ITS 
phase was abbreviated to study its effect on the course of neural differentia-
tion. With this in mind, we developed two new protocols, in which the ITS 
phase was reduced from the original 7 days to 4 (medium protocol) and 1 
(short protocol) days, respectively. These three protocols (long, medium and 
short) were characterized over time both morphologically as well as using im-
munocytochemistry, RT-PCR and flow cytometric analysis. 
Morphology
Comparing across all three protocols using light microscopy, we identified 
similar differentiation patterns morphologically, including similarities in 
appearance and size of neurite outgrowth (Figure 2). 
Immunocytochemistry
Fluorescent staining of key proteins for neural differentiation was performed 
using immunocytochemistry and studied under a fluorescence microscope 
(Table 1 and Figure 3). Expression of SSEA1 was found abundantly from the 
start of the protocol at day 0 to day 6 and was reduced over time to low 
expression levels. Expression of nestin positive cells was observed from day 5 
onwards through the whole EB and decreased after replating of the EB over 
time and was still present at the end stages of all three models. The first 
βIII-tubulin positive cells were observed from day 5 onwards and the number 
validated in the test system using the HPRT and GUSb housekeeping genes 
and gene expression for all genes in the experiments was corrected for these 
stable housekeeping genes.
Cytotoxicity Assay
To determine cytotoxicity of methylmercury chloride (MeHg) (Sigma-Adrich, 
Zwijndrecht, The Netherlands), ESC were plated in 96-well plates at 500 cells 
per well in CM supplemented with LIF and allowed to attach for 2 hours 
before MeHg exposure at concentrations of 3.3 nM, 33 nM, 100 nM, 200 
nM, 550 nM and 1 µM. Cells were subsequently cultured for 5 days at 37°C 
and 5% CO2, with a medium renewal containing MeHg for exposure on day 
3. On day 5 (approximately 80% cell confluence in non-exposed controls), 
CellTiter-blue (Promega, Leiden, The Netherlands) was added to each well and 
incubated for 2 hours. After the incubation period, fluorescence was read 
using a FLUOstar spectrofluorometer (FLUOstar Optima, BMG Labtech, de 
Meeren, The Netherlands) at 544 (excitation) and 590 nm (emission). Three 
independent experiments were performed. Concentration-response analysis 
was performed using PROAST (Possible Risk Obtained from Animal Studies) 
software (RIVM, Bilthoven, The Netherlands).
Morphological scoring and flow cytometry for effects on 
neural outgrowth
The short 13 day neural differentiation protocol was used to test the effects of 
MeHg on neural differentiation (Figure 1). MeHg was tested during different 
phases of the protocol: the serum-containing phase (day 3-6), the serum-free 
phase (day 6-13), or the combined exposure protocol (day 3-13). MeHg was 
diluted in DMSO and added to the medium to final concentrations in culture 
of 2.5 nM, 25 nM and 250 nM and control EB were treated with 0.01% 
DMSO. Effects were determined using morphological assessment on the extent 
of neural outgrowth at day 11  using an IX51 inverted microscope (Olympus, 
Zoeterwoude, The Netherlands) with CellD software (Olympus, Zoeterwoude, 
The Netherlands). Morphological neural outgrowth was scored as <75% or 
≥75% of the neural corona surrounding each EB, irrespective of the distance of 
outgrowth from the EB. Flow cytometric analysis was performed on day 13 to 
study (neural)-differentiation key proteins (βIII-tubulin, nestin and SSEA1). 
Morphological scoring (day 11) and flow cytometric analysis (day 13) were 
performed on different days for logistic reasons. Three individual experiments 
(each with n=3) were performed. 
A B C
Figure 2  Typical final morphological appearance of the A) short (Day 13) (10x),  
B) medium (Day 17) (10x) and C) long (Day 20) protocols (10x)
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comparing the short and long protocol (p<0.01). No significant differences 
(p<0.05) were identified for the SSEA1 and nestin protein when comparing 
across all three protocols. 
of βIII-tubulin positive cells increased over time in all three models. The first 
signs of GFAP positive cells were observed in the EB at day 13 in all three 
models. From day 13 onwards, GFAP positive cells migrated out of the EB, 
resulting in GFAP positive cells mainly found in the EB in the short protocol, 
and GFAP positive cells both in- and outside the EB at the end of the medium 
and long protocols. During the whole culture period, no positive staining for 
oligodendrocytes was observed using the markers O4 and MOBP.
Flow Cytometry
For all three protein differentiation markers (βIII-tubulin, nestin and SSEA1) 
we did not observe a significant (p<0.05) difference between separate experiments 
within any of the three protocols (Figure 4A-C). Quantities of total protein at 
the end of culture were highly consistent and reproducible within each of the 
protocols (data not shown).
We observed a tendency of increasing numbers of positive cells with protocol 
duration for each differentiation marker studied (Figure 4D). This was reflected 
in significant difference of the percentage of βIII-tubulin positive cells when 
Table 1   Presence of neural differentiation proteins over time observed by 
fluorescence microscopy during the shared first phase and at the end 
phase of each of the three protocols
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SSEA1 Pluripotency ++ ++ ++ ++ ++ + + +
Nestin Neural Precursor - - - + ++ ++ ++ ++
βIII-Tubulin Neurofilament - - - + + ++ ++ ++
GFAP Astrocytes - - - - - + ++ ++
O4 Immature Oligodendrocytes - nt nt nt - - - -
MOBP Mature Oligodendrocytes - nt nt nt - - - -
++ = abundantly present; + = low presence; - = not present; nt = not tested
Figure 3  Fluorescence labeling of fixed cells. Protein staining in green, nucleus 
staining in red. A) SSEA1 staining at day 3 on frozen section of EB (20x); B) Astrocyte 
staining at day 13 of short protocol (20x); C) nestin staining at day 6 (10x) and D) at 
day 13 of the short protocol (10x); E) βIII-tubulin staining on day 6 (10x) and F) on day 
13 of the short protocol (10x).
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C D
E F
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were shown to contain cells of each of the three germ layers, as well as various 
neural cell types with neural markers increasing with culture time.
Neural differentiation at endpoint of three models
RT-PCR assessment of nine different neural markers at the end stage of each 
of the three protocols generally revealed no significantly different expression 
levels between protocols (p<0.05). The only exception was GFAP expression, 
which was significantly (p=0.04 short versus medium; p=0.003 short vs. long) 
more intense in the medium and long protocol as compared to the short 
protocol (Figure 6). Nevertheless, the short protocol still showed significant 
levels of this marker.
Early neural differentiation upon serum deprivation
To further characterize the protocol, a series of differentiation markers was 
studied from day 5 to day 7 using RT-PCR during serum deprivation. This 
stage of the assay is shared by the three protocols studied. Two independent 
experiments were performed (Figure 5). Concerning the ectodermal markers, 
whilst Sox1 and Pax6 did not show significant changes over time.  The neural 
precursor marker nestin increased with time (p=0.009). No significant changes 
were observed for the early mesoderm marker T and Nkx2-5 and the cardiac 
muscle marker Myh6. Also no significant differences (p<0.05) were observed 
for the endodermal markers Gata4, AFP, and HNF4α. The neuron-type 
specific genes studied (VGluT2 p=0.007, GAD65 p=0.02, VGAT p=0.02) 
showed a particularly remarkable significant increased expression from day 5 
to 7 in the protocol. The two independent experiments essentially showed the 
same trends over time. Thus, between day 5 and 7 of the protocol the cultures 
Figure 5  Gene expression for specific germ layers and neuron type genes. RT-PCR of 
ectodermal (Sox1, Pax6 and nestin), mesodermal (T, Nkx2-5 and Myh6),  endodermal 
genes (Gata4, AFP and HNF4α) and specific neuron types (VGluT2, GAD65 and 
VGAT) at day 5, 6 and 7 of the protocols was performed in two separate experiments. 
The following markers are significantly different over time according to one way 
Anova; nestin p=0.009; VGluT2 p=0.007; GAD65 p=0.02; VGAT p=0.02. –ΔCT is 
the relative difference of the cycle of threshold (Ct) of an investigated gene corrected for 
a housekeeping gene.
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Figure 4  Reproducibility of the A) short, B) medium and C) long protocols by flow 
cytometric analysis for SSEA1, nestin and βIII-tubulin (n=4 per experiment, error bars 
in S.E.M.). D) Comparison of percentage of SSEA1, nestin and βIII-tubulin positive 
cells for the short, medium and long protocols by flow cytometric analysis. Each 
experiment was performed 4 times with n=4 per experiment (error bars in S.E.M.)
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outgrowth in addition to cell death was observed after exposure during the 
day 6-13 and the day 3-13 protocol. This in contrast to the observed outgrowth 
after day 3-6 exposure, which indicates a higher sensitivity to MeHg in serum 
free medium compared to medium with serum. In addition, exposure to MeHg 
during the serum free only period showed a stronger effect at 2.5 and 25 nM 
when compared to treatment during the combined exposure protocol. 
Developmental toxicity: Flow cytometric analysis
Effects of MeHg on the percentages of cells positive for the markers SSEA1, 
nestin and βIII-tubulin were assessed after exposure during different phases of 
the protocol: the serum-containing phase (day 3-6) (Figure 9A), the serum-free 
phase (day 6-13) (Figure 9B), or the combined exposure protocol (day 3-13) 
(Figure 9C). Samples were analyzed using flow cytometry at the end stage of the 
short protocol on day 13. No significant differences were observed for βIII-tubulin 
for all exposure windows and all concentrations tested (p<0.05). A significant 
increase of nestin positive cells (p<0.02) was observed at 250 nM in all exposure 
protocols when compared to control. Also, a significant increase (p<0.002) of 
SSEA1 positive cells was observed at 250 nM after exposure from day 6-13.
Effects of the neurotoxicant MeHg
MeHg was used as a model compound to test effects in the neural differentia-
tion protocol. In undifferentiated embryonic stem cells, using the Alamar Blue 
cytotoxicity assay, the half maximal inhibitory concentration for cytotoxicity 
(IC50) was 222 nM (188.4 nM - 264.4 nM 95% confidence interval) (Figure 
7) (test performed in triplicate). This data was used as a reference level for 
MeHg IC50 in following experiments.
Developmental toxicity: Morphological scoring
Effects of MeHg (2.5, 25 and 250 nM) on cell morphology in the assay was 
tested after exposure during different phases of the short term protocol: the 
serum-containing phase (day 3-6), the serum-free phase (day 6-13), or these 
time windows combined (day 3-13) (Figure 8). Three independent experiments 
were performed in triplicate. EB outgrowth was morphologically scored at day 
11. All three treatment periods showed a significant concentration-effect on 
neural outgrowth. At a concentration of 250 nM, an absence of neural 
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Figure 7  Alamar Blue cytotoxicity concentration-response of MeHg. IC50: 222 nM 
(188 nM – 264 nM).
Figure 6  RT-PCR on neural precursors (nestin), specific neuron types (VGluT1, 
VGluT2, GAD65, VGAT, TH, Brn3 and Hb9) and astrocytes (GFAP) at the end 
stages of the short (day 13), medium (day 17) and long (day 20) protocols. *p=0.04; 
**p=0.003
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Figure 9  Flow cytometric analysis of the effect of MeHg on the percentage cells 
positive for the markers SSEA1, nestin and βIII-tubulin after treatment with 2.5, 25 or 
250 nM MeHg during A) day 3-5, B) day 6-13 or C) day 3-13. * p<0.02, ** p<0.002, 
all differences in comparison to vehicle control (Error bars in S.E.M.).
Figure 9  Continued. * p<0.02, ** p<0.002, all differences in comparison to vehicle 
control (Error bars in S.E.M.).
Figure 8  Morphological scoring. Percentage of EB with >75% neural outgrowth after 
MeHg treatment (2.5, 25 and 250 nM) during the serum containing phase of the 
protocol (day 3-5), the serum free phase of the protocol (day 6-13) or the combined 
exposure protocol (d3-13). * p<0.05, ** p<0.005, *** p<0.005, # p<0.00005, ## 
p<10-13. All differences are compared to DMSO control (Error bars in S.E.M.).
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especially ectodermal and endodermal, but also mesodermal gene expression 
was present, which offers that the assay captures a broader spectrum of 
developmental mechanisms, suggesting the possibility for improved prediction 
for compounds indirectly affecting neural cell differentiation. 
Our system uses standardized EB formation with the hanging drop method 
and maintains EB structure throughout the entire protocol, which supports 
stable culture conditions. In some developmental toxicity studies, ESC 
monolayer culture was used for neural differentiation [106], or EB were 
dissociated to single cells during the protocol [41], creating a less stable 
protocol. In our model EB are replated, instead of dissociated, to keep the 
multi-cellular spatial structure of the EB intact. EB formation furthermore 
allowed differentiation to mimic the in vivo developmental process in a more 
complete manner compared to monolayer differentiation, due to the presence 
of all three germ layers [38]. 
Characterization of the short protocol
RT-PCR showed that early neural differentiation genes, such as Sox1 and 
Pax6, were stably expressed between days 5 and 7 (Figure 5). Nestin expression 
was increasing from days 5 to 7, indicating increasing neural differentiation, 
with a comparable expression level at day 13 of the culture compared to day 7 
(Figure 6). Expression of several endodermal and ectodermal genes was 
detected from day 5-7. Mesodermal gene expression was also detected in our 
assay, although the genes studied were expressed at lower levels compared to 
the ectodermal and endodermal differentiation. These results showed that all 
three major embryonic differentiation routes were affected in the culture from 
day 5 through day 7. Furthermore, we showed that in our model GABA-ergic 
and glutamatergic neurons are formed early on, at least from day 5 onwards. 
These neural cell types belong to the first classes of neurons to develop in vivo 
and have an important role in controlling cell division, neuronal migration and 
maturation during neural development [133-135]. It has been shown that the 
neurotransmitters of these two neuronal classes have an effect on further 
neural differentiation pathways in vivo and in vitro. At the end of the culture 
(day 13), a higher expression for VGluT2 is observed compared to low 
expression levels for VGluT1, which are both markers for different types of 
glutamatergic neurons. In vivo, it is shown that during embryonic development, 
VGluT2 expressing glutamatergic neurons are more abundant compared to 
VGluT1 expressing glutamatergic neurons [135]. After birth VGluT2 positive 
neurons decline in number and VGluT1 positive neurons increase in number 
[136]. The higher expression of VGluT2 expression compared to VGluT1 
expression at the end stage of our culture reflects the in vivo situation during 
Discussion
Abbreviation of the protocol
The first aim of this study was to design an efficient ESC neural differentiation 
assay.  To abbreviate the published 20 day protocols, the ITS phase was reduced 
from 7 days in the long protocol to 4 days and 1 day in the medium and short 
protocols, respectively. Morphological observations (Figure 2) and immunocy-
tochemical staining of key markers for pluripotency, neural precursor cells and 
mature neural cells (Figure 3) showed similar profiles when comparing all 
three protocols. Flow cytometry using these markers showed that each of the 
protocols gave reproducible results, indicating the robustness of the model 
(Figure 4). Expression levels of neural precursor genes and genes for a range of 
specific neuron types (Figure 6) showed a very similar expression profile at the 
end stage of all three protocols. These findings confirmed the similarity of 
neural differentiation in the three protocols and showed at the same time the 
feasibility of the abbreviated protocol.
Concerning glial cell differentiation, immunocytochemistry showed that the 
amount of GFAP positive cells at the end stage of the short protocol was visibly 
lower compared to the medium and long protocol. In the short protocol, GFAP 
positive cells were observed mainly inside or very near to the EB, whereas in 
the other protocols, GFAP positive cells were abundant both in and outside the 
EB (data not shown). Similarly a lower expression of the GFAP gene (Figure 6) 
also showed a lower expression in the short protocol compared to the other 
protocols, confirming the immunocytochemical observations. Although the 
amount of GFAP positive cells appeared lower in the short protocol, still a 
considerable number of cells expressing GFAP were observed, retaining the 
possibility that effects on differentiation towards astrocytes can be monitored. 
Together, these data show that abbreviation of the ITS phase from 7 days to 1 
day provides similar neural differentiation profiles. Therefore, the short 
protocol was used for further experiments.
Advantages of the protocol for developmental toxicity testing
Our abbreviated neural differentiation assay has a number of advantages over 
previously described systems for early neurodevelopmental toxicity screening. 
An often used method for in vitro neurodevelopmental toxicity makes use of 
neural progenitor cells (NPC) [130-132]. These cells are already in an advanced 
stage of neural differentiation as compared to ESC. Therefore, early effects on 
the formation and balance between ectoderm, mesoderm and endoderm germ 
layers and their consequences for neural differentiation cannot be detected 
using NPC. In our ESC neural differentiation culture, RT-PCR showed that 
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development. Taken together, the abbreviated protocol appeared to display an 
array of characteristics reminiscent of germ layer development and neuronal 
differentiation, which may be useful in the detection of chemicals affecting 
these processes.
Neurodevelopmental toxicity testing
Previous studies performed in our laboratory showed that proliferation and 
differentiation of ESC in the cardiac EST (ESTc) are highly intertwined 
processes [137]. It was recommended that, to largely limit exposure to the dif-
ferentiation phase of the assay, it would be advantageous that EB be exposed 
to compounds from day 3 in the assay onwards [137]. Up to day 3, the ESTc 
and our neural differentiation assay protocols are identical. Therefore, in the 
present study MeHg exposure was performed from day 3 onward. EB were 
treated either during the serum-containing phase (day 3-6), the serum free 
phase (day 6-13), or the combined exposure protocol (day 3-13), in order to 
determine whether the presence of serum would influence the sensitivity of the 
cells. Morphological scoring for neural outgrowth was performed on day 11 
(Figure 8) and flow cytometric analysis was performed on day 13 (Figure 9). 
For morphological scoring, all three treatments showed clear dose-responses 
in the 2.5 – 25 nM range, indicating that the assay is highly sensitive to MeHg. 
In an earlier study, effects of MeHg on MAP2 gene expression in human ESC 
were shown at 320 nM [138] and a study using human NSC [132] reported an 
effect on neurite outgrowth at concentrations between 500 and 700 nM 
MeHg. Furthermore, a study using mouse ES cell neural differentiation [41] 
using a variation of the long protocol based on the protocol described by 
Okabe et al.[52] found an effect on Mtap2 gene expression after 14 days of 
neural differentiation at a concentration of 100 nM MeHg. In our assay, a 
significant effect is observed at 2.5 nM MeHg, indicating that our model 
appeared relatively sensitive in detecting effects of MeHg on neural differen-
tiation. 
The MeHg concentration-responses showed a more severe effect after day 6-13 
exposure as compared to day 3-6 and day 3-13 exposure protocols (Figure 8). 
The fact that the latter two are similar indicates that early effects largely 
determine the overall outcome of the assay. The culture composition at the 
start of day 6-13 treatment in terms of cell populations is likely different with 
and without previous day 3-6 exposure, which may explain the more severe 
effect observed after day 6-13 treatment only. The complete absence of neural 
outgrowth observed exclusively after late (day 3-13 and day 6-13) exposures to 
the highest concentration tested may be related to the cytotoxicity of the 
compound observed at this concentration (Figure 7), which is likely more 
pronounced under serum free conditions. The suggestion that high exposure 
may modulate cell population ratios was supported by flow cytometric analysis 
performed for the pluripotency marker SSEA1, the neural precursor marker 
nestin and the neuron specific cytoskeletal protein βIII-tubulin (Figure 9). 
Significantly more nestin positive cells were identified in a concentration-de-
pendent fashion in culture using all three exposure protocols. Also, after high 
concentration day 6-13 treatment, the number of SSEA1 positive cells was 
significantly higher compared to control. These findings suggest that MeHg 
exposure resulted in increased undifferentiated and neural precursor cells in 
the assay relative to βIII-tubulin positive neural cells. In addition, the observed 
SSEA1 increase implies that MeHg may be more toxic to neural cells than to 
undifferentiated cells. 
The morphological effect of reduced neural outgrowth in our assay is not 
reflected in the percentage of βIII-tubulin positive cells after MeHg treatment. 
However, it has been shown that MeHg has an effect on dendrite and axon 
growth in PC12 cells [139] and in primary mouse dopaminergic mesencephalic 
cells [140]. In another study, the effect of MeHg on a range of neural differen-
tiation related genes was studied on mouse ESC neural differentiation [41]. 
Only the marker Mtap2 showed a significant decrease at non-cytotoxic MeHg 
levels. In addition to its role in the maturation of neurons, Mtap2 is also 
associated with dendrite and axon growth [141]. Our combined morphological 
and flow cytometric data suggest that MeHg did not affect the number of 
βIII-tubulin positive cells, but did reduce the growth and migration of neurites. 
In summary, we have successfully designed an abbreviated 13-day mouse ESC 
neural differentiation protocol. We have shown that each of the three embryonic 
germ layers as well as multiple lineages of neural and other brain-associated 
cells were represented in our protocol. In addition, using a variety of differen-
tiation markers we showed differential effects of MeHg exposure on different 
cell types as well as on neuronal outgrowth. We consider these findings 
promising as we anticipate that the multi-lineage character of the assay may 
allow improved detection of neurodevelopmental toxicants in view of the large 
spectrum of possible target cell types present in the assay. The model is not yet 
ready to be used as a standardized assay for assessing developmental toxicity 
in vitro.  The applicability of the assay for the detection of neurodevelopment 
toxicants awaits further assessment of assay performance with a series of neu-
rodevelopment toxicants. 
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Introduction
T he new European chemical safety regulation REACH (Regulation, Evaluation and Authorization of Chemicals) requires many compounds to be tested. 
Current chemical hazard assessment for developmental toxicity is built upon 
globally harmonized OECD animal test guidelines, providing a structure for 
chemical risk assessment and in addition encouraging the development of 
alternative testing strategies. Under REACH guidelines, approximately 60% 
of all animals will be used for reproductive and developmental toxicity studies 
[12]. In order to reduce the number of experimental animals needed for 
developmental toxicity testing, cell based alternative test methods are being 
developed, such as embryonic stem cell tests (EST) studying multiple differen-
tiation lineages [14, 17, 42, 142], the whole embryo culture (WEC) [14] and the 
zebrafish embryo test (ZET) [16, 78]. A common target for developmental 
toxicity is the developing nervous system. Classical developmental toxicants, 
such as methylmercury (MeHg), valproic acid and ethanol particularly target 
neural development resulting in neural tube defects (NTDs), craniofacial 
malformations, mental retardation and fetal alcohol syndrome [143-145]. To 
specifically examine known and unknown neurodevelopmental toxic compounds, 
in vitro test systems are being developed which mimic and/or partially represent 
nervous system development in vivo [41, 142, 146-148]. In particular, embryonic 
stem cells (ESC) provide a promising in vitro model for neural differentiation 
as they can be differentiated into multiple lineages of neural and other brain-
associated cells [52, 103]. In our previous study using mouse embryonic stem 
cells (ESC) [142] we designed an abbreviated 13-day neural differentiation 
protocol to examine the effects of neurodevelopmental toxic compounds. 
Using the classical neurodevelopmental toxicant MeHg, we demonstrated the 
ability to examine the potential for neurodevelopmental toxicity based on 
morphological scoring of neural outgrowth from stem cell-derived embryoid 
bodies (EB).  
While this test system and others show promise in being used for the prediction 
of neurodevelopmental toxicity, current criteria in assessing neurodevelopmen-
tal toxicity take into account limited endpoints of toxicity, such as cell morphology 
(neural outgrowth, cytotoxicity and migration) [149, 150], functional parameters 
determined by electric potential [147] or RNA transcripts of a small selected 
number of genes [41]. The complexity of the developing nervous system warrants 
a more comprehensive assessment at the molecular level of exposure effects by 
neurodevelopmental toxicants. Currently, emerging genomic technologies such 
as transcriptomics, which can be employed to assess effects on the whole-genome 
level are being implemented into in vitro and in vivo neurotoxicological studies 
Abstract
C urrent globally harmonized OECD animal test guidelines for developmental toxicity require high numbers of experimental animals. To reduce animal 
use in this field, alternative developmental toxicity assays are highly desirable. 
We previously developed a dynamic in vitro model for screening effects of 
possible neurodevelopmental toxicants, using neural cell differentiation of 
pluripotent murine embryonic stem cells. To further mechanistically characterize 
the mouse neural embryonic stem cell test (ESTn) and to improve detection of 
possible neurodevelopmental toxicants, gene expression patterns were studied 
describing neural cell differentiation over time, as well as the impact on gene 
expression of exposure to the well known neurotoxicant methylmercury (MeHg). 
A transcriptomics study was performed to examine whole-genome expression 
changes during the first seven days of the cell differentiation protocol. Specific 
gene clusters were identified and enrichment analysis of Gene Ontology (GO) 
terms and gene sets derived from literature was performed using DAVID and 
Tox-profiler. Over time, a decrease of blastocyst and trophectoderm GO-terms 
was observed, which included well characterized pluripotency genes. Furthermore, 
an increase of a range of neural development related GO-terms, such as neuron 
differentiation and the wnt-signalling pathway, was observed. Analysis of gene 
expression using principal component analysis (PCA) showed a time-dependent 
track in untreated cells, describing the process of neural differentiation. Furthermore, 
MeHg was shown to induce deviation from the predefined differentiation 
track. The compound inhibited general development GO-terms and induced 
neural GO-terms over time. This system appears promising for studying compound 
effects on neural differentiation in a mechanistic approach.
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(Sigma-Aldrich, Zwijndrecht, The Netherlands) and 2.5 µg/ml fibronectin 
(Invitrogen, Carlsbad, CA, USA). N2 medium contained DMEM/F12 medium 
(Gibco, BRL, Gaithersburg, MD, USA) supplemented with 0.2 µg/ml bovine 
insulin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1% penicillin/
streptomycin  (Gibco BRL, Gaithersburg, MD, USA), 30 nM sodium selenite 
(Sigma-Aldrich, Zwijndrecht, The Netherlands), 50 µg/ml apo-transferrin 
(Sigma-Aldrich, Zwijndrecht, The Netherlands), 20 nM progesteron (Sigma-
Aldrich, Zwijndrecht, The Netherlands) and 100 µM putrescine (Sigma-
Aldrich, Zwijndrecht, The Netherlands).
Embryonic Stem Cell Culture
Murine embryonic stem cells (ESC) (ES-D3, ATCC, Rockville, MD, USA) 
were routinely sub-cultured every 2–3 days and grown as a monolayer in CM 
supplemented with leukemia inhibiting factor (LIF) (Chemicon, Temecula, 
CA, USA) at a final concentration of 1000 units/ml. The cells were maintained 
in a humidified atmosphere at 37°C and 5% CO2.
Neural Differentiation Culture
Differentiation of murine ESC into the neural lineage was carried out as 
described earlier [142]. In brief, stem cell suspensions (3.75 × 104 cells/ml) were 
placed on ice before the initiation of the culture. Drops (20 µl) containing 750 
cells in CM were placed onto the inner side of the lid of a 90 cm Petri dish filled 
with phosphate-buffered saline (PBS) (Gibco BRL, Gaithersburg, MD) and 
incubated at 37 °C, 90% relative humidity and 5% CO2. After 3 days of 
hanging drop culture embryoid bodies (EB) had formed and were subsequently 
transferred to 60 mm bacterial Petri dishes (Greiner Bio-one, Frickenhausen, 
Germany) containing CM supplemented with 0.5 µM retinoic acid (RA) 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). On day 5, EB were plated on 
laminin (Roche, Basel, Switzerland) coated dishes (Corning Incorporated, 
Corning, NY, USA) in LS medium supplemented with 2.5 µg/ml fibronectin 
(Invitrogen, Carlsbad, CA, USA). One day later, on day 6, the LS medium was 
replaced by ITS medium. On day 7, EB were washed with PBS and incubated 
in cell dissociation buffer (Gibco BRL, Gaithersburg, MD, USA) for 3 minutes. 
Then EB were carefully detached from each Petri dish without dissociating the 
EB and the entire content was replated on poly-L-ornithine (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and laminin coated dish in N2 medium 
supplemented with 10 ng/ml basic fibroblast growth factor (bFGF) (Srtath-
mann-Biotec AG, Englewood, CO, USA). The N2 medium supplemented with 
bFGF was replaced every other day for 7 days (Figure 1).
[82, 151, 152]. The assessment of multiple endpoints both at the level of gene 
expression as well as considering molecular pathways is expected to provide a 
robust mechanistic approach to analyze and predict toxicity [83, 142, 153-155]. 
To improve detection of developmental neurotoxicity and mechanistic 
understanding in the neural embryonic stem cell test (ESTn) model, a tran-
scriptomics study was performed to assess the regular gene expression changes 
in unexposed differentiating ESC cultures. Furthermore, we studied the impact 
of the developmental toxicant MeHg on gene expression changes over time. 
During the past century, catastrophic MeHg poisonings in Japan and Iraq 
have shown its neurodevelopmental toxicity [109, 111]. Since then, MeHg has 
become a well-characterized and widely used model compound for neurode-
velopmental toxicity [156, 157].
In the present study, transcriptomics analysis over time of early differential 
gene expression appeared to provide a robust method to monitor ultimate 
neural differentiation in the ESTn model. In addition, MeHg was shown to 
affect neurodevelopmental and proliferation-related gene pathways in 
association with affected neural differentiation, illustrating the added value of 
transcriptomics analysis of neural cell differentiation in vitro for the detection 
of developmental neurotoxicants and the study of developmental toxicity 
mechanisms of action. 
Materials and Methods
Culture Media
Complete medium (CM) contained Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco BRL, Gaithersburg, MD, USA) supplemented with 20% fetal 
bovine serum (Hyclone, Logan, UT, USA), 1% nonessential amino acids 
(Gibco BRL, Gaithersburg, MD, USA), 1% penicillin/streptomycin (Gibco 
BRL, Gaithersburg, MD, USA), 2 mM L-glutamine (Gibco BRL, Gaithersburg, 
MD, USA) and 0.1 mM β-mercaptoethanol (Sigma–Aldrich, Zwijndrecht, The 
Netherlands). Low serum medium (LS), had the same composition as CM 
except that the serum percentage is 10%. Insulin-transferrin-selenite-fibronec-
tin medium (ITS) contained DMEM/Ham’s nutrient mixture F12 (DMEM/
F12) medium (Gibco, BRL, Gaithersburg, MD, USA) supplemented with 0.2 
µg/ml bovine insulin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1% 
Penicillin/Streptomycin  (Gibco BRL, Gaithersburg, MD, USA), 2 mM 
L-glutamine (Gibco BRL, Gaithersburg, MD, USA), 30 nM sodium selenite 
(Sigma-Aldrich, Zwijndrecht, The Netherlands), 50 µg/ml apo-transferrin 
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Treatment and morphological scoring for effects on neural 
outgrowth
Methylmercury chloride (MeHg) (CAS number 115-09-3, Sigma–Aldrich, 
Zwijndrecht, The Netherlands) was diluted in dimethyl sulfoxide (DMSO) and 
added to the medium to final concentrations in culture of 25 nM MeHg and 
control EB were treated with 0.01% DMSO as described earlier from day 3 of 
the protocol until day 11 [142]. This concentration of MeHg did not affect cell 
viability in the model. Effects were determined by assessing of the morphological 
extent of neural outgrowth, at day 11, observed using an IX51 inverted 
microscope (Olympus, Zoeterwoude, The Netherlands) with CellD software 
(Olympus, Zoeterwoude, The Netherlands). Morphological neural outgrowth 
was scored as <75% or ≥75% of the neural corona surrounding each EB, 
irrespective of the distance of outgrowth from the EB. Parallel cultures were 
harvested for gene expression analysis at earlier time points.
RNA isolation and whole-genome expression profiling
Control differentiation cultures were harvested on culture days 0, 3, 4, 5, 6 
and 7 (eight replicates per group). MeHg exposed differentiation cultures were 
exposed from day 3 onwards and harvested on day 4, 5, 6 and 7 (24, 48, 72 
and 96h exposure, respectively; eight replicates per group) (Figure 1). Cells 
(~40 to 50 EB/sample) were directly collected in RNA Protect (Qiagen Benelux, 
Venlo, The Netherlands) to stabilize RNA, and total RNA was purified using 
the Qiagen RNEasy Plus Mini Kit (Qiagen Benelux, Venlo, The Netherlands) 
following manufacturer’s instructions. RNA quantity was determined using 
the NanoDrop Spectrophotometer (Isogen Lifescience, de Meern, The 
Netherlands). RNA integrity was assessed on the 2100 Bioanalyzer (Agilent, 
Santa Clara, CA, USA) using the RNA 6000 Nano Chip Kit (Agilent, Santa 
Clara, CA, USA), and good quality RNA was used for gene expression analysis 
(RNA integrity number (RIN) > 8.0). Labeled aRNA target was generated by 
using the Affymetrix genechip (Affymetrix, Santa Clara, CA, US) (3’IVT 
express kit 4x24 reactions; P/N 901225) according to the instructions in the 
user’s manual. Briefly, 250 ng of each total RNA sample and also controls 
were used to prepare first-strand complementary DNA (cDNA). After making 
the complementary second strand, the double stranded cDNA is amplified by 
in vitro transcription (IVT). During this IVT reaction a biotinylated nucleotide 
analog is incorporated in the aRNA. This IVT reaction was followed by aRNA 
purification with magnetic beads and fragmentation (15 µg) of each aRNA 
sample. The whole process from first-strand cDNA synthesis till fragmentation 
of the aRNA was performed by the Xiril Neon 150 robotic system (GC-Biotech, 
Alphen aan den Rijn, The Netherlands).
Figure 1  Hanging drops containing ESC were made on day 0. Single cells formed 
embryoid bodies (EB). On day 3, the EB were transferred to suspension medium 
supplemented with 0.5 µM all-trans-retinoic acid (RA). On day 5, EB were plated on 
laminin coated dishes and kept in medium containing 10% serum. On day 6, the 
medium was replaced with a serum-free medium (ITS). On day 7, EB were detached 
from the dish and replated on PLO/laminin coated dishes and N2 medium was added. 
On day 11, morphological scoring for neural outgrowth was performed. MeHg 
treatment was started on day 3 of the protocol and treated samples were collected after 
24, 48, 72 and 96h exposure (n=8 per group). Control samples were collected on days 
0, 3, 4, 5, 6 and 7 (n=8 per group).  
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gov/) [162]. Terms with a p<10-4 and a Functional Annotation Clustering 
Enrichment Score > 3 were considered enriched, and if terms clustered together, 
the most significant functional term within that cluster was used. For 
pathway-level analysis, each gene was corrected for its average across all time 
points, after which Tox-profiler [99] was used to score the difference between 
the mean expression level of predefined groups of genes (e.g. GO-terms or 
literature based gene sets) and that of the remainder of the 20,979 probe sets 
defined earlier. Gene sets were significantly regulated if T > 3.5 and E >0.05. 
The T-value is the value obtained by a T-test between the expression changes 
for a defined set of genes versus all other genes. The corresponding formula 
and other calculation details can be found in Boorsma et al. [99]. The E-value 
is the associated two-tailed P-value with Bonferroni correction for the number 
of gene sets tested. Literature gene sets were derived from Kuegler et al. (mouse 
ESC and neural stem cell (NSC) gene sets) [62] and the GNF1M Gene Atlas 
data set described by Su et al. [163] (downloaded from GEO accession number 
GSE1133) describing mouse tissue-specific gene sets. To correct for overlap 
between tissue-specific gene sets, forward selection was performed. In short, 
the gene set with the highest absolute T-value is used and the mean contribution 
of each gene in the set is subtracted from all genes in the gene set. Then a new 
T-value is calculated with the changed values and the same process is repeated 
until no significant gene sets are found. The gene expression over time and the 
effect of MeHg on gene expression was further studied by means of the dif-
ferentiation track algorithm, an approach based on principal component 
analysis (PCA) [86]. In this analysis, a principal component is defined as a 
mathematically derived combination of genes and their expression characteris-
tics which can be used to depict part of the process observed. A number of 
principal components that are mutually independent can be derived which in 
combination describe the process under study. For the differentiation track 
algorithm, at first a gene list was defined, which comprised the genes that were 
identified to be significantly differentially expressed among ESC differentia-
tion sampled at different stages over time. Next, PCA analysis was performed 
using these genes using R. We connected a line between the average array gene 
expression at days 0, 3, 4, 5, 6 and 7 on our PCA plot to display the continuous 
representation of the ESC differentiation over time based on the dynamics of 
gene expression. This curve was defined as the ‘differentiation track’ over time. 
For describing the effects of MeHg on the track at a particular day, a 
comparison was made with a differentiation track derived on the basis of genes 
showing differential expression between the day before, the same day, and the 
day after the time point analyzed. Limiting the analysis to genes that show 
time-related expression in the protocol avoided the contribution of genes not 
After fragmentation a 250 µl hybridization cocktail with 12,5 µg of fragmented 
aRNA was prepared. 200 µl of this cocktail (10 µg aRNA target) was applied 
to the Mouse Genome 430 2.0 arrays (P/N 900497, Affymetrix, Santa Clara, 
CA, US) and hybridized for 16 hours at 45°C in a Genechip Hybridization 
Oven 640. After hybridization the arrays were washed and stained with a 
Genechip Fluidics Station 450 using the Affymetrix genechip hybridization 
wash and stain kit (P/N 900720). Washed and stained arrays were scanned 
using the genechip scanner 3000 from Affymetrix. Hybridization was performed 
at Affymetrix (Santa Clara, CA, US). 
Data Analysis and statistics
Affymetrix CEL files were normalized using the Robust Multichip Average 
(RMA) algorithm   [158] using  RMAexpress [159]. For probe to gene mapping, 
a custom Chip Description File (CDF) was used according to the assembly by 
de Leeuw et al. [160] (http://mad-db.science.uva.nl/~wdeleeuw/HybridAnnot/
version6.html). Of the hybrid probe-set definitions included in the custom 
annotation, 16,331 probe sets defined by the Brainarray custom CDF version 
11 http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF) 
[161] and 4648 additional probe sets defined by Affymetrix chip annotation 
26 were used in further analyses, giving a total of 20,979 probe sets. Probe sets 
for Affymetrix internal controls or probe sets that did not correspond to an 
Entrez Gene ID were not used in further analyses. Statistical analyses were 
carried out using the R statistical software environment (http://www.R-project.
org) using log-transformed values. For each gene, maximal fold ratios (FC) 
in gene expression between the experimental groups were determined by 
comparing the average normalized signal values per group and were calculated 
as the maximum/minimum ratio. For the time series, expression of a gene was 
compared to the median expression of all samples. For MeHg toxicity effects, 
the treated samples were compared to the time matched controls.  Genes 
differentially expressed between any of the experimental groups were identified 
by a one-way ANOVA on the normalized data. A significance threshold of 
p<0.001 and FC > 2 were used to select genes that were significantly differentially 
expressed when ESC differentiate over time. A p<0.001 with FC>1 restriction 
was applied for the identification of significantly differentially expressed genes 
caused by MeHg exposure. Hierarchical clustering of genes significantly 
differentially expressed over time in the neural differentiation cultures was 
performed in GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium), 
using Euclidean distance and Ward linkage. Functional annotation and 
enrichment for Gene Ontology (GO) biological processes and KEGG pathways 
were studied using the tools on the DAVID Web site (http://david.abcc.ncifcrf.
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system development). Cluster F genes were mainly increased on days 6 and 7, 
and genes in cluster G were mainly increased over time from days 4, 5, 6 and 
7 and relatively low on day 0. Cluster H genes were low expressed on days 0 
and 3 and highly increased on days 5, 6 and most on day 7. A high overlap was 
observed for GO-terms enriched in clusters F, G and H, which consisted mainly 
of neural associated GO-terms (neuron differentiation, -fate commitment and –
migration) and other development-related GO-terms (pattern specification, 
skeletal development, inner ear development and eye development). In the 
enriched neuron differentiation GO-term, many markers known to play a 
critical role in neuronal development were highly (FC>16) induced, such as 
Pax6, Tubb3 and Nefl [166, 167]. 
ESC (neural) differentiation cultures express tissue specific gene sets 
Gene sets for embryonic day 8.5, 9.5 and 10.5 extracted from GEO, and mouse 
tissue-specific gene sets were analyzed in Tox-profiler to determine the most 
prominent tissues developing over time in our neural differentiation protocol 
(Figure 2C). Embryonic_day_8.5 showed an increase in gene expression from 
day 4 onwards, peaking on day 5 and a decrease in gene expression from day 
6 onwards. Embryonic_day_9.5 showed a similar expression profile compared 
to embryonic_day_8.5, but with a higher T-value and significance. The first 
significant increase for the embryonic_day_10.5 set was observed on day 5, 
and expression further increased on days 6 and 7. Over time, gene sets 
representing very early development (blastocyst and oocyte) were induced on 
day 0 and their expression diminished over time. Furthermore, sets important 
during the post implantation period (placenta and umbilical cord) were 
increased from day 5 onwards. Gene sets of tissues derived from the ectodermal 
lineage (different regions of the brain and spinal cord) were starting to increase 
on day 6 and were strongly increased on day 7. Regarding the endodermal 
derived tissues, expression for lung was decreased significantly only on day 4 
and gene expression for the small intestine and salivary gland was not 
significantly regulated over time. Furthermore, the gene sets describing 
mesodermal derived kidney and testis were reduced from day 6 onwards. 
Neural differentiation culture shows a time dependent change in PCA
PCA was performed on control samples (days 0, 3, 4, 5, 6 and 7) using the 
4393 genes differentially expressed over time (Figure 2D). 76% of the variance 
could be assigned to the first (60%) and second (16%) principal components of 
the PCA. Groups of each time point clustered together, forming a chronological 
representation of neurological differentiation, which we will refer to as the 
‘differentiation track’ [142].  
regulated during neural development in the protocol. Coordinates along the 
first and second principal components were calculated for each sample. 
Deviation of compound-exposed cultures from the differentiation track was 
analyzed by applying a Hotelling t-test to these coordinates compared with 
those of time-matched control cultures. Significant deviation from the differ-
entiation track (p < 0.05) was considered characteristic for developmental 
toxicants. Genes significantly changed (p<0.001, FC>2.0) in the period of the 
3 days surrounding the specific treatment day of interest were used to set up 
the track and the gene expression of the MeHg samples was placed in the 
track.
Results
ESC (neural) differentiation is accompanied by gene expression 
changes over time
We identified 4393 genes which were significantly differentially expressed 
(p<0.001 and FC>2) in control cultures across time (days 0, 3, 4, 5, 6 and 7). 
Eight gene clusters (A-H) were defined by hierarchical clustering (Euclidean 
distance, ward linkage) on the basis of expression dynamics over time (Figure 
2A and 2B). Cluster A showed a high gene expression early (day 0) and later in 
time (days 6 and 7), but low expression on d3-5. Due to the small amount of 
genes present in this cluster, no significant (p<1*10-4) GO-terms were found. 
Genes in cluster B were mainly increased at early time points (day 0 and 3). 
GO-terms enriched within this cluster were associated with transcription 
(nucleolus, rRNA, tRNA, and DNA metabolic process), cell metabolism 
(mitochondrion), and pluripotency (blastocyst formation and trophectoderm 
cell differentiation). Highly upregulated genes in this cluster (FC>16) included 
the pluripotency-related genes Pou5f1 and Nodal [164, 165]. In cluster C, 
genes were mainly increased on day 3 and in GO-terms involved in early 
development (pattern specification, embryonic morphogenesis, and blastocyst-, 
mesoderm- and endoderm-related clusters) and cell migration. Cluster D was 
increased on day 4 and 5. Due to the small amount of genes present in set D, 
no significant (p<1*10-4) GO-terms were found. In cluster E, genes were 
increased from day 4 onwards and expression increased over time. This cluster 
was enriched for the Wnt-signaling pathway and TGFβ-signaling pathway, 
both important in development. In addition, a broad range of developmental 
GO-terms were enriched (neuron development, tube development, skeletal 
development, vasculature development, limb development and urogenital 
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Morphological Scoring shows MeHg effects
As described earlier [142] MeHg (25 nM, exposure from day 3-11) resulted in 
a significant decrease in neural outgrowth as compared to concurrent controls. 
MeHg-exposed samples showed a 63% (±10%) decrease of EB with >75% 
outgrowth around the EB.
MeHg increases expression of neural development related genes
Gene expression changes in cultures treated with MeHg (treatment from day 3 
onwards for 24h, 48h, 72h and 96h) were compared to their time matched 
control on days 4, 5, 6 and 7 by a one-way ANOVA (p<0.001 and FC>1.0). 
After 24h treatment, 490 genes were significantly regulated, after 48h 
treatment, 6 genes, after 72h, 29 genes and after 96h, 97 genes were significantly 
regulated. In total, 611 genes were significantly differentially regulated by 
MeHg over time. Clustering of these genes showed predominantly a group 
downregulated over time and a group upregulated over time (Figure 3A). 
Analysis using DAVID showed the downregulated group had significant 
changes in transcription- and embryonic development-related terms. The 
Figure 2A  Gene expression describing differentiation over time in the ESTn. Heatmap 
of all genes differentially expressed over time (p>0.001; FC>2.0) in unexposed differ-
entiation cultures. Each row represents a single gene. Eight clusters were defined based 
on comparable expression profiles over time. For each cluster, GO-terms enriched  for 
that cluster are indicated. GO and KEGG terms enriched for cluster F, G and H were 
comparable.
Figure 2B  Mean expression values of genes differentially expressed over time in each 
cluster (A-H).
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upregulated group showed significant enrichment for cell motion and neuron 
development terms.
MeHg increases late differentiation genes and decreases early 
differentiation genes
Gene set clusters derived from neural differentiation over time (Figure 2A, 
clusters A-H) and clusters describing mouse ESC and neural stem cell (NSC) 
gene expression [62] were used to study the effect of MeHg with Tox-profiler 
(Figure 3B). A significant increase in gene expression by MeHg at most time 
points was observed in the late time clusters (E, F, G and H) and in the NSC 
set. In set A, only on day 6 a small significant increase in expression was 
observed. In contrast, the early time clusters (B, C and D) and the mESC set 
were significantly downregulated by MeHg at most time points.
Figure 2C  Heatmap of T-values for tissue-specific gene sets derived from GEO over 
time Values were derived using T-profiler and sets were selected using forward selection. 
*T > 3.5 and E > 0.05.
Embryonic day 8.5
Embryonic day 9.5
Embryonic day 10.5
Blastocyst
Oocyte
Placenta
Umbilical Cord
Uterus
Amygdala
Cerebellum
Cerebral Cortex
Dorsal Root Ganglia
Frontal Cortex
Hypothalamus
Medial Olfactory Epithelium
Olfactory Bulb
Preoptic
Snout Epidermis
Spinal Chord, Upper
Substantia Nigra
Lung
Salivary Gland
Small Intestine
Kidney
Testis
Embryonic Day
Very Early 
Development
Post Implantation
Ectoderm
Mesoderm
Endoderm
0 3 4 5 6 7
T-values of expression of
BioGPS tissue gene sets 
over time on days
*
*
**
*
*
****
*
****
*
**
***
*
*
**
* *
*
***
***
*
*
*
*
*
* * * *
* *
*
**
*
*
**** **
* *
**** **
**** **
*
*
*
*
*
* * ***
**
* *
*
0 5 10 15-5-10-15
-40 -20 0 20
-4
0
-2
0
0
20
40
PC1, 60%
PC
2,
 1
6%
Day 0
Day 3
Day 4
Day 5
Day 6
Day 7
Figure 2D  Principal component analysis (PCA) plot of control (colored full circles) 
differentiation cultures over time The PCA is based on the 4339 genes regulated over 
time (p>0.001 and FC>2).
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on days 6 and 7 and embryonic_day_10.5 showed a significant increase on day 
5. No significant changes were observed for the embryonic_day_9.5 gene set 
(data not shown). In contrast, gene sets of tissues related to neuroectoderm 
were significantly increased by MeHg on days 6 and 7 and in a few cases also 
on day 4. Non neural ectodermal gene sets (retina and snout epidermis) showed 
no differences or a small decrease. Expression of mesodermal and endodermal 
gene sets was predominantly decreased on day 7. 
   
MeHg increases neurectodermal gene sets and decreases 
developmental, mesodermal and endodermal derived tissue gene sets
Mouse tissue-specific gene sets were analyzed in Tox-profiler to determine the 
most important tissues affected by MeHg compared to time matched controls 
(Figure 3C). Gene sets associated with very early development were down 
regulated by MeHg as was the placenta gene set. Gene sets of specific embryonic 
days showed a decrease in average gene expression by MeHg in early embryonic 
days (6.5 and 7.5). The embryonic_day_8.5 only showed a significant decrease 
Figure 3A  Effects of MeHg on gene expression in the ESTn. Heatmap of the 611 
genes differentially expressed by MeHg compared to time matched controls (p>0.001; 
FC>1.0). Each row represents a single gene.
+/- 1-3 3
MeHg treated samples
compared to 
day matched control 
after hours treatment
24 48 72 96
GO Terms
Chordate embryonic 
development
Transcription
Cell Motion
Neuron Development
Ooep Ovol2
Esrrb Epha2
Tdgf1 Dlc1
Dnmt3l Man2a1
Eomes Prdm1
Ccnb1ip1 Tsc1
Tcf15 Cdh1
Gjb5 Map2k1
Tbx3 Tead4
Gab1 Vasp
Wnt1 Ndn
Fezf2 Pax3
Hes5 Boc
Lhx2 Fgfr1
Slitrk5 Nr2f6
Nefl Rtn4rl2
Pcsk9 Ntrk2
Alcam Neurog2
Stmn3 Nr4a2
Efnb3 Pbx3
Irx5 Pou4f2
F
H
E
G
NSC
A
D
C
mESC
B
MeHg compared to day 
matched control in T-values 
after hours treatment
24 48 72 96
0-30 -20 -10 10 20 30
*
* * **
* * * *
* *
* * * *
* * *
***
*
**
** *
*
**
***
Figure 3B  Effects of MeHg on gene expression in the ESTn. Heatmap of T-values for 
clusters derived from differentiation over time due to MeHg compared to time matched 
controls. Values were derived using T-profiler. *T > 3.5 and E > 0.05.
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MeHg exposed cultures deviate over time from the neural 
 differentiation track
The effect of MeHg on gene expression was further studied using PCA by means 
of the differentiation track algorithm. Genes significantly regulated in controls 
“day 3/4/5” (1509  genes), “day 4/5/6” (782 genes) and “day 5/6/7” (586 genes) 
were compared to gene expression after exposure to MeHg as assessed on days 
4, day 5 and day 6, respectively. MeHg treatment measured on day 4 deviated 
significantly from the track (p=0.0008) (Figure 4A), but MeHg measured on 
day 5 (p=0.19) (Figure 4B) and day 6 (p=0.08) (Figure 4C) were not significantly 
different as compared to their control 3-day differentiation track.
Figure 3C  Effects of MeHg on gene expression in the ESTn. Heatmap of T-values for 
tissue-specific gene sets derived from GEO due to MeHg compared to time--matched 
controls. Values were derived using T-profiler. *T > 3.5 and E > 0.05.
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Figure 4  PCA plots of control (colored full circles) over three time points and 25 nM 
MeHg exposed (black open triangles) on the middle time point. The PCA are based on 
the regulated genes over the three time points within the plot (p>0.001 and FC>2). The 
track-p describes the difference between the MeHg group compared to the time-matched 
control. A) Control day 3 (red), day 4 (gold), day 5 (green) and MeHg on day 4 (black); 
B) control day 4 (red), day 5 (gold), day 6 (green) and MeHg on day 5 (black); C) control 
day 5 (red), day 6 (gold), day 7 (green) and MeHg on day 6 (black).
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Discussion
ESC neural differentiation and gene expression changes over time
Transcriptomics analyses were instrumental in the description of the neural dif-
ferentiation process of ESC (Figure 2AB), showing a reduction of pluripotency 
and an induction of neural differentiation-related gene sets over time. In addition, 
two gene clusters (C and D) were found to be transiently regulated at day 3 and 4 
of the ESTn protocol, respectively. Gene clusters behaving similarly were observed 
in gene expression profiles over time for the cardiac embryonic stem cell test 
(ESTc) [142]. A number of the top regulated genes (FC>16) in ESTn gene cluster 
D are involved in RA metabolism and brain development, such as Cyp26a1 [168]. 
It has been suggested that genes in these clusters could be important in early 
stages of differentiation [142]. The differentiation processes observed over time 
were reminiscent of developmental pathways observed in the embryo in a similar 
time-dependency (Figure 2C), and showed clear germ line specificity for induction 
of neurodevelopmental pathways. Furthermore, the differentiation process within 
the ESTn over time could be visualized in a two-dimensional PCA plot (Figure 
2D). Our results support the observations of neuronal differentiation and the loss 
of pluripotency in the ESTn over time described earlier [142] and provide a more 
detailed mechanistic assessment of the dynamic changes underlying neural 
development in the model. Previously, genomics studies using a broad variety of 
mouse ESC neural differentiation culture techniques and time points [80, 169, 
170] described similar changes in expression of genes as observed in our study. 
For instance, Abranches et al. [169] described comparable regulated genes at time 
points which correspond to the ESTn protocol (early differentiation genes Frzb, 
Id2 and Lrp2, late differentiation genes Pax6, Neurog1, Nhlh1, Notch1 and 
Lx9). Furthermore, gene expression profiles in our study correspond to published 
mouse in vivo developmental gene sets describing early neural differentiation. 
Mitiku and Baker [171] described the mouse transcriptome of gastrulation 
through organogenesis from E6.25 to E9.0. One of the specific clusters they 
identified was highly enriched for neural development-related GO-terms. The 
expression profile of the clusters F-H in our study correspond with the gene 
expression profile found in the cluster described by Mitiku and Baker (72 of 227 
genes), with enriched GO-terms for neural development, neuron migration, 
axiogenesis and axon guidance, among others. Analysis of the cluster defined by 
Mitiku and Baker in Tox-profiler on our time data showed an increase in 
expression from day 4 to day 7. Therefore, ESTn transcriptomics shows an 
extensive correlation with morphological neurodevelopment while providing a 
more detailed assessment of dynamic changes in gene expression and the 
associated functional processes over time.
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MeHg induced gene expression changes over time in neural 
 differentiating ESC
MeHg exposure resulted in down-regulation of transcription- and development- 
related genes and in up-regulation of neurodevelopment and cell motion-related 
gene sets (Figure 3AB). MeHg retarded embryonic development as observed by 
stage-specific gene expression, but specifically increased expression of neural 
differentiation gene sets (Figure 3C). The relatively small gene expression changes 
early in the protocol as compared to the more robust morphological effects 
observed at the end of the protocol is probably related to the difference in timing 
of both parameter types. The molecular mechanisms behind MeHg neurodevel-
opmental toxicity have currently not been identified, but in vivo and in vitro 
studies have suggested mechanisms involving oxidative stress, cell cycle regulatory 
proteins, protein phosphorylation and intracellular calcium homeostasis [144, 
172]. In our previous study focusing on protein and cellular effects, MeHg 
inhibited mESC neurite growth and migration, and at higher concentrations 
increased the neural precursor marker protein nestin [142]. In another study, 
MeHg was shown to decrease the expression of the neuron-specific cytoskeletal 
protein Mtap2 gene expression after 14 days of mESC neural differentiation at 
a concentration of 100 nM [41]. Studies describing MeHg developmental 
toxicity using genomics in mouse embryos undergoing neurulation [151, 152] 
and the rat whole embryo culture (WEC) [82] showed up-regulation of early 
neural differentiation gene sets associated with neurodevelopmental malformations 
observed subsequently. In vivo studies showed that 8h and 12h after MeHg 
exposure in utero, neural developmental pathways, such as the wnt signaling 
pathway [152] were upregulated at dose levels which were associated with 
neural tube defects (NTDs) and other malformations [173]. In the rat WEC 
study [82], MeHg induced neural gene expression up-regulation at 4h in 
association with multiple developmental defects at 48h (NTDs and effects on 
yolk sac, branchial bar, eye, mandibular, heart and limb). These observations 
from three different models indicate that up-regulation of neuro-developmental 
genes at an early time point was related to impaired morphological development 
at a later time point. 
Differentiation track analysis of  neuro-developmental toxicity effects in ESTn
Specific manifestations of developmental toxicity at the morphological level can 
be caused by diverse effects on the gene expression level, representing different 
mechanisms of toxic action [151]. Studying individual genes or proteins in stem 
cell differentiation assays gives only limited information about mechanisms of 
action of compounds [41, 142, 174]. Larger sets of functionally related genes 
may help to further clarify mechanisms of neurodevelopmental toxicity. In 
previous studies using the ESTc, van Dartel et al. [40, 83, 142, 155] used the 
differentiation track method to determine compound toxicity in a temporal 
manner. In the present study, we used the time related differentiation track 
method [142] to study gene expression over time. The effects of MeHg on cell 
differentiation were determined through the deviation of the treated samples 
from the differentiation track. Analysis of three-day differentiation tracks 
revealed that the 24h exposure time point gave the most significant deviation 
from the differentiation track after MeHg exposure, whereas 48h and 72h 
exposure samples did not deviate significantly from the track. This may be due 
to increasing sample variance over time, both in controls and treated samples, 
as well as to the fact that in the PCA plot the 24h time point showed the highest 
dynamics in gene expression changes as compared to remaining time points 
(Figures 2D and 4ABC). Furthermore, the largest number of significantly 
regulated genes by MeHg exposure was observed at this time point, including 
many genes also regulated by time. Earlier studies with ESTc determined the 
same optimal time point for studying compound effects, and for similar reasons 
[83]. In the classic ESTc, MeHg developmental toxicity was misclassified using 
the classical prediction model of the ECVAM validation study [175] and, 
depending on the predicting gene sets used, was borderline or not identified as 
a developmental toxicant in the same test system with transcriptomics analysis 
using the differentiation track [155]. In the present study we clearly showed a 
significant deviation of MeHg treated samples on the differentiation track after 
24h exposure at a lower tested concentration, indicating that the ESTn is more 
sensitive for detecting MeHg-induced developmental toxicity as compared to 
the ESTc. This is in line with the developmental toxic properties of MeHg which 
are primarily neurodevelopmental in nature [144, 172]. 
In this study we described the process of neural differentiation in our ESC model 
at the whole-genome level. Using multiple types of analysis pluripotency was 
found to be reduced and neural development was induced with time. Furthermore, 
effects of MeHg on neural differentiation at the gene expression level could be 
identified using multiple methods, including the differentiation track. MeHg was 
shown to specifically enhance neural differentiation-related gene expression and 
reduce other embryonic differentiation routes, confirming other studies and 
contributing further molecular information accompanying MeHg embryotoxicity. 
Future studies will have to show whether this model can be applied more widely 
for neurodevelopmental toxicity testing of chemical compounds.  
 C
ha
pter 4
Transcriptomic 
concentration-response evaluation 
of valproic acid, cyproconazole 
and hexaconazole 
in the neural embryonic stem cell test 
(ESTn)
Theunissen PT, Robinson JF, Pennings JL, 
de Jong E, Claessen SM, Kleinjans JC and Piersma AH.
Toxicological Sciences (2011) 125: 430-8.
CHAPTER 4 TRANSCRIPTOMIC CONCENTRATION-RESPONSE EVALUATION IN ESTN
74 75
Introduction
D ue to the high use of experimental animals needed for regulatory developmental toxicity testing [10, 12], there is increased momentum to 
develop, refine and establish in vitro screening assays to replace classical in 
vivo tests [34]. In the embryonic stem cell test (EST), mouse embryonic stem 
cells (mESC) are exposed to compounds during cardiomyocyte differentiation, 
giving an indication of developmental toxicity by scoring foci of beating cells 
[34]. The EST is widely being evaluated as a developmental toxicity screening 
assay in both chemical and pharmaceutical industry. The ECVAM (European 
Centre for Validation of Alternative Methods) validation study found this test 
to provide a predictivity score of 78%, but subsequent validation studies were 
less successful  [37, 176]. To improve the predictivity of the EST, it was advised 
to add additional differentiation lineages to the testing strategy, such as neural 
and osteoblast differentiation and to use objective and mechanistic informative 
molecular techniques to determine compound effects [36, 37]. In this line of 
thought, we developed an 11-day mESC neural differentiation protocol (ESTn). 
Using this assay, we were able to detect specific adverse effects of the neurode-
velopmental toxicant methylmercury (MeHg) [142], a compound which was 
misclassified in the ECVAM EST validation study [17]. Further investigations 
using additional developmental toxicants are needed to establish the applicability 
domain of this test for developmental toxicity testing.
Toxicogenomic approaches might be incorporated into alternative test systems 
to further increase predictivity and provide mechanistic insight.  In our initial 
transcriptomic study in the ESTn, we characterized gene expression changes 
over time in non-exposed cultures and described the specific time-dependent 
gene expression profile after MeHg exposure [177]. Recent transcriptomic 
studies in the cardiac EST (ESTc) have shown that testing a compound at one 
concentration provides only limited information on the effect profile of the 
compound [83, 155]. A recent study describing the effects of flusilazole in the 
ESTc illustrated the added value of concentration-response testing in EST tran-
scriptomics experiments [81]. 
Therefore, in this study, a similar concentration-response approach was performed, 
to discern effects of three model compounds on neural differentiation in the 
ESTn: the triazole fungicides cyproconazole (CYP) and hexaconazole (HEX) 
and the anticonvulsant, valproic acid (VPA). CYP and HEX have been 
identified to be developmentally toxic in vivo [178-180].  In rats, CYP increased 
the prevalence of skeletal malformations, including delayed ossification of 
Abstract
A lternative developmental toxicity assays are urgently needed to reduce animal use in regulatory developmental toxicology. We previously 
designed an in vitro murine neural embryonic stem cell test (ESTn) as a model 
for neurodevelopmental toxicity testing [142]. Toxicogenomic approaches have 
been suggested for incorporation into the ESTn to further increase predictivity 
and to provide mechanistic insights. Therefore, in this study, using a 
transcriptomic approach, we investigated the concentration-dependent effects 
of three known (neuro)developmental toxicants, two triazoles, cyproconazole 
(CYP) and hexaconazole (HEX) and the anticonvulsant valproic acid (VPA). 
Compound effects on gene expression during neural differentiation and 
corresponding regulated gene ontology (GO) terms were identified after 24h 
of exposure in relation to morphological changes on day 11 of culture. 
Concentration dependent responses on individual gene expression and on 
biological processes were determined for each compound, providing 
information on mechanism and concentration-response characteristics. All 
compounds caused enrichment of the embryonic development process. CYP 
and VPA but not HEX significantly enriched the neuron development process. 
Furthermore, specific responses for triazole compounds and VPA were 
observed within the GO-term sterol metabolic process. The incorporation of 
transcriptomics in the ESTn was shown to enable detection of effects which 
precede morphological changes and provides a more sensitive measure of 
 concentration-dependent effects as compared to classical morphological 
assessments. Furthermore, mechanistic insight can be instrumental in the 
extrapolation of effects in the ESTn to human hazard assessment.  
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final DMSO concentration of 0.1%, which did not affect cell viability. Viability 
was tested in the following concentration ranges: CYP 0.1 – 300 µM, HEX 
0.01 – 300 µM and VPA 0.1 – 2.5 mM. Tests were performed in triplicate.
Treatment and morphological scoring for effects on neurite 
outgrowth
Highest concentrations tested were selected on basis of the Resazurin viability 
assay, wherein the highest concentration provided a minimum viability of 
80%, or 1000 µM, chosen as the highest concentration feasible in vivo. A 
concentration of 100 µM CYP and 25 µM HEX reduced viability to 80% and 
1000 µM VPA did not affect cell viability in the ESTn. For both morphological 
and gene expression assessments, compounds were tested at the following 
concentrations: CYP 1.5 µM, 6.0 µM, 25 µM and 100 µM; HEX 0.5 µM, 1.5 
µM, 6.0 µM and 25 µM; VPA 15 µM, 60 µM, 250 µM and 1000 µM. Control 
embryoid bodies (EB) were treated with 0.1% DMSO. For morphological 
scoring, cultures were treated for 72h from initiating suspension culture on 
day 3 of the protocol until the start of the serum free period on day 6 
(Theunissen et al., 2011). Morphological effects were determined by assessment 
of the extent of neurite outgrowth from the EB, at the end of the differentiation 
protocol (day 11), observed using an IX51 inverted microscope (Olympus, 
Zoeterwoude, The Netherlands) with CellD software (Olympus, Zoeterwoude, 
The Netherlands). Morphology of neurite outgrowth was scored as the 
percentage of neural corona surrounding each EB, irrespective of the distance 
of outgrowth from the EB. For scoring neurite outgrowth, a cutoff was chosen 
at or ≥75% neurite outgrowth around the EB, based on historical control data. 
For each concentration, three cultures each with 30 to 40 EB were assessed. 
Parallel cultures were harvested for gene expression analysis at earlier time points.
RNA isolation and whole-genome expression profiling
Exposed differentiation cultures were treated with concentrations as described 
earlier from day 3 of the protocol onwards and sampled after 24h exposure 
(day 4) (8 replicates per group). The 24h exposure was chosen as the time point 
expressing the least variability between samples as observed in our earlier 
time-course study with the neurodevelopmental toxicant MeHg [183]. RNA 
from control differentiation cultures was sampled on protocol days 3 (8 
replicates), 4 (5 replicates), and 5 (5 replicates). Gene expression background 
over time correlated well with previous studies [183]. Cells (approximately 
30-40 EB/sample) were directly collected in RNA Protect (Qiagen Benelux, 
Venlo, The Netherlands) to stabilize RNA, and total RNA was purified using 
the Qiagen RNeasy Plus Mini Kit (Qiagen Benelux, Venlo, The Netherlands) 
skull bones, cleft palate [178], hydrocephalus and hydronephrosis [180]. In the 
cardiac differentiation EST, CYP has been shown to induce neural differentia-
tion [15], inducing deviation from the normal differentiating pattern. In rats, 
HEX caused skeletal malformations, however, no specific effects on neural 
development have been observed in vivo or in vitro [15, 179]. The widely used 
anticonvulsant and histone deacetylase (HDAC) inhibitor VPA is well known 
for its induction of central nervous system (CNS) congenital abnormalities, 
including spina bifida and other neural tube defects (NTDs), but also heart 
anomalies and skeletal malformations [181, 182]. 
Using these three model compounds (CYP, HEX, VPA), we investigated the 
concentration-dependent effects of compound exposure in the ESTn on gene 
expression in relation to neural differentiation in vitro and to morphological 
effects observed in vivo.  Using a toxicogenomic approach, we are able to 
discriminate between compound classes and between mechanisms of action on 
the basis of differential gene expression during neural differentiation. 
Materials and Methods 
Embryonic Stem Cell Culture and Neural Differentiation
Murine embryonic stem cells (ESC) (ES-D3, ATCC, Rockville, MD, USA) 
were routinely sub-cultured every 2–3 days and grown as a monolayer in 
Dulbecco’s Modified Eagle Medium (DMEM)-based (Gibco BRL, Gaithersburg, 
MD, USA) medium supplemented with leukemia inhibiting factor (LIF) 
(Chemicon, Temecula, CA, USA) at a final concentration of 1000 units/ml. 
The cells were maintained in a humidified atmosphere at 37°C and 5% CO2. 
Induction of neural differentiation was performed as described earlier [142, 
183]. 
Resazurin cell viability assay
To determine compound effects on cell viability, a Resazurin dye reduction 
assay (Promega, Leiden, The Netherlands) was used as a measure for the 
number of viable cells, as described previously [142].  Cyproconazole  (CYP) 
(CAS number 94361-06-5, Sigma–Aldrich, Zwijndrecht, The Netherlands), 
hexaconazole  (HEX) (CAS number 79983-71-4, Sigma–Aldrich, Zwijndrecht, 
The Netherlands) and valproic acid sodium salt (VPA) (CAS number 1069-66-5, 
Sigma–Aldrich, Zwijndrecht, The Netherlands) were diluted in dimethyl 
sulfoxide (DMSO), and cell cultures (including controls) were exposed to a 
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pression-linked GO gene categories, we used GO-Quant [95] to calculate the 
average absolute log2 fold change (FC) associated with genes within each GO 
subset for each compound separately. Venn diagrams describing relations of 
significant gene expression and enrichment of GO-terms between compounds, 
were created using Venny (Oliveros, 2007). Hierarchical clustering of changes 
to control for all significantly differentially expressed genes (or subsets thereof 
selected on the basis of venn diagrams and GO-terms) was performed in 
GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium), using 
Euclidean distance and Ward linkage.
Results
Concentration-dependent effects of CYP, HEX and VPA on 
viability and neurite outgrowth
CYP, HEX and VPA affected cell viability in a concentration-dependent 
manner (Figure 1).  Compound concentrations reducing cell viability to 80% 
(IC20) were 117.6 µM for CYP, 19.8 µM for HEX and 2200 µM for VPA. This 
data was used as a reference level for the highest concentration tested in the 
ESTn for both gene expression and neural morphological assessments. On day 
11, after a 72h compound exposure from day 3 onwards, both CYP and VPA 
significantly altered neurite outgrowth in the ESTn in a dose responsive manner 
(Figure 1). At the tested concentrations (0-25 µM), HEX did not significantly 
impact neurite outgrowth at concentrations tested. However, in earlier 
performed concentration range-finding experiments, HEX did reduce neurite 
outgrowth at 100 µM (data not shown), a highly cytotoxic concentration at 
which viability was reduced to approximately 10%.  
Gene expression is regulated by CYP, HEX and VPA in a 
 concentration-dependent manner
Compound-induced differential gene expression was compared between 
exposed murine ESC neural differentiation cultures and time-matched control 
cultures, using one-way ANOVA (FDR<0.01). We identified 663, 761 and 
3626 genes to be significantly regulated by CYP, HEX and VPA, respectively 
(Figure 2a). CYP regulated 0, 215, 134, 281 genes with increasing concentrations 
tested. For Hex and VPA, these numbers were 0, 20, 87, 779 and 0, 147, 574, 
2355, respectively. We observed 252 genes to be significantly regulated by all 
three compounds. In total, the expression levels of 3980 unique genes were 
concentration-dependently regulated by any of the compounds (Figure 2b). 
following manufacturer’s instructions. RNA quantity was determined using 
the NanoDrop Spectrophotometer (Isogen Lifescience, de Meern, The 
Netherlands). RNA integrity was assessed on the 2100 Bioanalyzer (Agilent, 
Amstelveen, The Netherlands) using the RNA 6000 Nano Chip Kit (Agilent, 
Amstelveen, The Netherlands), and good quality RNA was used for gene 
expression analysis (RNA integrity number (RIN) > 8.0). Gene expression 
analysis using the Mouse Genome 430 2.0 arrays (Affymetrix, Santa Clara, 
CA, USA) was performed as described previously [183]. Quality controls, 
including scaling factors, average intensities, present calls, background intensities, 
noise, and raw Q values, were performed according to the manufacturer’s 
instructions and showed to be within acceptable limits for all chips.
Data Analysis and Statistics
Affymetrix CEL files were normalized using the Robust Multichip Average 
(RMA) algorithm   [158] using  RMAexpress [159]. For probe to gene mapping, 
a custom Chip Description File (CDF) was used according to the assembly by 
de Leeuw et al. [160] (http://mad-db.science.uva.nl/~wdeleeuw/HybridAnnot/
version6.html). Of the hybrid probe-set definitions included in the custom 
annotation, 16,331 probe sets defined by the Brainarray custom CDF version 
11 (http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF) 
[161] and 4648 additional probe sets defined by Affymetrix chip annotation 26 
were used in further analyses, giving a total of 20,979 probe sets. Probe sets 
for Affymetrix internal controls or probe sets that did not correspond to an 
Entrez Gene ID were not used in further analyses. Statistical analyses were 
carried out using the R statistical software environment (http://www.R-project.
org) using log-transformed values. For each gene, maximal fold change (FC) in 
gene expression between the experimental groups were determined by 
comparing the average normalized signal values per group and were calculated 
as the maximum/minimum ratio. For compound toxicity effects, the treated 
samples were compared to the time-matched day 4 controls.  Genes differentially 
expressed between any of the experimental groups (four concentrations and 
control) were identified by a one-way ANOVA. A significance threshold of 
FDR<0.01 were used to select genes that were significantly differentially 
expressed due to compound exposure.  Functional annotation and enrichment 
for Gene Ontology (GO) biological processes were studied using DAVID 
(http://david.abcc.ncifcrf.gov/) [162] and GenMAPP [96]. Significantly 
enriched GO categories were based on a set criteria of permutation value 
(p<0.01), Z-score (>2), and genes changed within each specific GO gene 
category (>5). GO-terms with >5000 genes and redundant GO-terms were not 
included in the analysis.  To quantitatively evaluate changes within gene ex-
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These genes were significantly differentially expressed after exposure to at 
least one of the compounds in at least one test compound concentration, as 
determined by one way ANOVA including all tested concentrations plus 
control. 
GO-terms regulated by CYP, HEX and VPA specifically
To study the effects of compounds at the biological process level, GO-terms 
significantly enriched by each of the three compounds were identified (Figure 
2c). Within the 663 genes observed to be significantly altered by CYP, 93 
enriched GO-terms were identified (Figure 2c), including GO-terms involved 
in general development (e.g. general, embryonic, central nervous system, 
organ), differentiation (cell, neuron), metabolism (sterol, lipid, isoprenoid, 
organic) transcription, biological regulation, cell cycle and protein kinase 
pathways (data in supplementary data of original article). For the 761 genes 
regulated by HEX, only 28 GO biological processes were enriched (Figure 2c), 
including GO-terms related to development (e.g. general, embryonic, CNS, organ), 
metabolism (lipid, sterol, isoprenoid, organic), cell cycle and transcription 
(data in supplementary data of original article). Within the 3626 genes 
regulated by VPA, 74 distinct GO-terms were enriched (Figure 2b), related to 
a wide array of processes, including development (general, embryonic, central 
Figure 1  CYP, HEX and VPA effects on viability and morphological neuron out - 
growth. Concentration response effects on cell viability in ESC (CYP 0.1 – 300 µM, 
HEX 0.01 – 300 µM and VPA 0.1 – 2.5 mM) (triangles) and concentration response 
effects on the percentage of EB with >75% neurite outgrowth (CYP 1.5 µM, 6.0 µM, 
25 µM and 100 µM; HEX 0.5 µM, 1.5 µM, 6.0 µM and 25 µM; VPA 15 µM, 60 µM, 
250 µM and 1000 µM) (circles) for A) CYP (IC20: 117.6 µM), B) HEX (IC20: 19,8 
µM) and C) VPA (IC20: 2200 µM).
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nervous system, organ), differentiation (cell, neuron), metabolism (sterol, lipid, 
isoprenoid, organic, nucleic acid and protein), cell cycle, cell death, oxidative 
stress and localization (data in supplementary data of original article). 
Significance (p≤0.01) and degree of significance (indexed as z*-log(p-value) for 
selected GO-terms is shown in figure 2d (complete list of GO-term significance 
values is provided in the in supplementary data of the original article), to 
illustrate degrees of  GO-term enrichment. For example steroid metabolic 
process is highly enriched in the triazoles compounds, but only slightly enriched 
in VPA, whereas neuron development is highly enriched in VPA, but slightly 
enriched in CYP and not enriched in HEX. 
The 12 GO-terms significantly enriched by all three compounds were related 
to embryonic morphogenesis, metabolic processes (including sterol and lipid 
metabolic process) and regulation of cell cycle (Figure 2C). The 26 GO-terms 
regulated by CYP and VPA but not HEX were involved in general development 
(e.g. developmental process, anatomical system development), nervous system 
development (neuron development, axon guidance) and cell differentiation and 
morphology (Figure 2C). The 10 GO-terms significantly enriched by CYP and 
HEX but not VPA were involved in steroid metabolic processes, embryonic 
development and RNA processing (Figure 2C). No GO-terms were significantly 
enriched by both HEX and VPA which were not also enriched by CYP.
 
Concentration-dependent effects of genes within selected enriched GO-terms 
(embryonic morphogenesis, neuron development, regulation of cell cycle, 
programmed cell death, sterol metabolic process and RNA processing) were 
examined for CYP, HEX and VPA (Figure 3ABC). Concentration dependent 
changes in gene expression were associated with selected GO-terms. For 
example, 21 genes associated with sterol metabolic process on average showed 
a concentration dependent increase in effect with CYP with a peak change in 
the high dose of 1.5 FC. Across selected functional groups, we observed genes 
associated with embryonic morphogenesis followed by neuron differentiation 
to have greater changes as compared to genes associated with regulation of cell 
cycle and programmed cell death with all three compounds at all concentrations 
tested.
Effects on expression changes of single genes within the GO biological 
processes embryonic morphogenesis (Figure 4A), neuron development (Figure 
4B) and sterol metabolic process (Figure 4C) were visualized by hierarchical 
clustering. Genes significantly regulated (FDR<0.01) by at least two out of 
three compounds are shown. In general, independent of significance, genes 
Figure 2  Venn diagrams and hierarchal clustering plots. Venn diagrams and 
hierarchal clustering plots describing A) overlap of genes significantly concentration-
dependently expressed for CYP (663 genes), HEX (761 genes) and VPA (3625 genes) 
(FDR 0.01) and B) Hierarchal clustering plot of all 3980 genes regulated by any of the 
compounds (One-way ANOVA FDR<0.01, log2 scale). C) overlap of GO-terms con-
centration-dependently enriched for CYP (93), HEX (28) and VPA (74) (p<0.01, z>2, 
number changed>5). D) Hierarchal clustering plot of GO biological processes showing 
significance of concentration-dependent enrichment response by CYP, HEX or VPA (* 
= p ≤ 0.01, grey scale = z-score * -log(p-value)).
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associated with embryonic morphogenesis were regulated by all three 
compounds in the same concentration responsive manner in terms of 
directionality, with the exception of the highest concentration of VPA tested 
(1000 µM). For approximately 50% of embryonic morphogenesis genes 
regulated by two of the three compounds, VPA at 1000 µM resulted in 
differential directional regulated expression compared to the other exposure 
groups (Figure 4A). Within the GO-term neuron development (Figure 4B), a 
similar pattern of concentration-dependent regulation was observed across the 
three compounds, again with VPA at 1000 µM regulating genes in an opposite 
direction compared to lower doses and to the triazole compounds. Within the 
GO-term sterol metabolic process (Figure 4C), the majority of the genes were 
concentration-dependently upregulated in the triazole compounds, but con-
centration-dependently downregulated in VPA. For example, Cyp51, a gene 
which is important in sterol metabolism, but also in retinoic acid (RA) 
metabolism, was upregulated in a concentration-dependent way by the triazole 
compounds, but downregulated by VPA.
Figure 3   Continued
Figure 3  Compound effects on GO-terms fold change. Average absolute FC of selected 
key biological processes (embryonic morphogenesis, neuron development, regulation 
of cell cycle, programmed cell death, sterol biosynthetic process and RNA processing) 
for A) CYP, B) HEX and C) VPA. (** = significantly enriched GO-term by compound)
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Discussion
I n recent years, several additions to the EST developmental toxicity assay have been proposed, including the introduction of additional differentiation 
routes [36, 37]. We developed the complementary ESTn model to predict 
compound effects on the neuroectodermal lineage and investigated the effects 
of the neurodevelopmental toxicant MeHg [142]. Studies describing molecular 
endpoints [184-186] and transcriptomics techniques [40, 83, 187] in the EST 
proved to be useful in further increasing the predictivity of the EST [84, 155]. 
Therefore, we studied the effects of MeHg over time in the ESTn using tran-
scriptomics [177] and concluded that the most robust measurements can be 
achieved after 24h treatment on day 4 of the standardized differentiation 
protocol. In the present study, concentration-dependent transcriptomic responses 
are studied testing three known developmental toxicants cyproconazole (CYP), 
hexaconazole (HEX) and valproic acid (VPA) to further characterize the ESTn. 
The compounds were chosen such that we should be able to discriminate a 
triazole specific response (CYP and HEX versus VPA) and a neurodevelop-
mental toxicity specific response (CYP and VPA versus HEX), thus investigating 
whether the differential gene expression responses would display mechanistic 
specificity and add greater value than morphological assessments alone.
Relationships between compound effects on morphology and 
gene expression changes
CYP, HEX and VPA impacted cell viability with different potencies, with 
HEX being the most potent and VPA the least. Compound effects on neurite 
outgrowth around the EB were concentration-dependent for CYP and VPA. 
VPA severely reduced neurite outgrowth at concentrations without reduced 
viability, with approximately a 10 fold difference between the IC20 for viability 
and the ID20 for differentiation, showing that neurite outgrowth is a much 
more sensitive parameter compared to viability in this assay specifically for 
VPA. In contrast, only minor sensitivity differences were observed for CYP 
between compound effects on cytotoxicity and neurite outgrowth. We did not 
observe any sensitivity differences between cytotoxicity and neurite outgrowth 
for HEX.  Associated with effects on cell viability and neurite outgrowth, we 
observed concentration-dependent effects on gene expression and corresponding 
functional GO-terms. Despite using a similar range in potencies, VPA significantly 
altered the expression of approximately four times more genes than CYP and 
HEX, primarily driven by the greater gene expression response at the highest 
concentration tested, which was in line with the relatively large effect on 
neurite outgrowth in the morphological test. 
Figure 4  Genes significantly concentration-dependently expressed in at least two of 
three compounds CYP (C), HEX (H) and VPA (V) compared to control (FDR<0.01, 
log2 scale) for the GO-terms A) Embryonic Morphogenesis, B) Neuron Development 
and C) Sterol Metabolic Process
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Concentration-dependent compound effects on GO-term 
enrichment 
Analysis of GO-terms regulated revealed major themes within genes significantly 
enriched by CYP, HEX and VPA. In association with concentration-dependent 
effects on morphology, we observed common enrichment of GO-terms related 
to development, metabolism and cell cycle.  Uniquely, GO-terms related to cell 
differentiation and neuron differentiation were only significantly enriched by 
CYP and VPA, and not by HEX. In addition, published data have also shown 
neurodevelopmental effects for CYP and VPA but not HEX, confirming the 
correlation between ESTn gene expression readout and existing in vivo and in 
vitro data [15, 179-181]. VPA specifically regulated programmed cell death 
and apoptosis related GO-terms, at a concentration that was not found to be 
cytotoxic in culture. VPA, which is also an HDAC inhibitor, is known to 
induce apoptosis through this mechanism [188]. Enrichment of apoptosis 
accompanied with no observed cytotoxicity in the cells was also observed 
earlier in the pluripotent mouse embryonal carcinoma cell line after 24h 
exposure to 1 mM VPA [76]. In addition, effects on development related 
GO-terms were observed at concentrations at which no effects were observed 
on neural morphology or cell viability, implicating that gene expression can be 
a more sensitive endpoint.
CYP, HEX and VPA disturb genes involved in embryonic 
development 
Most GO-terms were already regulated at the lowest concentration and 
 concentration-dependently upregulated in all three compounds, indicating 
that effects on the RNA transcript level can occur without inducing adverse 
effects on morphology. The direction of gene regulation within embryonic 
morphogenesis was comparable for the triazoles, signifying a comparable 
mode of action on the regulation of this GO-term. However, VPA regulated 
gene expression of well characterized developmental associated genes in an 
opposite direction compared to the triazoles (Figure 4a), of which the majority 
is also important during neural development. These included Hox-pathway 
related genes (Hoxb4, Hoxc4, Hoxb5, Dlx5, Msx1) [189], genes of the TGF-β 
pathway (Lefty1) [190], early ectodermal formation and patterning (Fgf8) 
[191] early mesodermal formation (T) [192] and retinoic acid pathway related 
genes (Rarb, Cyp26b1) [193, 194]. The different direction in which these genes 
are regulated by VPA as compared to the triazoles, suggests a different 
mechanism of action, leading to comparable morphological outcomes in the 
ESTn.
CYP and VPA responses significantly target neural development
Genes regulated within the neuron development GO-term showed a similar 
response for both the triazole compounds and VPA at the gene level, although 
only CYP and VPA significantly enriched this GO-term. Genes regulated by 
both CYP and VPA included Mtap2 which is important for dendrite micro - 
tubule formation during neuron development [141] and the well characterized 
Pax6, an important transcription factor during early ectodermal development 
[195]. Compound effects on the genes within the neuron development GO-term 
observed in the ESTn corresponded with developmental toxic effects found in 
vivo. VPA is well known for its induction of spina bifida and NTDs [181] and 
CYP was observed to increased incidence of hydrocephalus in rats [180] and 
furthermore induced neural differentiation in the ESTc [15]. No effects of 
HEX on neural development have been observed in vivo [15, 179], which is in 
line with the absence of a significant regulation of the neuron development 
GO-term in this study.
CYP and HEX increase sterol metabolic process related gene 
expression, whereas VPA decreases their expression
As a main mechanism of action, triazoles inhibit the enzyme lanosterol 14-α-
demethylase (Cyp51) which catalyses the synthesis of ergosterol, an important 
protein for membrane integrity [196]. Valproic acid was observed to inhibit 
sterol synthesis in the developing rat brain [197] and more recent studies show 
that VPA causes a general down-regulation of expression of genes encoding for 
enzymes early in steroidogenesis in the human carcinoma cell line H295R and 
mouse Y1 adrenocortical cells [198, 199]. All three compounds significantly 
regulated pathways involved in sterol synthesis in a concentration-dependent 
manner. For example, in the GO-term sterol metabolic process, gene expression 
was increased by both triazoles, however, VPA showed a decrease in the 
majority of the genes regulated in this pathway. Cyp51, for instance, was 
upregulated by CYP but downregulated by VPA. This indicates that, although 
all three compounds have an effect on sterol metabolism, the mechanisms 
behind the effect are clearly different. 
HDAC inhibition pathways are specifically disturbed by VPA
A well characterized mode of action of VPA is HDAC inhibition [200], a 
mechanism by which VPA is thought to change overall gene expression [188, 
201, 202]. A core set of 15 gene markers regulated by three HDAC inhibitors 
was described earlier [76, 200]. Out of these 15 genes, 9 genes were significantly 
regulated (FDR<0.01) by VPA in this study, whereas the triazoles CYP and 
HEX only regulated 2 of these genes (data not shown). Furthermore, direction 
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of regulation by VPA was comparable to effects observed earlier in the 
pluripotent mouse embryonal carcinoma cell line P19 [76], showing that this 
VPA specific main mechanism of action could be discerned in the ESTn.
Conclusion
The present study showed that differential gene expression provides a sensitive 
tool for studying the effects of chemicals on neural differentiation in the ESTn 
detecting effects at concentrations below those inducing morphological effects. 
Moreover, chemical-specific gene expression signatures can be discriminated, 
such as the triazole signature and the neurodevelopmental toxicity signature in 
the present study, which allow mechanistic insight into the action of chemicals 
tested. This methodology therefore potentially offers significant added value to 
existing morphological effect assessment in ESTn and to the elucidation of the 
nature of developmental neurotoxicity of chemicals. Such mechanistic insights 
are instrumental in determining the extrapolation of adverse effects in 
alternative assays to human hazard assessment.  
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Introduction
C urrent legislation for chemical and pharmaceutical developmental toxicity testing requires a high number of experimental animals, creating momentum 
for development of alternative screening assays to precede or replace classical 
in vivo tests [10, 12]. The embryonic stem cell test (EST) was designed as a 
screening assay for developmental toxicity of compounds [18]. The EST is used 
to assess compound effects on murine embryonic stem cell (mESC) differentia-
tion into cardiomyocytes, providing an indication of developmental toxicity by 
scoring foci of beating cells [34]. Initial validation studies using the cardiac 
EST (ESTc) [17, 37, 176] suggest promise in predictivity of developmental 
toxicants, but also areas of needed improvement, including refined protocol 
development, the implementation of additional differentiation routes (e.g. neural) 
and the introduction of objective and mechanistic informative techniques to 
determine compound effects [36, 37].
Previously, we described the mESC neural differentiation protocol (ESTn), in 
which we were able to detect compound-induced adverse effects on neural 
outgrowth using the model neurodevelopmental toxicant, methylmercury 
(MeHg) [17, 142]. In order to provide further mechanistic insight and increase 
the predictivity of the ESTn, a transcriptomics approach was incorporated. We 
identified time-dependent induced gene expression alterations, providing a 
signature for MeHg developmental toxicity in the ESTn which preceded 
observed morphological effects in our system [177]. Furthermore, we were 
able to discriminate between compound classes and mechanisms of action on 
the basis of concentration dependent differential gene expression during neural 
differentiation for two triazole antifungal compounds and valproic acid [203]. 
In the present study, the added value of the transcriptomics readout in the 
ESTn is investigated and possible common biomarker gene sets describing 
(neuro)developmental toxicity are explored. We investigated concentration-
dependent effects of six structurally and mechanistically diverse compounds 
on the transcriptome in relation to effects on neural differentiation and viability 
(Table 1). Four out of six compounds investigated were selected based on their 
in vivo induction of neurodevelopmental defects: the active ethanol metabolite 
acetaldehyde (ACE), anti-convulsants carbamazepine (CBZ) and phenytoin 
(PHE) and mono-ethylhexyl phthalate (MEHP), the active metabolite of bis(2-
ethylhexyl)phthalate (DEHP) [204-210]. Additionally, two in vivo non-neuro-
developmental toxic compounds were tested, of which flusilazole (FLU) was 
observed to induce skeletal malformations in vivo [211, 212], and the antibiotic 
penicillin G (PENG), which is known to induce no developmental toxicity in 
mammals [213]. In order to select genes only differentially expressed at 
Abstract
A lternative assays for developmental toxicity testing are needed to reduce animal use in regulatory toxicology. The in vitro murine neural embryonic 
stem cell test (ESTn) was designed as an alternative for neurodevelopmental 
toxicity testing. The integration of toxicogenomic-based approaches may further 
increase predictivity as well as provide insight into underlying mechanisms of 
developmental toxicity. In the present study, we investigated concentration-
dependent effects of six mechanistically diverse compounds, acetaldehyde (ACE), 
carbamazepine (CBZ), flusilazole (FLU), monoethylhexyl phthalate (MEHP), 
penicillin G (PENG) and phenytoin (PHE), on the transcriptome and neural 
differentiation in the ESTn. All compounds with the exception of PENG altered 
ESTn morphology (cytotoxicity and neural differentiation) in a concentration-
dependent manner. Compound induced gene expression changes and corresponding 
enriched gene ontology biological processes (GOBP) were identified after 24h 
exposure at equipotent differentiation-inhibiting concentrations of the compounds. 
Both compound-specific and common gene expression changes were observed 
between subsets of tested compounds, in terms of significance, magnitude of 
regulation and functionality. For example, ACE, CBZ and FLU induced robust 
changes in number of significantly altered genes (≥687 genes) as well as a 
variety of GOBP, as compared to MEHP, PHE and PENG (≤55 genes with no 
significant changes in GOBP observed). Genes associated with  developmentally 
related processes (embryonic morphogenesis, neuron differentiation and Wnt 
signaling) showed diverse regulation after exposure to ACE, CBZ and FLU. In 
addition, gene expression and GOBP enrichment showed concentration 
dependence, allowing discrimination of non-toxic versus toxic concentrations 
on the basis of transcriptomics. This information may be used to define 
adaptive versus toxic responses at the transcriptome level. 
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MD, USA) and 0.1 mM mercapto-ethanol (Sigma–Aldrich, Zwijndrecht, The 
Netherlands). Low serum medium (LS) had the same composition as CM, 
except that the serum percentage was 10%. Insulin–transferrin–selenite–
fibronectin medium (ITS) contained DMEM/Ham’s nutrient mixture F12 
(DMEM/F12)medium (Gibco, BRL, Gaithersburg,MD, USA) supplemented 
with 0.2 µg/ml bovine insulin (Sigma–Aldrich, Zwijndrecht,The Netherlands), 
1% penicillin/streptomycin (Gibco BRL, Gaithersburg,MD, USA), 2 mM 
l-glutamine (Gibco BRL, Gaithersburg, MD, USA), 30 nM sodium selenite 
(Sigma–Aldrich, Zwijndrecht, The Netherlands), 50 µg/ml apo-transferrin 
(Sigma–Aldrich, Zwijndrecht, The Netherlands) and 2.5 µg/ml fibronectin 
(Invitrogen, Carlsbad, CA, SA). N2 medium contained DMEM/F12 medium 
(Gibco,BRL, Gaithersburg, MD, USA) supplemented with 0.2 µg/ml bovine 
insulin (Sigma–Aldrich, Zwijndrecht, The Netherlands), 1% penicillin/
streptomycin (GibcoBRL, Gaithersburg, MD, USA), 30 nM sodium selenite 
(Sigma–Aldrich, Zwijndrecht, The Netherlands), and 50 µg/ml apo-transferrin 
(Sigma–Aldrich, Zwijndrecht, The Netherlands), 20 nM progesteron (Sigma-
Aldrich, Zwijndrecht, The Netherlands) and 100 µM putrescine (Sigma-
Aldrich, Zwijndrecht, The Netherlands).
concentrations inhibiting neural differentiation in the ESTn, transcriptomics 
profiles were investigated at a concentration inhibiting neurite outgrowth in 
the ESTn as well as a ~30-fold lower concentration inducing no morphological 
effects. The present study reveals common and unique gene expression profiles 
between the six compounds tested and provides clues for the distinction 
between transcriptomics responses of toxic and non-toxic concentrations that 
may relate to adaptive versus adverse outcomes.
Materials and Methods 
Culture Media
Complete medium (CM) contained Dulbecco’s modified eagle’s medium 
(DMEM) (Gibco BRL, Gaithersburg, MD, USA) supplemented with 20% fetal 
bovine serum (Hyclone, Logan, UT, USA), 1% nonessential amino acids 
(Gibco BRL, Gaithersburg, MD, USA), 1% penicillin/streptomycin (Gibco 
BRL, Gaithersburg, MD, USA), 2 mM l-glutamine (Gibco BRL, Gaithersburg, 
Table 1   Background information on compound developmental toxicity data
Compound Abbreviation LEL (mg/kg BW) Species Developmental Toxicity Proposed mode of action Reference
Acetaldehyde ACE Not reported Human Fetal alcohol syndrome (FAS) Disrupted cell-cell interactions, oxidative stress, growth factor 
signaling disruption, altered gene expression
[206]
Carbamazepine CBZ >1000 Rat None Unknown
Not reported Human Small head circumference, 
mild facial, dysmorphia,  
and developmental delay
[205]
Flusilazole FLU 0,4 Rat Urogenital malformations Disturbance of CYP26 metabolic pathway [224], disturbance of 
sterol biosynthesis through Cyp450
[212]
20 Mice Skeletal malformations [211]
MEHP MEHP 0,5 Mouse Anterior neural tube defects 
and skeletal abnormalities
Endocrine disruption [207, 208]
100 Rat Neural tube defects and 
vascular abnormalities
[209]
Penicillin G PENG Not reported Human None observed None [213]
Phenytoin PHE Not reported Human Congenital 
hydantoin syndrome, 
neurodevelopmental delay
Oxidative stress [204, 210]
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Resazurin cell viability assay
To determine compound effects on cell viability, a Resazurin dye reduction 
assay (Promega, Leiden, The Netherlands) was used as a measure for the 
number of viable cells. ESC were plated in 96-well plates at 500 cells per well in 
CM supplemented with LIF and allowed to attach for 2 h before compound 
exposure was started in the following concentration ranges (n=6 per 
concentration): ACE 3 – 1000 µM, CBZ 3 – 600 µM, FLU 0.01 - 300 µM, 
MEHP 30 - 1000 µM, PenG 3 – 1000 µM and PHE 0.3 – 100 µM. As a positive 
control in the viability assay, 5-fluorouracil was tested at 0.15 µM. Concentration 
ranges were based on earlier concentration-response range finding studies in the 
same model with which the range between no cytotoxicity and complete cell 
death was determined (data not shown). The maximum concentration tested 
was either 1000 µM or based on the solubility of the compound in the medium. 
Cells were subsequently cultured for 5 days at 37°C, 90% relative humidity, 
and 5% CO2, with a medium renewal containing compound for exposure on 
day 3. On day 5 (approximately 80% cell confluence in non-exposed controls), 
CellTiter-blue (Promega, Leiden, The Netherlands) was added to each well and 
incubated for 2 h. After the incubation period, fluorescence was read using a 
FLUOstar spectrofluorometer (FLUOstar Optima, BMG Labtech, de Meeren, 
The Netherlands) at 544 nm (excitation) and 590 nm (emission). Three independent 
experiments were performed. Concentration–response analysis to determine 
the 20% maximal inhibitory concentration (IC20) for cytotoxicity was 
performed using PROAST (Possible Risk Obtained from Animal Studies) 
software (RIVM, Bilthoven, The Netherlands), a freeware program with which 
concentration-response curves can be fitted and benchmark concentrations can 
be determined (http://www.rivm.nl/en/Library/Scientific/Models/PROAST).
Treatment and morphological scoring for effects on neural 
outgrowth
Highest concentrations tested in the transcriptomics experiment were selected 
on the basis of 1) concentration range finding studies in the ESTn (data not 
shown) providing an inhibition of approximately 50% reduction in neural 
outgrowth, 2) the Resazurin viability assay, wherein the highest concentration 
provided a minimum viability of 80% (IC20), or 3) a highest dose of 1000 µM, 
chosen as the highest concentration feasible in vivo. The βlowestβ concentration 
tested in the transcriptomics experiment was always a factor 30 lower compared 
to the highest concentration tested. The highest concentrations tested for ACE, 
CBZ, MEHP and PHE were equal to the concentration resulting in 50% 
reduction of neural outgrowth (ID50) (ACE 30 µM; CBZ 100 µM; MEHP 100 
µM and PHE 30 µM), the highest concentration for FLU was equal to the IC20 
Test Compounds
The following compounds were used in experiments. Acetaldehyde (99% ≤ 
purity) (ACE) (CAS number 75-07-0, Sigma-Aldrich, Zwijndrecht, The 
Netherlands), carbamazepine (CBZ) (CAS number 298-46-4, Sigma-Aldrich, 
Zwijndrecht, The Netherlands), flusilazole (FLU) (CAS number 85509-19-9, 
Sigma-Aldrich, Zwijndrecht, The Netherlands), monoethylhexylphthalate 
(MEHP) (CAS number 4376-20-9), Wako Chemicals GmbH, Neuss, Germany), 
penicillin G sodium salt (PENG) (CAS number 69-57-8, Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and phenytoin (99%≤ purity) (PHE) (CAS 
number 57-41-0, Sigma-Aldrich, Zwijndrecht, The Netherlands), were diluted 
in dimethyl sulfoxide (DMSO), and cell cultures (including controls) were 
exposed to a final DMSO concentration of 0.1%. 
Embryonic Stem Cell Culture and Neural Differentiation
Mouse embryonic stem cells (ESC) (ES-D3, ATCC, Rockville, MD, USA) were 
routinely sub-cultured every 2–3 days and grown on 35-mm dishes (Corning 
Incorporated, Corning, NY, USA) as a monolayer in Dulbecco’s Modified 
Eagle Medium (DMEM)-based (Gibco BRL, Gaithersburg, MD, USA) medium 
supplemented with leukemia inhibiting factor (LIF) (Chemicon, Temecula, 
CA, USA) at a final concentration of 1000 units/ml. The cells were maintained 
in a humidified atmosphere at 37°C and 5% CO2. Induction of neural differ-
entiation was performed as described earlier [142, 177]. 
In brief, ESC suspensions (3.75 3 104 cells/ml) were placed on ice before the 
initiation of the culture. Drops (20 µl) containing 750 cells in CM were placed 
onto the inner side of the lid of a 90-cm Petri dish filled with PBS (Gibco BRL, 
Gaithersburg,MD, USA) and incubated at  37°C, 90% relative humidity, and 
5% CO2. After 3 days of hanging drop culture, embryoid bodies (EB) had 
formed and were subsequently transferred to 60-mm bacterial Petri dishes 
(Greiner Bio-one, Frickenhausen, Germany) containing CM supplemented with 
0.5 µM retinoic acid (RA). On day 5, EB were plated on laminin (Roche, Basel, 
Switzerland) coated 35-mm dishes (Corning Incorporated, Corning, NY) in LS 
medium supplemented with 2.5 µg/ml fibronectin (Invitrogen, Carlsbad, CA, 
USA). One day later, on day 6, the LS medium was replaced by ITS medium. On 
day 7, EB were washed with PBS and incubated in cell dissociation buffer (Gibco 
BRL, Gaithersburg, MD, USA) for three minutes. Then EB were carefully 
detached from each Petri dish without dissociating the EB, and the entire content 
was replated on poly-L-ornithine (Sigma-Aldrich, Zwijndrecht, The Netherlands) 
and laminin coated dish in N2 medium supplemented with 10 ng/ml basic 
fibroblast growth factor (bFGF; Srtathmann-Biotec AG, Englewood, CO). The 
N2 medium supplemented with bFGF was replaced every other day for 7 days.
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replicates). Gene expression changes over time correlated well with previous 
studies, both qualitatively and quantitatively [177]. Cells (approximately 30-40 
EB/sample) were directly collected in RNA Protect (Qiagen Benelux, Venlo, 
The Netherlands) to stabilize RNA, and total RNA was purified using the 
Qiagen RNeasy Plus Mini Kit (Qiagen Benelux, Venlo, The Netherlands) 
following manufacturer’s instructions. RNA quantity was determined using the 
NanoDrop Spectrophotometer (Isogen Lifescience, de Meern, The Netherlands). 
RNA integrity was assessed on the 2100 Bioanalyzer (Agilent, Amstelveen, The 
Netherlands) using the RNA 6000 Nano Chip Kit (Agilent, Amstelveen, The 
Netherlands), and RNA with RNA integrity number (RIN) > 8.0 was used for 
gene expression analysis. Gene expression analysis using the Mouse Genome 
430 2.0 arrays (Affymetrix, Santa Clara, CA, USA) was performed as described 
previously [177]. Quality controls, including scaling factors, average intensities, 
present calls, background intensities, noise, and raw Q values, were performed 
according to the manufacturer’s instructions and showed to be within acceptable 
limits for all chips. Raw and normalized data are available at ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/ ) under accession number E-TABM-1216.
Data Analysis and Statistics
Affymetrix CEL files were normalized using the Robust Multichip Average 
(RMA) algorithm   [158] using  RMAexpress [159]. For probe to gene mapping, 
a custom Chip Description File (CDF) was used according to the assembly by 
de Leeuw et al. [160] (http://mad-db.science.uva.nl/~wdeleeuw/HybridAnnot/
version6.html). Of the hybrid probe-set definitions included in the custom 
annotation, 16,331 probe sets defined by the Brainarray custom CDF version 
11 (http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF) 
[161] and 4648 additional probe sets defined by Affymetrix chip annotation 26 
were used in further analyses, giving a total of 20,979 probe sets. Probe sets 
for Affymetrix internal controls or probe sets that did not correspond to an 
Entrez Gene ID were not used in further analyses. Statistical analyses were 
carried out using the R statistical software environment (http://www.R-project.
org) using log-transformed values. For each gene, maximal fold change (FC) in 
gene expression between the experimental groups were determined by 
comparing the average normalized signal values per group and were calculated 
as the maximum/minimum ratio. For compound toxicity effects, the treated 
samples were compared to the time matched day 4 controls.  Genes differentially 
expressed between any of the experimental groups (two concentrations and 
control) were identified by a one-way ANOVA. A significance threshold of 
FDR<0.05 was used to select genes that were significantly differentially 
expressed due to compound exposure. Functional annotation and enrichment 
concentration (10 µM) and PENG was tested at a highest concentration of 
1000 µM. For morphological assessments, compounds were tested at the 
following concentrations, of which the lowest and highest concentrations were 
included in the transcriptomics experiment: ACE 1, 3, 10 and 30 µM; CBZ 3, 
10, 30 and 100 µM; FLU 0.3, 1, 3 and 10 µM; MEHP 3, 10, 30 and 100 µM; 
PENG 30, 100, 300 and 1000 µM and PHE 1, 3, 10 and 30 µM. Control EB 
were treated with 0.1% DMSO. The ESTn and morphological scoring were 
performed as described earlier [142, 177]. For morphological scoring, cultures 
were treated for 72h from initiating suspension culture on day 3 of the protocol 
until the start of the serum free period on day 6. Morphological effects were 
determined by assessment of the extent of neurite outgrowth from the EB, at 
the end of the differentiation protocol (day 11), observed using an IX51 
inverted microscope (Olympus, Zoeterwoude, The Netherlands) with CellD 
software (Olympus, Zoeterwoude, The Netherlands). Morphology of neural 
outgrowth was scored as the percentage of neural corona surrounding each 
EB, irrespective of the distance of outgrowth from the EB, as was described 
earlier [142]. For scoring neurite outgrowth, a cutoff was chosen at ≥75% 
neural outgrowth around the EB, based on historical control data. Thus, when 
more than 75% of the corona around an EB contained microscopically 
observable neural outgrowth, the EB was scored positive, whereas below 75% 
it was scored negative. Three 35-mm Petri dishes per concentration were scored 
(containing approximately 40 EB per dish) and each dish was regarded as one 
independent observation. A concentration-range finding study was performed 
for each compound to determine half maximal inhibitory concentration of dif-
ferentiation (ID50) on neural differentiation, consisting of three separate 
experiments. Within each experiment three dishes per concentration were 
scored (with 40 EB per dish). Statistical analysis to determine the ID50 on 
neural differentiation was performed using PROAST.
During the final gene expression experiment a concentration–response study 
was performed in parallel for each compound to determine ID50 on neural 
differentiation in this specific experiment using PROAST. For gene expression 
analysis, parallel cultures were harvested at earlier time points (see next section).
RNA isolation and whole-genome expression profiling
Exposed differentiation cultures were treated from day 3 of the protocol 
onwards and sampled after 24h exposure (day 4) (eight replicates per group). 
The 24h exposure was chosen as the time point expressing the least variability 
between samples as observed in our earlier time-course study with the neuro-
developmental toxicant MeHg [177]. RNA from control differentiation cultures 
was sampled on protocol days 3 (eight replicates), 4 (five replicates), and 5 (five 
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Results
Concentration-dependent compound effects on viability and 
neurite outgrowth
ACE, CBZ, FLU, MEHP and PHE perturbed pluripotent mESC viability in a 
concentration-dependent manner, whereas PENG did not have an effect on cell 
viability up to a concentration of 1000 µM (Figure 1). Compound concentrations 
reducing cell viability by 20% (IC20) were 80.4 µM for ACE, 204.5 µM for 
CBZ, 12.9 µM for FLU, 572.4 µM for MEHP and 35.1 µM for PHE. On day 
11 in the assay, ACE, CBZ, MEHP and PHE significantly altered neural 
 differentiation in the ESTn at the highest concentration tested (Figure 1). FLU 
and PENG did not significantly impact neural differentiation at concentrations 
tested.
Genes and GO-biological processes regulated by compounds
Compound-induced differential gene expression was compared between 
exposed mESC neural differentiation cultures and time-matched control 
cultures, using one-way ANOVA (FDR<0.05). Test concentrations were at the 
ID50 for positive compounds or at the highest concentration tested for negative 
compounds, as well as concentrations 30 fold lower for each compound. Con-
centration-dependently, 1024, 687, 1574, 4, 3 and 55 genes were identified to 
be significantly regulated by ACE, CBZ, FLU, MEHP, PENG and PHE, 
respectively (Table 2A). For all compounds tested, the number of genes 
significantly differentially expressed was highest at the high concentration 
tested, as determined by post-hoc analysis. The most responsive compounds, 
ACE, CBZ and FLU showed significant commonalities in genes differentially 
expressed (for instance, ACE and FLU commonly regulated 339 genes) (Table 
2a). In total, 2639 unique genes were regulated by any of the compounds at 
any concentration tested. Hierarchical clustering of FC ratios for these 2639 
genes provided specific concentration-dependent gene expression patterns for 
each compound (Figure 2). 
Distribution of regulation of GO-terms among compounds
Enrichment of GO biological processes (p<0.01) by gene sets derived per 
compound was observed for ACE, CBZ and FLU. However, due to a limited 
number of genes regulated, MEHP, PENG and PHE exposure did not result in 
enrichment of any GO biological processes (Table 2B). Given differential gene 
expression changes across compounds, functional analysis using Tox-profiler 
was performed to identify significant quantitative changes at the level of 
GO-terms (Figure 3). By at least one compound and concentration of any of 
for Gene Ontology (GO) biological processes were studied using DAVID 
(http://david.abcc.ncifcrf.gov/) [162]. Significantly enriched GO categories 
were based on p<0.01. 
For pathway-level analysis, the expression of each gene was corrected for its 
timed control after which Tox-Profiler [99] was used to score the difference 
between the mean expression level of  GO biological processes and that of the 
remainder of the  20,979 probe sets defined earlier. Gene sets were significantly 
regulated if T > 4.0 and E < 0.05. The T-value is the value obtained by a T-test 
between the expression changes for a defined set of genes versus all other 
genes. The corresponding formula and other calculation details can be found 
in Boorsma et al., 2005 [99]. The E-value is the associated two-tailed P-value 
with Bonferroni correction for the number of gene sets tested. 
Hierarchical clustering of changes to control for all significantly differentially 
expressed genes (or subsets thereof selected on the basis of GO-terms) was 
performed in GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium), 
using Euclidean distance and Ward linkage. Venn diagrams describing relations 
of significant gene expression were created using Venny [214]. 
The effect of the highest concentration analyzed for gene expression changes 
per compound on gene expression was further studied using principal 
component analysis (PCA) by means of the differentiation track algorithm, as 
was described earlier [177, 187]. In this analysis, a principal component is 
defined as a mathematically derived combination of genes and their expression 
characteristics which can be used to depict part of the process observed. A 
number of principal components that are mutually independent can be derived 
which in combination describe the process under study. For the differentiation 
track algorithm, at first a gene list was defined, which comprised the genes that 
were identified to be significantly differentially expressed among mESC neural 
differentiation over time sampled at days 3, 4 and 5 of the mESC neural dif-
ferentiation protocol. PCA analysis was performed with these genes using R 
statistical software, resulting in a curve describing the differentiation track. A 
differentiation track derived on the basis of genes showing differential 
expression between day 3, day 4 and day 5 (FDR < 0.01, FC > 1.5) in the ESTn 
was used to describe compound effects on the track at day 4 (after 24h 
exposure). Limiting the analysis to genes showing a time-related change in 
expression in controls avoided the contribution of genes not regulated during 
neural differentiation in the ESTn. Coordinates along the first and second 
principal components were calculated for each sample.
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the six compounds, we identified 136 enriched GO-terms (T > 4, E < 0.05). 
Hierarchal clustering of enriched GO-terms produced three clusters of 
expression profiles and GO-term themes (indicated as clusters A, B and C in 
Figure 3). In general, GO-terms in cluster A were mostly up-regulated in a 
concentration dependent manner by the majority of the six compounds (Figure 
3A). For example, MEHP and PENG significantly regulated ion transport and 
oxidation reduction and FLU significantly regulated sterol- and cholesterol 
biosynthetic processes (FLU). GO-terms in cluster B were all down-regulated 
by compound exposures (Figure 3B). For instance, PHE down-regulated 
GO-terms in this cluster related to kinase activity, cell division, phosphoryla-
tion, ubiquitination and apoptosis, while FLU, MEHP, PENG and PHE 
down-regulated genes related to transcription. GO-terms in cluster C were 
up- or down-regulated in a compound- and concentration-dependent manner 
and mainly consisted of GO-terms related to development (60%) and 
transcription (14%). GO-terms were up-regulated by ACE and CBZ, and 
down-regulated by FLU, MEHP, PHE, whereas PENG only showed a limited 
number of GO-terms being significantly regulated related to transcription 
(Figure 3C). All terms in cluster C were upregulated by ACE, representing a 
broad range of general and specific organ development related GO-terms. 
MEHP and PHE both down-regulated general development and transcription 
related GO-terms, whereas MEHP specifically affected genes related to skeletal 
development and PHE specifically affected genes present in cardiovascular 
development and cell differentiation related GO-terms. 
Figure 1  Compound effects on viability (Resazurin cell viability assay) and morphological 
neuron outgrowth (ESTn).Concentration-response effects on cell viability in mESC 
(triangles) and concentration response effects on the percentage of EB with >75% 
neural outgrowth (circles). Smaller circles and triangles represent separate experiments. 
The large circles and triangles represent the geometric mean of experiments at the 
specific concentration. Curves were fit using PROAST software.
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Figure 2  Hierarchal clustering plot of all 2639 genes regulated concentration- dependently 
by any of the compounds (One-way ANOVA FDR<0.05, log2 scale). Number of genes 
regulated by each compound and number of GO biological processes enriched by these 
genes are presented under the hierarchal clustering.
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CFigure 3  Hierarchal clustering plot of T-values describing gene distribution shifts 
within GO biological processes. (White with grey lining = significantly up-regulated 
(T>4, E<0.05), Black = significantly down -regulated (T<-4, E<0.05), blue to grey to 
red: not-significant gradient of T-values). Figure 3   Continued
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Direction of gene expression within selected GO biological 
processes
We further evaluated gene expression changes within selected compound(s)-
specific enriched GO biological processes relevant for development. These 
included embryonic morphogenesis (Figure 4A), neuron differentiation (Figure 
4B), and wnt receptor signaling pathway (Figure 4C). In general, genes within 
these three processes were primarily regulated only after exposure to ACE, 
CBZ or FLU. Most genes associated with these processes were up-regulated by 
ACE and CBZ when down-regulated by FLU, and vice versa. For example, 
Pax6 was down-regulated by ACE and CBZ at the high concentration, but 
up-regulated by the high concentration FLU (Figure 4B). As a trend, MEHP, 
PENG and PHE gene expression direction followed FLU expression profiles, 
but changes were not significant due to variation between samples.  In addition, 
the GO-term sterol metabolic process was analyzed as a known specific target 
for flusilazole (Figure 4D). The GO biological process sterol metabolic process, 
was specifically significantly enriched by FLU and not by the other compounds. 
FLU up-regulated the expression of genes related to sterol metabolism (18 out 
of 19 genes).  
Compound induced deviation from the differentiation track
Compound effects on gene expression related to differentiation were visualized 
by PCA using the differentiation track algorithm (Figure 5). Genes significantly 
differentially expressed (FDR<0.01, FC>1.5) over time in control differentiation 
culture on days 3, 4 and 5 (4006 genes) were used to derive the differentiation 
track. Using these genes, for the location of each compound in the PCA was 
determined. In figure 5A, each separate control sample was plotted in the 
PCA and for exposed samples the mean of all samples (n=8) was shown. 
A magnification of the PCA is shown in figure 5B to highlight the deviation of 
the compound exposed samples from the day 4 control. ACE and CBZ findings 
indicated reduced differentiation on the track as compared to controls and 
PENG, whereas the remaining compounds tended to indicate enhanced 
 differentiation (to the lower right of the average day 4 control). The grouping 
of these compounds by PCA is comparable to the directional differences 
observed in gene expression changes.
Low versus  high concentration comparison for CBZ and FLU
Differences in compound effects on gene expression and GO biological process 
enrichment at the non-toxic versus differentiation-inhibiting concentrations 
tested were performed for CBZ and FLU. For CBZ of the 76 and 489 genes 
regulated at the low and high concentrations, respectively, 47 genes were 
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Figure 4  Genes significantly concentration-dependently expressed by at least two of 
the six compounds compared to control (FDR<0.05, log2 scale) for the GO biological 
processes A) Embryonic Morphogenesis, B) Neuron Differentiation, C) Wnt receptor 
signaling pathway and expressed by at least one of six compounds for D) Sterol 
Metabolic Process. Genes significantly changed are marked with A (ACE), C (CBZ) or 
F (FLU). No genes were significantly regulated by MEHP, PENG or PHE in any of the 
GO biological processes. Significant enrichment of the GO biological process by a 
compound as determined by DAVID is marked with * and significant distribution shift 
as determined by Tox-Profiler is marked with #. Number of genes regulated in the 
figure and in the GO biological process (in brackets) are displayed under each column.
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regulated at both concentrations (Figure 6A). FLU significantly regulated 95 
and 1185 genes at the low and high concentration, respectively, with 62 genes 
regulated at both concentrations (Figure 6B). CBZ enriched 2, 4 and 113 GO 
biological processes for low-specific, common and high-specific genes, respectively 
(Figure 6C). GO biological processes significantly enriched (p<0.05) by the 
low-specific and common genes included processes involved in methylation 
(histone methylation, chromosome modification) and transcription. For 
transcription, significance values were concentration-dependently increased, 
whereas for methylation related GO biological processes they were not. At the 
high concentration CBZ significantly regulated processes involved in general 
and organ development, neural development, transcription, cellular processes 
and metabolism. FLU enriched 0, 7 and 256 GO biological processes for 
low-specific, common and high-specific genes, respectively (Figure 6D). GO 
biological processes significantly enriched by the low-specific genes included 
processes involved in transcription and glucose metabolism. High-concentra-
tion specific significantly regulated genes related to enriched processes involved 
in general and organ development, neural development, transcription, cellular 
processes, metabolism and apoptosis. 
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Figure 5  Principal component analysis (PCA) presenting compound deviation from 
the differentiation track. A) PCA plot based on the 4006 genes significantly regulated 
over time on days 3 (red), 4 (yellow) and 5 (green) of the neural  differentiation protocol 
(FDR<0.01 and FC>1.5). Compound exposed cultures (mean of n=8 samples, triangles 
(in vivo neuro-developmental toxicants) and crosses (in vivo non-neuro-developmental 
toxicants)) are plotted in the PCA using the 4006 genes regulated over time. B) 
Magnification of the day 4 control samples and exposed samples (* = Compounds 
significantly deviating from the day 4 control (p<0.05)).
Figure 4   Continued
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Discussion
W e recently developed a neural differentiation variant of the classic cardiac EST, the ESTn, aimed at predicting neurodevelopmental toxicity, and 
conducted a series of studies investigating the potential implementation of 
transcriptomic analyses in the assay [142, 177]. Our data suggest that tran-
scriptomics implementation in the ESTn may provide added value information 
on compound-related mechanisms of action over time and concentration, 
which may improve predictivity. In the present study, we further examined the 
relationship between concentration-dependent transcriptomic responses and 
neural differentiation in the ESTn using six mechanistically diverse compounds. 
PENG appeared negative as expected, and the non-neurodevelopmental 
toxicant FLU inhibited neural differentiation at cytotoxic concentrations only. 
However, ACE, CBZ, MEHP and PHE induced inhibition of neural differen-
tiation at non-cytotoxic concentrations, in concordance with the known ability 
of these compounds to act as neural developmental toxicants in humans and/
or in vivo [204-207].
Equipotent concentrations were selected across compounds as determined by 
neural differentiation inhibition on day 11 in ESTn. In contrast, they showed 
different potencies as regards gene expression changes after 24h exposure. 
Concentration-dependently, ACE, CBZ and FLU induced robust changes with 
≥687 genes identified to be significantly altered, >10 fold more compared to 
MEHP and PHE. These differences in gene expression changes after 24h 
exposure may represent differing response time courses between compounds, 
which indicate possible differences in modes of action. Similar phenomena in 
compound potencies for the induction of differential gene expression have 
been described in the cardiac ESTc, zebrafish embryo toxicity test (ZET) and 
the rat whole embryo cultures (WEC) [81, 82, 215]. For example, in the ZET, 
for glycol-ether and triazole compounds tested at concentrations equally 
embryotoxic at 72h, glycol ethers induced >20 fold more genes than triazoles 
after 24h exposure, [215]. Consequently, dependent on the effectiveness in 
ESTn over time of the compound tested, the 24h exposure time point may or 
may not be optimal for the detection by transcriptomics of neurodevelopmen-
tal toxicity in the assay. Additional time-response studies for compounds less 
responsive at 24h may increase the sensitivity of this approach. 
The present study revealed no genes regulated by all of the embryotoxic 
compounds tested, which is obviously caused largely by the low gene expression 
response to MEHP and PHE. In addition, the overlap in genes regulated 
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Figure 6  Venn diagrams and hierarchal clustering plots describing overlap of genes 
significantly expressed compared to control (One-way ANOVA with post hoc t-test 
(FDR < 0.05))  at the low and high concentration tested. Venn diagrams present the 
number of genes regulated by the low concentration only, the high concentration only or 
both concentrations for A) CBZ (3 and 100 µM) and B) FLU (0.3 and 10 µM)). Hierarchal 
clustering plots describe GO-biological processes significantly enriched (p<0.05, ranked 
by general theme and by number changed) by low concentration only (L), the high 
concentrations only (H) or both concentrations (C) for C) CBZ and D) FLU.
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between any two compounds was also limited. Out of the six compounds, 
ACE and FLU shared the most overlap in gene expression changes (339 genes). 
On the other hand, genes regulated by both developmental neurotoxicants 
ACE and CBZ (177 genes) enriched 51 GO biological processes (p<0.01), 
mainly involved in (neural) development (n=21) and differentiation (n=12). In 
addition, genes within these processes (for instance neuron differentiation, 
figure 4B) were predominantly regulated in the same direction by both 
compounds. In contrast, the limited response to the neurodevelopmental 
toxicant PHE limited the overlap between PHE and ACE or CBZ (8 and 13 
genes, respectively) resulting in no common GO biological processes. The 
limited overlap between compound induced gene expression profiles suggests 
different modes of action and different toxicity pathways for the compounds 
used in this study. Transcriptomic studies examining multiple mechanistically 
diverse classes of compounds in WEC [82], ZET [216] and cardiac EST [81] 
support our observations of compound-induced specificity of signatures despite 
common morphological effects. For example, in the WEC, four compounds 
inducing similar neural tube defects at equipotent concentrations, showed 
distinct gene expression profiles and enriched developmental GO biological 
processes [82]. Within the top 1000 regulated genes, only 10-16% of the genes 
overlapped between any two compounds despite all four compounds inducing 
neural tube defects. Thus, distinct gene expression disruption profiles may 
underlie similar compound induced developmental defects. Therefore, gene set 
biomarkers for developmental toxicity should not only be based on common 
responses between embryotoxicants, but complementary responses should 
also be considered. This notion corroborates the concept of “pathways of 
toxicity”, as described in the trend setting US-NAS Report on toxicity testing 
in the 21st century [217]. Clearly, the challenge is in defining the critical 
“pathways of toxicity” for developmental toxicity, for which the current study 
provides another set of background data.  
Functionally relevant developmental pathways as represented in GO-terms 
appeared informative about compound-specific effects. Significant regulation 
was observed in the Wnt-receptor signaling pathway, important during 
neural tube formation [218]. In addition, embryonic morphogenesis and neural 
differentiation were regulated by ACE, CBZ and FLU, mainly including early 
development related genes (T, Wnt5a, Fgf8 and early Hox genes) and well known 
early neuroectodermal related genes such as Pax6 [219]. Interestingly, a number 
of gene clusters disrupted by ACE and CBZ were inversely regulated compared 
to FLU and to a lesser extent MEHP and PHE. On a more general level, this was 
also apparent in the differentiation track method, showing delayed differentiation 
induced by ACE and CBZ, whereas FLU and PHE treated cultures appeared 
ahead on the differentiation track. Similarly, as observed in the morphological 
test at day 11 of the ESTn, ACE and CBZ decreased neural differentiation 
concentration dependently, whereas FLU did not affect differentiation. These 
findings, observed at three distinct levels (morphology, gene expression and 
pathway level), further imply that different mechanisms of action are responsible 
for developmental toxicity between these compounds.
 
ACE, ethanol’s active metabolite which causes developmental toxicity, induces 
fetal alcohol spectrum disorder (FASD) in humans, encompassing a whole 
range of developmental defects, including effects on neurodevelopment [206]. 
In vitro, ACE in a concentration-dependent manner retarded embryonic 
growth by disrupting cell growth and differentiation in the WEC [220]. 
Possible mechanisms of action behind ACE induced developmental toxicity 
include disrupted cell-cell interactions, oxidative stress, growth factor signaling 
disruption and altered gene expression [206]. Pathway analysis of ACE 
exposure in the ESTn shows signs of many of the proposed ACE mechanisms 
of action being regulated, including the above stated disruption of genes 
involved in neural differentiation.
A comprehensive review of cohort studies examining the teratogenic effects of 
CBZ treatment during the first trimester in humans described a strong 
association between CBZ exposure and spina bifida [205]. Mechanisms of 
action of CBZ developmental toxicity remain poorly understood. In the present 
study, CBZ mainly regulated processes related to transcription and methylation, 
neural and blood vessel development and phosphorylation.
FLU exposure on gestational days 6-15 induced skeletal malformations and 
variations in mice, but no malformations related to neural development were 
reported [211]. However, in the WEC, delay in neuropore development and 
subtle effects on hindbrain segmentation, neural crest cell migration and 
cranial nerve abnormalities were detected after FLU exposure [221, 222]. FLU 
developmental toxicity may in part be explained through disruption of retinoic 
acid (RA) homeostasis. There is evidence that triazoles inhibit the catalytic 
activity of Cyp26 enzymes, which play an important role in RA degradation 
[223, 224]. Excess RA in the cell induces Cyp26a1 and Cyp26b1 gene 
expression in order to maintain RA homeostasis [225]. Changes in RA 
concentration may affect cell differentiation. FLU effects on Cyp26a1 and 
Cyp26b1 gene expression observed in the present study support this theory 
(Data not shown). Furthermore, in our study, FLU clearly induces genes 
involved in sterol- and cholesterol metabolic processes, being the triazole mode 
of action as antifungal agents. 
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Although only a limited number of genes were regulated by MEHP, PENG and 
PHE, pathway gene distribution analysis did provide additional insight in 
possible developmental toxicity and mechanisms of action of these compounds. 
MEHP and PHE both downregulated a number of developmental related 
pathways. Furthermore, MEHP and PENG mainly induced pathways related 
to ion transport and oxidation, while PHE mainly inhibited a range of pathways 
involved in transcription, cell cycle, phosphorylation, ubiquitination and cell 
death. 
The current knowledge on the diversity of in vivo mechanisms of action of the 
studied compounds is in line with the differences in gene expression profiles 
between compounds observed in the present study. It shows that the ESTn 
combined with transcriptomics can provide additional mechanistic information 
compared to the classical readout.
In this study, we additionally compared gene expression responses between a 
non-developmental toxic and a developmental toxic exposure concentration. 
This approach is in line with a recent proposal for validation of in vitro 
alternatives, in which not the compound per se but an “exposure”, defined as 
a compound concentration or dose, is classified as a developmental toxicant, 
[101]. Our design was aimed at distinguishing between adaptive and adverse 
responses at the gene expression level. With the increased sensitivity of 
innovative molecular techniques for effect assessment, this distinction has 
gained importance in view of interpreting findings for risk assessment [226]. 
We observed that CBZ and FLU at the low concentrations enriched pathways 
involved in transcription and compound metabolism. Additionally, the low 
concentration CBZ enriched histone methylation related processes which 
represent a known pharmacological mechanism of action of CBZ [227]. Genes 
regulated only at the highest concentration CBZ or FLU perturbed a range of 
developmental, transcription and cellular related processes. In addition, the 
FLU high concentration resulted in enriched developmentally related genes as 
well as sterol metabolism-related genes, the triazole mechanism of action for 
antifungal activity [228]. Recently, a number of concentration response studies 
have been performed in multiple models, attempting to distinguish adaptive 
and adverse compound effects [229, 230]. For instance, in rat nasal cells, at 
low concentrations formaldehyde regulated p53 pathways, followed at 
increasing concentrations by regulation of pathways involved in cell cycle, 
DNA damage and apoptosis [229]. Furthermore, a study in the cardiac EST 
described FLU concentration dependent mechanisms of action at the transcriptome 
level [230]. Effects on processes related to development were observed at lower 
concentrations than those related to sterol metabolism, followed by enrichment 
of cell cycle gene expression at even higher concentrations. Taken together, current 
evidence suggests that up to a certain level of induction, general physiological 
pathways such as related to transcription and metabolism may indicate 
adaptive responses, whereas the induction of developmental pathways may be 
more specifically indicating adverse responses. In addition, the magnitude of 
induction should be considered. More detailed studies will be needed to define 
the thresholds between adaptive and adverse responses in in vitro assays, in the 
interest of their interpretation in view of hazard and risk assessment. 
 C
ha
pter 6
An optimized gene set 
for transcriptomics based 
neurodevelopmental toxicity prediction 
in the neural embryonic stem cell test 
(ESTn)
Pennings JL, Theunissen PT and Piersma AH.
Toxicology (2012) 300(3):158-67.
CHAPTER 6 OPTIMIZED GENE SET FOR NEURODEVELOPMENTAL TOXICITY DETECTION IN ESTN
122 123
Introduction
T oxicological hazard identification is currently built upon animal test guidelines globally harmonized by the Organization for Economic 
Co-operation and Development (OECD). Under the new European chemical 
safety regulation (Regulation, Evaluation, and Authorization of Chemicals, 
REACH), reproductive and developmental toxicity studies are estimated to 
require approximately 60% of the number of animals needed for toxicity testing 
[12]. Therefore, increasing international research effort is put into developing 
alternative testing methods to predict reproductive and developmental toxicity, 
in order to allow for reduction, refinement and replacement of animal use. An 
in vitro developmental toxicity testing system validated by the European Centre 
for the Validation of Alternative Methods (ECVAM), is the embryonic stem cell 
test (EST) [17]. In the EST, compound developmental toxic effects on stem cell 
differentiation towards beating cardiomyocytes are determined. However, as 
the EST is primarily based on mesodermal-derived cardiomyocyte differentia-
tion, it is likely less predictive for compounds that disturb ectodermal or 
endodermal tissue development [17]. Given that a common target for 
developmental toxicity is the developing nervous system, an assay based on 
neural differentiation of embryonic stem cells can be particularly valuable to 
further improve in vitro prediction accuracy for these compounds. 
Building upon protocols described by Okabe et al. [52] and Bibel et al. [103], 
Theunissen et al. [142] designed a novel protocol for the neural embryonic stem 
cell test (ESTn). In this assay, mouse embryonic stem cells are stimulated 
towards multiple lineages of neural and other brain-associated cells by means of 
embryoid body formation, retinoic acid (RA) stimulation and serum deprivation. 
The potential of the ESTn in toxicity testing was demonstrated using the neuro-
developmental toxicant methylmercury chloride [142]. In subsequent studies 
performed in our lab, Theunissen et al. tested a range of compounds in the 
ESTn by means of microarray gene expression profiling [177, 203, 231]. These 
studies were motivated by the knowledge that molecular biological readout 
methods such as transcriptomics had already shown potential to improve the 
accuracy of the classic (cardiac) EST by providing more quantitative endpoints 
as well as providing mechanistic information [83, 232]. In these studies, also 
different time points [177] and compound concentrations [203, 231] were studied 
for both mechanistic comparisons between compound-induced responses as well 
as neuro develop mental toxicity prediction. 
The ‘differentiation track algorithm’ initially developed for classic EST tran-
scriptomics studies [83, 233, 234] was found to be applicable for toxicity 
prediction in the ESTn as well. This algorithm is based on (1) the finding that 
Abstract
T he murine neural embryonic stem cell test (ESTn) is an in vitro model for neuro developmental toxicity testing. Recent studies have shown that 
application of transcriptomics analyses in the ESTn is useful for obtaining more 
accurate predictions as well as mechanistic insights. Gene expression responses 
due to stem cell neural differentiation versus toxicant exposure could be 
distinguished using the Principal Component Analysis based differentiation 
track algorithm. In this study, we performed a de novo analysis on combined 
raw data (10 compounds, 19 exposures) from three previous transcriptomics 
studies to identify an optimized gene set for neurodevelopmental toxicity 
prediction in the ESTn. By evaluating predictions of 200,000 randomly selected 
gene sets, we identified genes which significantly contributed to the prediction 
reliability. A set of 100 genes was obtained, predominantly involved in (neural) 
development. Further stringency restrictions resulted in a set of 29 genes that 
allowed for 84% prediction accuracy (area under the curve 94%). We anticipate 
these gene sets will contribute to further improve ESTn transcriptomics studies 
aimed at compound risk assessment. 
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64 times below the high concentration) as a non-neuro develop mentally toxic 
‘adaptive phase’ control (no observed ESTn inhibition). This led to 218 out of 
314 samples being selected for further analyses. An overview of selected 
compounds and concentrations is given in Table 1.
All statistical calculations used in this study were performed in R (www.r-project.
org) [236] unless indicated otherwise. The algorithm for calculating p-values 
for differentiation track deviation has been described previously [83, 234]. 
Briefly, normalized gene expression data for a set of genes are log-transformed, 
and data for unexposed samples at 0h, 24h, and 48h, together with compound 
treatment samples at 24h, are used in a PCA. Coordinates along the first and 
second principal component are calculated for each sample. P-values for 
deviation of the 24h compound-exposed samples from the differentiation track 
are determined by applying a Hotelling T-test to these coordinates compared 
to those of the 24h control cultures. 
Gene set optimization
For the assembly of a predictive gene set for ESTn neural differentiation track 
deviation, we used a five-step approach that is largely analogous to an 
integrated analysis on EST cardiac differentiation transcriptomics data [84]. 
First, the data set was restricted to genes consistently regulated during (normal 
neural) differentiation in all three included data sets. For each study we selected 
the genes that showed significant differences in expression between the 
unexposed samples at 0h, 24h, and 48h (False Discovery Rate (FDR) 1%, 
Absolute Fold Ratio (AFR) > 1.25), after which we determined the intersection 
between these lists. This first step reduced the number of genes in the data set 
from 20979 (all annotated genes on the microarray) to 4579. 
Next, 200,000 randomly selected sets of 30 genes each were taken from the 
data set, so that each gene was sampled well over a 1000 times (average 1310 
± 36 times). For each gene set, we calculated the p-value for differentiation 
track deviation for each 24h compound exposed group, using the data of this 
group plus data of the matched 0, 24, and 48h unexposed groups from the 
same study. Unexposed 24h samples were used in the analysis as a time-matched 
reference group with (by definition) no differentiation track deviation. For 
each set, the calculated p-values for the various compound exposures were 
compared to their neuro develop mental toxicity (1 for yes, 0 for no) by 
calculating the Spearman (rank-based) correlation. The lower p-values have a 
more pronounced differentiation track deviation corresponding to neurodevel-
opmentally toxic exposures; therefore gene sets that have a strong negative 
correlation to the binary value for neurodevelopmental toxicity can be 
considered as most predictive. Genes in a gene set were scored as a hit if the 
a Principal Component Analysis (PCA) applied to expression data for different 
time points during embryonic stem cell differentiation results in a visualization 
that represents a ‘track’ of their chronological order [234, 235] and (2) that 
compound-induced differentiation perturbation leads to deviation from this 
track [234]. An important requirement for algorithm prediction accuracy is to 
base the calculations on a set of genes which are regulated by normal (unexposed) 
differentiation and/or toxicity-related compound exposure. For classic EST 
transcriptomics, several such gene sets have been described [40, 83]. By means 
of an integrated analysis combining microarray and toxicological data from 
multiple studies, Pennings et al. assembled an optimized gene set for developmental 
toxicity prediction on classic EST transcriptomics data [84]. This set outperformed 
previously obtained gene sets, allowing for 83% overall accuracy with all mis-
classifications being attributable to ineffective data [84].
In the present study, a similar integrated analysis is applied to ESTn transcrip-
tomics data from three previous studies [177, 203, 231]. By means of randomly 
sampling 200,000 gene sets and evaluating these in differentiation track algorithm 
toxicity prediction on 19 exposures using 10 compounds, genes significantly 
contributing to high prediction accuracy are determined. Following additional 
cross-validation, consistently high-scoring genes are combined into a novel gene 
set providing 84% accuracy for neurodevelopmental toxicity prediction.
Methods
Microarray samples and analysis
Methods and data regarding ESTn culture conditions, compound exposures, 
assessment of differentiation inhibition, and microarray transcriptional 
profiling have been described in full detail in previous publications from our 
group [142, 177, 203, 231]. Raw and normalized microarray data used in this 
study are available at ArrayExpress (www.ebi.ac.uk/ arrayexpress/), under 
accession numbers E-TABM-1108, E-TABM-1205, and E-TABM-1216. As the 
three data sets used are not fully identical in their experimental design 
regarding time points and concentrations, some restrictions were applied to 
ensure mutual comparability. Unexposed controls at 0, 24, and 48h after 
neural induction were included for each of the three studies; compound 
exposed samples at 24h were included for the highest concentration tested in 
the ESTn (ID50 for neurodevelopmental toxicants, maximally feasible 
concentration without affecting cellular viability for non-developmental 
toxicants) and, when available, the lowest exposure concentration tested (30 or 
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A network with gene, protein, and compound interactions was build in 
Cytoscape using data obtained from the STITCH database [239] (http://stitch.
embl.de/). We used the gene symbols in the ESTn_enriched set as input, to let 
the STITCH search tool determine mutual interactions among the input genes 
as well as proteins or chemicals that the STITCH search tool finds associated 
with them. This query was performed twice, using both mouse and human as 
organism and otherwise default settings. The network description output files 
for mouse and human were merged into a single network description file to 
remove redundancy. This file was combined with gene information from 
Supplementary Table 2 for visualization in Cytoscape [240].
Results
Gene set optimization and cross-validation
After evaluating 200,000 randomly selected gene sets for the prediction of 19 
exposure conditions, we found 100 genes to be significantly enriched among 
gene sets that show strong correlation between neuro develop mental toxicity 
and differentiation track deviation. These genes were combined into a novel 
gene set which we name ESTn_enriched (Table 2). Using this gene set, predicted 
differentiation track showed 74% agreement with observed or literature-based 
neurodevelopmental toxicity at a p-value cutoff of 0.05 (Table 1). Other 
prediction parameters support the predictive capacity of the gene set (AUC = 
0.90, R = −0.67).
Subsequent predictions using a leave-one-out cross-validation gave comparable 
p-values for most exposures as with the ESTn_enriched gene set. Overall 
accuracy here was 58%, with an AUC of 70% and an R of −0.34. Of the initial 
100 genes, 92 were found to be significantly enriched in a majority, and 29 
genes in all of the cross-validations. This latter, restricted, set was named 
ESTn_restricted (see upper part of Table 2) and largely corresponds to the 
genes in the former set that have the highest scoring ratios (Table 2, Figure 1). 
Predictions using the ESTn_restricted gene set showed an improved accuracy 
compared to those based on the ESTn_enriched set, as the accuracy was 84%, 
the AUC was 0.94 and the correlation was −0.74.
Biological characterization
PCA on ESTn_enriched set gene expression for the 0h, 24h, and 48h controls, 
together with the various 24h compound exposures, shows the differentiation 
track for normal (unexposed) differentiation (Figure 2). Compound exposures 
correlation for a gene set was less than −0.60, which corresponds to the top 
5% of the obtained correlations.
In the third step, after the correlations for 200,000 gene sets were determined, 
it was determined how many times each gene was sampled and how many 
times it had scored a hit (i.e. was part of the top 5% best predictive sets). This 
latter value was compared to the expected number of hits (i.e. 5% of the 
number of samplings). As for most of the genes this scoring ratio (actual hits / 
predicted hits) followed a Gaussian distribution, this distribution was used to 
determine which genes had a significantly higher ratio, at an FDR of 5%. All 
identified genes were combined in a set (ESTn_enriched) and track deviation 
p-values were calculated using this set. 
Fourth, a leave-one-out cross-validation (LOOCV) was carried out. This 
involved repeating the above procedure with each time one of the compound 
exposed groups left out and determining which genes were significantly 
enriched in the top 5% sets. These cross-validation gene sets were used to 
calculate the p-value for the left out group. Finally, those genes in the ESTn_
enriched set that were confirmed by all cross-validations were combined in a 
restricted gene set (ESTn_restricted), after which track deviation p-values were 
calculated using this set.
Further gene set analyses
The two obtained gene sets were evaluated for neurodevelopmental toxicity 
identification, using 19 compound/concentration exposure cultures from the 
data sets [177, 203, 231] and the differentiation track algorithm. Compound/
concentration combinations were considered neurodevelopmentally toxic if they 
showed significant deviation from the differentiation track (at p < 0.05) and as 
non-toxic otherwise. Additional accuracy evaluation was carried out by calculating 
the Area Under the Curve (AUC) for a Receiver Operating Characteristic (ROC) 
curve of p-values against the neurodevelopmental toxicity binary value. 
Gene expression changes during normal (unexposed) differentiation or 
between compound exposures and their matching control were visualized in R 
(using averaged values per experimental condition)by means of PCA or by 
hierarchical clustering (Euclidean distance, Ward linkage). 
Enrichment for Gene Ontology (GO) and other functional terms was determined 
using the DAVID Bioinformatics Resource website (http://david.abcc.ncifcrf.
gov) [237] using default settings. Additionally, an in-house developed R 
application (based on the DAVID methodology) was used to determine 
enrichment for literature gene sets such as the MSigDB curated from genomics 
literature [238] and a stem cell development literature database described 
earlier [234] updated with additional more recent literature gene sets.
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are positioned mostly close to the unexposed 24h control for the non-toxic 
exposures but deviate further from the track for toxic exposures (Figure 2). 
Visualization of compound-induced gene expression changes as compared to 
time-matched unexposed controls shows that, in general, higher compound 
exposure levels result in a stronger gene expression response (Figure 3). 
Functional enrichment analysis on the ESTn_enriched in DAVID showed 
significant enrichment for a number of GO terms related to neural development 
such as “neuron differentiation”, “neurogenesis”, “neural crest cell development”, 
“axonogenesis”, and “neuron recognition”; which together covered 18 genes in 
the set. Additionally, several other development related terms were enriched, 
such as “anterior/posterior pattern formation”, “embryonic morphogenesis”, 
“embryonic organ development”, “cell morphogenesis”, and “Wnt-signaling 
pathway” which, when combined, together comprise 30 genes. Also functional 
terms involving homeobox genes or domains were enriched (12 genes), as was the 
case for transcription (25 genes). These functional associations are summarized 
in Table 2. 
Table 1   Compound exposures and corresponding p-values obtained using  
the different gene sets. 
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mehgH 1 Methylmercury chloride 0.025 0.045 0.086 * 0.009 yes
cypL 2 Cyproconazole 1.5 0.300 0.154 0.280 no
cypH 2 Cyproconazole 100 0.379 * 0.624 * 0.160 * yes
hexL 2 Hexaconazole 0.4 0.472 0.530 0.548 no
hexH 2 Hexaconazole 25 0.454 0.004 * 0.587 no
vpaL 2 Valproic acid 15 0.442 0.282 0.305 no
vpaH 2 Valproic acid 1000 < 0.001 < 0.001 < 0.001 yes
aceL 3 Acetaldehyde 1 0.221 0.275 0.361 no
aceH 3 Acetaldehyde 30 0.006 0.009 0.009 yes
cbzL 3 Carbamazepine 3 0.746 0.707 0.815 no
cbzH 3 Carbamazepine 100 0.076 * 0.258 * 0.046 yes
fluL 3 Flusilazole 0.3 0.544 0.017 * 0.378 no
fluH 3 Flusilazole 10 0.002 0.002 0.002 yes
mehpL 3 Monoethylhexylphtalate 3 0.575 0.522 0.388 no
mehpH 3 Monoethylhexylphtalate 1000 0.006 0.019 < 0.001 yes
pengL 3 Penicillin G 30 0.554 0.502 0.568 no
pengH 3 Penicillin G 1000 0.036 * 0.018 * 0.035 * no
pheL 3 Phenytoin 1 0.024 * 0.016 * 0.020 * no
pheH 3 Phenytoin 30 0.055 * 0.228 * 0.045 yes
correct 14 11 16
% 73.7% 57.9% 84.2%
R -0.672 -0.336 -0.743
AUC 0.896 0.698 0.938
Incorrect classifications are marked with an asterisk
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Figure 1  Density plot for scoring ratios. Vertical ticks below the distribution curve 
indicate significance status of individual genes. Black, not significant; green, significantly 
enriched (FDR 5%); red, significant and also part of the ESTn_restricted set.
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Figure 2  Track visualization based on the ESTn_enriched gene set. (A) PCA for all 
experimental conditions (red, 0 h control; yellow, 24h control; green, 48h control; 
black, 24h toxic exposure; grey, 24h non-toxic exposure) (B) dashed cutout in detail.
Figure 3  Expression response to compound exposure for genes in the ESTn_enriched 
set. Peak expression time points are indicated along with gene symbols.
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Table 2   Genes in the ESTn_enriched set
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16842 2,502 yes Lef1 lymphoid enhancer binding factor 1 0h 0 1 0 1 1 0 11
67082 5,173 yes 1700011H14Rik RIKEN cDNA 1700011H14 gene 24h 0 0 0 0 0 0 0
72190 2,426 yes 2510009E07Rik RIKEN cDNA 2510009E07 gene 24h 0 0 0 0 1 0 0
12173 1,797 yes Bnc1 basonuclin 1 24h 0 0 0 1 0 0 0
14432 2,045 yes Gap43 growth associated protein 43 24h 1 1 0 0 0 0 3
15429 2,145 yes Hoxd1 homeobox D1 24h 0 1 1 1 1 1 1
17311 2,088 yes Kitl kit ligand 24h 1 0 0 0 0 0 12
16869 2,555 yes Lhx1 LIM homeobox protein 1 24h 1 1 1 1 1 1 3
27206 5,163 yes Nrk Nik related kinase 24h 0 0 0 0 0 0 0
18712 2,422 yes Pim1 proviral integration site 1 24h 0 0 0 0 0 0 2
269643 1,905 yes Ppp2r2c protein phosphatase 2 , regulatory 
 subunit B, gamma isoform
24h 0 0 0 0 0 0 2
106042 2,500 yes Prickle1 prickle homolog 1 (Drosophila) 24h 0 0 0 0 0 0 3
219151 2,794 yes Scara3 scavenger receptor class A, member 3 24h 0 0 0 0 1 1 0
20349 3,095 yes Sema3e semaphorin 3E 24h 1 1 0 0 0 0 2
21808 3,047 yes Tgfb2 transforming growth factor, beta 2 24h 1 1 0 0 1 1 8
21990 4,209 yes Tph1 tryptophan hydroxylase 1 24h 0 0 0 0 1 0 3
22418 3,689 yes Wnt5a wingless-related MMTV integration  
site 5A
24h 0 1 0 0 0 0 12
70441 3,243 yes 2610100L16Rik RIKEN cDNA 2610100L16 gene 48h 0 0 0 0 0 0 0
26358 2,697 yes Aldh1a7 aldehyde dehydrogenase family 1, 
 subfamily A7
48h 0 0 0 0 0 0 2
12903 4,656 yes Crabp1 cellular retinoic acid binding protein I 48h 0 0 0 0 0 0 6
14247 3,497 yes Fli1 Friend leukemia integration 1 48h 0 0 0 1 0 0 1
14462 2,158 yes Gata3 GATA binding protein 3 48h 0 0 0 1 0 0 5
15413 3,081 yes Hoxb5 homeobox B5 48h 0 1 1 1 1 0 1
15414 6,027 yes Hoxb6 homeobox B6 48h 0 1 1 1 1 0 1
16010 2,267 yes Igfbp4 insulin-like growth factor binding  
protein 4
48h 0 0 0 0 0 0 3
17294 2,145 yes Mest mesoderm specific transcript 48h 0 0 0 0 0 0 1
18186 2,319 yes Nrp1 neuropilin 1 48h 1 1 0 0 1 0 8
170676 2,729 yes Peg10 paternally expressed 10 48h 0 0 0 0 0 0 0
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Table 2   Continued
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22408 1,867 yes Wnt1 wingless-related MMTV integration site 1 48h 1 1 0 0 0 0 12
70415 1,677 no 2610018G03Rik RIKEN cDNA 2610018G03 gene 0h 0 0 0 0 0 0 0
11307 1,597 no Abcg1 ATP-binding cassette, sub-family G 
(WHITE), member 1
0h 0 0 0 0 0 0 2
72584 1,676 no Cul4b cullin 4B 0h 0 0 0 0 0 0 1
67603 1,642 no Dusp6 dual specificity phosphatase 6 0h 0 0 0 0 0 0 3
104156 1,694 no Etv5 ets variant gene 5 0h 0 0 0 1 0 0 3
14402 2,085 no Gabrb3 gamma-aminobutyric acid (GABA)  
A receptor, subunit beta 3
0h 1 0 0 0 0 0 1
226180 1,575 no Ina internexin neuronal intermediate filament 
protein, alpha
0h 1 1 0 0 0 0 0
16468 1,664 no Jarid2 jumonji, AT rich interactive domain 2 0h 0 1 0 1 0 0 1
100047943 1,906 no LOC100047943 similar to Ina protein 0h 0 0 0 0 0 0 0
26408 1,771 no Map3k5 mitogen-activated protein kinase kinase 
kinase 5
0h 0 0 0 0 0 0 1
17909 1,785 no Myo10 myosin X 0h 0 0 0 0 0 0 0
74035 1,732 no Nol9 nucleolar protein 9 0h 0 0 0 0 0 0 0
243771 1,915 no Parp12 poly (ADP-ribose) polymerase family, 
member 12
0h 0 0 0 0 0 0 1
236899 1,911 no Pcyt1b phosphate cytidylyltransferase 1,  
choline, beta isoform
0h 0 0 0 0 0 0 1
71801 2,076 no Plekhf2 pleckstrin homology domain containing, 
family F member 2
0h 0 0 0 0 0 0 0
228413 1,556 no Prrg4 proline rich Gla (G-carboxyglutamic 
acid) 4 (transmembrane)
0h 0 0 0 0 0 0 1
56532 1,648 no Ripk3 receptor-interacting serine-threonine 
kinase 3
0h 0 0 0 0 0 0 1
99377 2,150 no Sall4 sal-like 4 (Drosophila) 0h 0 1 0 1 0 0 5
21356 1,637 no Tapbp TAP binding protein 0h 0 0 0 0 0 0 0
57776 1,587 no Ttyh1 tweety homolog 1 (Drosophila) 0h 1 0 0 0 0 0 0
407812 1,567 no Zfp941 zinc finger protein 941 0h 0 0 0 1 0 0 0
11747 1,570 no Anxa5 annexin A5 24h 0 0 0 0 0 0 4
12350 1,880 no Car3 carbonic anhydrase 3 24h 0 0 0 0 0 0 0
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Table 2   Continued
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55987 1,691 no Cpxm2 carboxypeptidase X 2 (M14 family) 24h 0 0 0 0 0 0 0
12931 1,806 no Crlf1 cytokine receptor-like factor 1 24h 0 0 0 0 0 0 0
13082 1,977 no Cyp26a1 cytochrome P450, family 26, subfamily a, 
polypeptide 1
24h 1 1 0 0 0 0 7
73379 1,561 no Dcbld2 discoidin, CUB and LCCL domain  
containing 2
24h 0 0 0 0 0 0 1
17300 2,159 no Foxc1 forkhead box C1 24h 1 1 0 1 1 1 4
14472 2,493 no Gbx2 gastrulation brain homeobox 2 24h 1 1 1 1 1 1 3
15407 1,674 no Hoxb1 homeobox B1 24h 0 1 1 1 1 1 6
15426 2,212 no Hoxc8 homeobox C8 24h 1 1 1 1 0 0 2
15438 1,725 no Hoxd9 homeobox D9 24h 1 1 1 1 1 0 1
15980 2,394 no Ifngr2 interferon gamma receptor 2 24h 0 0 0 0 0 0 1
226856 1,732 no Lpgat1 lysophosphatidylglycerol  
acyltransferase 1
24h 0 0 0 0 0 0 1
328949 2,089 no Mcc mutated in colorectal cancers 24h 0 0 0 0 0 0 0
17395 2,389 no Mmp9 matrix metallopeptidase 9 24h 0 1 0 0 0 0 9
76626 2,093 no Msi2 Musashi homolog 2 (Drosophila) 24h 0 0 0 0 0 0 0
53627 2,589 no Porcn porcupine homolog (Drosophila) 24h 0 0 0 0 0 0 2
243548 1,558 no Prickle2 prickle homolog 2 (Drosophila) 24h 0 0 0 0 0 0 2
19283 1,643 no Ptprz1 protein tyrosine phosphatase, receptor 
type Z, polypeptide 1
24h 1 0 0 0 1 0 2
223881 1,731 no Rnd1 Rho family GTPase 1 24h 0 0 0 0 0 0 4
74442 1,655 no Sgms2 sphingomyelin synthase 2 24h 0 0 0 0 0 0 0
320145 1,601 no Sp8 trans-acting transcription factor 8 24h 0 1 0 0 0 0 0
20444 1,551 no St3gal2 ST3 beta-galactoside alpha-2,3- 
sialyltransferase 2
24h 0 0 0 0 0 0 0
20897 1,840 no Stra6 stimulated by retinoic acid gene 6 24h 0 0 0 0 0 0 4
99681 2,015 no Tchh trichohyalin 24h 0 0 0 0 0 0 0
66058 1,587 no Tmem176a transmembrane protein 176A 24h 0 0 0 0 0 0 1
65963 1,593 no Tmem176b transmembrane protein 176B 24h 0 0 0 0 0 0 1
100043272 1,809 no 5430417L22Rik RIKEN cDNA 5430417L22 gene 48h 0 0 0 0 0 0 0
320862 1,622 no A730054J21Rik RIKEN cDNA A730054J21 gene 48h 0 0 0 0 1 0 0
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Association with neural or stem cell development was also found among the 
most significantly enriched gene sets from literature gene set databases. The 
most significant among these were the “Pennings_Diff_Correlation” (19 genes) 
and “Pennings_Diff_crossval” (8 genes) sets from a previous gene set optimization 
on cardiac EST transcriptomics data [84]. Various other gene sets also showed 
significant enrichment, mainly those describing genes regulated during loss of 
self-renewal capacity [241-243]. From general omics literature gene sets, significant 
enrichment was found for the “Lee_Neural_Crest_Stem_Cell_Up” set that 
contains genes up-regulated in neural crest stem cells (NCS, defined as p75+/
HNK1+) [244], and the development-associated “cancer module 220” [245]. 
Table 2   Continued
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329154 1,600 no Ankrd44 ankyrin repeat domain 44 48h 0 0 0 0 0 0 0
65255 2,085 no Asb4 ankyrin repeat and SOCS box- 
containing 4
48h 0 0 0 0 1 1 1
12444 1,818 no Ccnd2 cyclin D2 48h 0 0 0 0 0 0 9
13713 1,772 no Elk3 ELK3, member of ETS oncogene family 48h 0 0 0 1 0 0 3
230904 1,592 no Fbxo2 F-box protein 2 48h 0 0 0 0 0 0 1
66569 1,667 no Gdpd1 glycerophosphodiester phosphodiesterase 
domain containing 1
48h 0 0 0 0 0 0 0
14622 1,585 no Gjb5 gap junction protein, beta 5 48h 0 1 0 0 0 0 0
73690 1,592 no Glipr1 GLI pathogenesis-related 1 (glioma) 48h 0 0 0 0 0 0 1
100036521 1,630 no Gm16039 predicted gene 16039 48h 0 0 0 0 0 0 0
14979 1,621 no H2-Ke6 H2-K region expressed gene 6 48h 0 0 0 1 0 0 0
15208 1,606 no Hes5 hairy and enhancer of split 5  
(Drosophila)
48h 1 1 0 1 0 0 2
15401 1,768 no Hoxa4 homeobox A4 48h 0 1 1 1 0 0 1
15416 2,958 no Hoxb8 homeobox B8 48h 0 1 1 1 0 0 2
15417 1,586 no Hoxb9 homeobox B9 48h 0 1 1 1 1 0 2
17701 1,764 no Msx1 homeobox, msh-like 1 48h 0 1 1 1 0 0 11
18072 1,669 no Nhlh2 nescient helix loop helix 2 48h 0 1 0 1 0 0 0
21664 1,563 no Phlda1 pleckstrin homology-like domain,  
family A, member 1
48h 0 0 0 0 1 0 2
24004 1,721 no Rai2 retinoic acid induced 2 48h 0 0 0 0 0 0 1
12309 1,656 no S100g S100 calcium binding protein G 48h 0 0 0 0 0 0 0
20346 1,573 no Sema3a semaphorin 3A 48h 1 1 0 0 0 0 7
22361 2,113 no Vnn1 vanin 1 48h 0 0 0 0 0 0 1
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Comparison of differential expression between normal (unexposed) ESTn time 
points showed that of the 100 genes in the ESTn_enriched set, 22 genes peaked 
at 0h, 43 peaked at 24h, and 35 peaked at 48h. For the ESTn_restricted set, 
these numbers were 1, 16, and 12, for 0h, 24h and 48h respectively (Table 2). 
We retrieved STITCH database interactions between proteins, genes, and 
compounds using the ESTn_enriched as input and visualized this into a 
molecular interaction network (Figure 4). This resulted in a network with 85 
nodes (proteins, genes, compounds) and 182 edges (interactions). Of the 
network nodes, 66 are genes in the ESTn_enriched set, with the STITCH tool 
adding 5 compounds and 14 proteins that meet its default interaction 
thresholds. When expression and cross-validation data (Table 2) is overlaid on 
the network, it can be seen that the network is tightly connected around nodes 
with a role in development. Retinoic acid, introduced in the network by 
STITCH interaction analysis, has a central position and the highest connectivity 
(31 edges) in the network. Among its interactions are those with RA-metabo-
lizing (Cyp26a1, Aldh1a7), and binding (Crabp1, Stra6) proteins, as well as 
several genes whose expression is affected by RA. Also in the network, other 
central positions and/or high connectivity can be found for genes involved in 
(stem cell) development such as Wnt5a, Wnt1, Ctnnb1, Pou5f1, Nanog, Lef1, 
and Msx1; growth factors (Tgfb2, Kitl, Igf1, Vegfa) and growth factor receptors 
(Kdr, Kit).
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Figure 4  Molecular interaction network based on STITCH interactions for genes in 
the ESTn_enriched set. Narrow lines indicate moderate evidence (STITCH score > 0.4) 
for interaction in either mouse OR human, wide lines strong evidence (> 0.7) in both 
mouse AND human. Nodes: red, 0 h peak expression; yellow, 24 h peak expression; 
green, 48 h peak expression; grey, protein added by STITCH; white, compound added 
by STITCH. Nodes shown as circles are only part of the ESTn_enriched set, nodes 
shown as diamonds are also part of the ESTn_restricted set.
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Figure 5  Examples of differentiation tracks for different misclassified compound 
exposures. Correctly classified valproic acid is shown in the upper left for comparison. 
Red circles, 0 h controls; yellow circles, 24 h controls; green circles, 48 h controls; black 
triangles, 24 h compound exposed samples. Labels are explained in Table 1.
CHAPTER 6 OPTIMIZED GENE SET FOR NEURODEVELOPMENTAL TOXICITY DETECTION IN ESTN
142 143
Discussion
I n a number of previous studies, we introduced the use of transcriptomics in the ESTn [177, 203, 231]. In these papers, we also showed that the differen-
tiation track algorithm previously developed for toxicity prediction in the 
classic (cardiac) EST, is effective in the ESTn as well. Given the possibilities for 
the ESTn as an alternative (neuro)developmental toxicity test system, further 
application of the differentiation track algorithm to the ESTn is of interest. 
Although current data are definitely not exhaustive, due to the wide range of 
molecular mechanisms and pathological outcomes known for neuro develop-
mental toxicity, the current three studies allow including data of 10 compounds 
in various concentrations amounting to 19 exposure conditions in an integrated 
analysis, which should provide an indication of the ESTn predictive potential 
at this moment. Moreover, such an integrated analysis would give an indication 
of which genes are most sensitive to different gene expression regulation by 
normal neural differentiation compared to neuro develop mental toxicant 
exposure, allowing focusing further research into in vitro screening assays.
The data used in this study contain both neurodevelopmental toxicants and 
non-toxicants (“positive” and “negative” compounds), but we also included 
exposures to non-toxic concentrations of neurodevelopmental toxicants as 
“negative” exposures. This is based on the notion that not the compound in 
itself but rather an “exposure”, defined as a compound concentration or dose, 
is considered as a (developmental) toxicant [101]. By including both toxic 
(adverse) as well as merely adaptive exposure levels, this distinction can be 
linked to the magnitude of gene expression perturbation [226], i.e. the 
magnitude of track deviation, leading to better insights into the interpretation 
of in vitro assay results for risk assessment. 
By sampling 200,000 gene sets and determining genes contributing to 
prediction accuracy, a set of 100 genes was obtained providing 74% prediction 
accuracy for the included data (p-value cutoff 0.05). Restricting the set by 
taking the intersection of cross-validation generated gene sets resulted in a 
smaller set of 29 genes providing 84% accuracy. 
Among the incorrectly predicted exposures, misclassification of cyproconazole 
might be attributed to its properties of both being able to induce or inhibit 
neural differentiation in vitro, depending on the concentration [15, 203]. A 
look at the other misclassified compound exposures indicates these can be 
considered as ‘borderline misclassified’, such as the high concentration 
carbamazepine (ESTn_enriched only), high concentration penicillin G (both 
gene sets) and high concentration phenytoin (ESTn_enriched only). Upon 
closer examination, it was found that such borderline p-values correspond to a 
low magnitude of track deviation (see for examples with the ESTn_restricted 
gene set Figure 5). In such cases, a borderline magnitude of the deviation 
(between 24 h exposed and control) might not lead to a correctly predicting 
p-value due to potential differences in intersample variation [84], indicating 
that such p-values should be considered with more caution than more clear-cut 
positive or negative p-values. 
The biological relevance of the ESTn_enriched gene set is reflected in its 
functional enrichment for (neuro)developmental terms from GO as well as 
additional databases. For two thirds of these genes, a STITCH interaction was 
retrieved which, when visualized as a molecular interaction network (Figure 
4), resulted in a compact network (diameter 7 links) that is strongly 
interconnected and built around a number of regulatory hubs in its center. The 
central position of RA and its high number of interactions (31, versus network 
average 4.3) corroborates the pivotal role of RA as a morphogen in the neural 
differentiation induction in the ESTn. Several additional network hubs are 
known as genes or proteins involved in development or growth, and are either 
part of the ESTn_enriched set or have STITCH interactions with several of 
them (Figure 4, Table 2). Several relatively peripheral nodes added by STITCH 
are of interest in neural development as well, including the neurotransmitter 
serotonin, two plexin genes (Plxna1 and Plxnb1) involved in axon guidance 
[246-248], and Slc6a15 which belongs to a family of neurotransmitter 
(precursor) transporters [249, 250] and has been associated with susceptibility 
to major depression [251]. Furthermore, cholesterol is of importance during 
early embryogenesis and deficiencies in its metabolism have been associated 
with a range of (neuro)developmental effects [82, 252-256]. For most of the 
proteins added by STITCH, we found no significant gene expression changes 
during normal neural differentiation, and all of them showed only weak 
expression changes upon compound exposure (data not shown). This is in line 
with the finding that these genes are not found the be predictive in our ESTn 
model system. Instead, for these added nodes, the literature evidence for their 
developmental function and interactions with ESTn_enriched genes should be 
interpreted as supportive evidence for the functional relevance of the network 
genes in neural differentiation. Altogether, the molecular concept network 
supports the observation that the majority of genes in the ESTn_enriched are 
directly or indirectly involved in (neural) development.
During unexposed differentiation in control cultures over time, the 100 genes 
regulated in the ESTn_enriched gene set peak in their expression at different 
time points, which is consistent with one of the principles behind the differen-
tiation track algorithm, namely allowing for continuous data visualization 
across a larger time window. Nevertheless, genes with an expression peak at 
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24h are somewhat overrepresented (43/100 genes). This overrepresentation is 
also apparent in the more stringent ESTn_restricted set with 16 out of 29 genes 
having their highest expression at 24h. Such enrichment was not found in the 
Pennings_Diff_Correlation set obtained by a similar analysis on classic 
(cardiac) EST transcriptomics, where 24 and 48h expression peaks (or those in 
between) were approximately equally present. Although comparative data 
between time points are limited, this emphasis on genes peaking at 24h is in 
line with our finding that the transient gene expression changes at 24h are 
clearly more sensitive to perturbation by methylmercury chloride compared to 
later time points in the ESTn [177]. For cardiac differentiation data after 24 
and 96h exposure to monobutyl phthalate and 6-aminonicotinamide, the 24h 
time point was the more sensitive to transcriptomics changes, although the 
difference with the later time point was less pronounced [234]. 
The algorithms for gene set optimization and differentiation track definition 
are not based on a premise of similar gene expression responses across multiple 
compounds as there is increasing evidence that (neuro)developmental toxicity 
can occur through different effects on the transcriptome [82, 203, 231]. In 
fact, the key to the algorithm is that a set of genes whose expression is regulated 
during normal differentiation might (additionally) each be regulated in a 
different manner by different toxic compound exposure, provided the extent 
of overall gene expression perturbation is predictive for (neuro)developmental 
toxicity (see for examples Figure 2, Figure 3 or the figures in [83, 234]). As the 
range of compounds tested vary considerably in mode of action regarding 
(neuro)developmental toxicity, gene expression changes for the various 
exposures to their matched control were also observed to be different (both 
qualitatively and quantitatively). Nevertheless, some similarities were found 
that are worth mentioning. Effects on RA-dependent genes by high 
concentrations of the three triazole compounds (flusilazole, cyproconazole and 
hexaconazole), such as their induction of Cyp26a1, Aldh1a7, and Rai2, are in 
agreement with the hypothesis that the triazole teratogenic mode of action lies 
in inhibiting common enzymes involved in RA metabolism, leading to 
disrupted RA homeostasis [225]. It should be noted that hexaconazole has 
developmentally toxic properties in causing skeletal malformations in rats, 
however no specific effects on neural development have been observed in vivo 
or in vitro [15, 257]. Similarities between acetaldehyde, carbamazepine and – 
to a lesser extent – also valproic acid are also present. However, these cannot 
be linked to a structural similarity, although it might be noted that these 
compounds have all been associated with neural tube defects. Although 
compound response comparisons are not the primary purpose of this study, 
these similarities do indicate the possibility of deriving gene expression 
signatures for specific structural or phenotypic classes of (neuro) develop mental 
toxicants and linking these to toxicity pathways [81, 203, 215, 231, 258-260]. 
Such signatures would be of additional interest for compound screening and 
risk assessment. 
In summary, we have combined data from three transcriptomics studies in a 
single new analysis to identify an optimized gene set for neurodevelopmental 
toxicity prediction in the ESTn. This gene set allows for 84% prediction 
accuracy and consists mainly of genes involved in (neural) developmental 
processes. We anticipate this set will prove to be helpful to further improve 
studies into the ESTn as an in vitro assay for compound risk assessment.
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Introduction
C urrent chemical hazard assessment for developmental toxicity is built upon globally harmonized OECD animal test guidelines, providing a 
structure for chemical risk assessment. Under the current European chemical 
safety regulation guidelines (REACH, Regulation, Evaluation and Authorization 
of Chemicals), approximately 60% of the animals used for toxicity testing are 
estimated to be required for reproductive and developmental toxicity studies 
[261]. In order to reduce the number of experimental animals needed for 
developmental toxicity testing, alternative test systems have been developed, 
including the embryonic stem cell test (EST) [17]. In this test system compound 
perturbation of mouse embryonic stem cell (ESC) differentiation into cardio-
myocytes is determined by manually counting beating cell foci. In the first in-
ter-laboratory EST validation tests, performed under supervision of the 
European Centre for Validation of Alternative Methods (ECVAM), the model 
predicted compound developmental toxicity with an overall accuracy of 78%. 
However, one of the compounds misclassified in four out of eight experiments 
was methylmercury (MeHg), a model neurodevelopmental toxicant [17]. In 
workshops following the validation studies, attempts were made to discern the 
applicability domain of the EST and to determine the improvements deemed 
necessary to increase prediction and throughput of the EST [36, 37]. Proposed 
improvements included integration of objective molecular parameters into 
the EST as predictors for developmental toxicity and development of ESC 
developmental toxicity assays using alternative differentiation methods into 
the ectodermal and endodermal lineage, including neural differentiation [36, 
37].
Previously, we developed a neural variant of the cardiac differentiation EST 
(ESTc), the neural embryonic stem cell test (ESTn) [142]. The ESTn was designed 
to complement the ESTc and therefore, culture methods were kept comparable 
to the ESTc, including embryoid body (EB) formation using hanging drop 
culture, EB suspension phase and plating of the EB [142]. In order to promote 
neural differentiation and repress mesodermal differentiation, a physiological 
concentration of 0.5 µM all-trans retinoic acid (RA) was added to the culture 
during the suspension phase [262]. In addition, medium serum deprivation was 
used to further select for neural differentiated cell types.
In order to characterize the ESTn and ESTc, transcriptomics studies were 
performed, analyzing global gene expression patterns in both models over time 
[40, 177, 187]. These studies formed the basis for the differentiation track, 
using principal component analysis (PCA) to describe differentiation over time 
in both models [187]. Furthermore, transcriptomics was used to study effects 
Abstract
I n developmental toxicity testing, in vitro screening assays are highly needed to increase efficiency and to reduce animal use. A promising in vitro assay 
is the cardiac mouse embryonic stem cell test (ESTc), in which the effect of 
developmental toxicants on cardiomyocyte differentiation is assessed. Recently 
we developed a neural differentiation variant of the stem cell test (ESTn), and 
performed transcriptomic studies to characterize both ESTn and ESTc over 
time and to detect developmental toxicity in both models. Here, we compare 
the gene expression profiles of ESTn and ESTc over time in both methods as 
well as model-specific changes induced by seven compounds, comprising six in 
vivo developmental toxicants. Time-related gene expression profiles showed 
similarities between the two models. However, groups of genes could be 
identified responding differently in each model, mainly related to cardiac 
development in ESTc and neural development in ESTn, indicating characteristic 
differences between ESTn and ESTc. Furthermore, compound-induced gene 
expression changes were generally different in either model, such as for 
methylmercury and flusilazole, which were predicted better in ESTn and in 
ESTc, respectively. In addition, VPA induced gene expression changes were 
comparable in both ESTn and ESTc, but varied at the process level. This 
indicates that both ESTn and ESTc results complement each other. Therefore, 
a combined approach incorporating ESTc and ESTn may improve developmental 
toxicant detection over individual assays. 
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data used in this study are available at ArrayExpress (www.ebi.ac.uk/), under 
accession numbers E-MTAB-300, E-TABM-1027, E-TABM-1108, E-TABM- 
1205, and E-TABM-1216. As the five data sets used are not fully identical in 
experimental design regarding time- and concentration points, some restrictions 
were applied regarding comparable time-courses and exposure scenarios, to 
ensure comparability.  Unexposed controls at 0, 24, and 48 h, calculated from 
3 days after the start of the protocols, were included for each of the five studies; 
compound exposed samples at 24h were included for compounds studied in 
both ESTc and ESTn at the concentration resulting in a 50% inhibition of dif-
ferentiation (ID50) for developmental toxicants or a maximally feasible 
concentration without affecting cellular viability for non-developmental 
toxicants. This led to 246 out of 555 samples being selected for further 
analyses. An overview of selected compounds and concentrations is provided 
in Table 1. All statistical calculations used in this study were performed in R 
(http://www.R-project.org) unless indicated otherwise. 
Data Analysis and Statistics
Affymetrix CEL files were normalized using the Robust Multichip Average (RMA) 
algorithm   [158] using  RMAexpress [159]. For probe to gene mapping, a custom 
Chip Description File (CDF) was used according to the assembly by de Leeuw et 
al. [160] (http://mad-db.science.uva.nl/~wdeleeuw/HybridAnnot/version6.html). 
Of the hybrid probe-set definitions included in the custom annotation, 16,331 
probe sets defined by the Brainarray custom CDF version 11 (http://brainarray.
of known developmentally toxic compounds on cardiac and neural differentiation 
in ESTc and ESTn, respectively [83, 155, 177, 203, 263]. Compound effects on 
gene expression were determined using the differentiation track algorithm by 
calculating the deviation of 24h exposed samples to the differentiation track 
consisting of 0h (day 3), 24h (day 4) and 48h (day 5) control samples [187]. 
Using this approach, developmental toxicity of 17 and 10 compounds has been 
evaluated in ESTc and ESTn, respectively, of which 7 compounds have been 
tested in both models [83, 155, 177, 203, 263]. Due to the similarities in design 
between ESTc and ESTn and comparable exposure scenarios using the differ-
entiation track algorithm, comparisons between the two models are straight-
forward. In this study, we aim to characterize differences and similarities in 
global gene expression changes between the ESTc and ESTn systems over time 
in control and exposed situations. 
Materials and Methods 
Microarray samples and analysis
Methods and data regarding ESTc and ESTn culture conditions, compound 
exposures, assessment of differentiation inhibition, and microarray transcriptional 
profiling have been described in full detail in previous publications by our 
group [83, 155, 177, 203, 263]. Raw and normalized Affymetrix microarray 
Table 1   Included data for compounds tested and numbers of genes regulated
ESTn ESTc
Compound Abbreviation
In vivo
classification Concentration
Concentration
Selection
# genes 
regulated
FDR<0.05; 
p<0.001 Concentration
Concentration
Selection
# genes 
regulated
FDR<0.05; 
p<0.001 Overlap % in ESTn % in ESTc
Carbamazepine CBZ Teratogen / NDT 100 uM ID50 531 160 uM ID50 1117 148 28% 13%
Flusilazole FLU Teratogen 10 uM IC20 994 5.4 uM ID50 588 105 11% 18%
Hexaconazole HEX Teratogen 25 uM IC20 1028 21 uM ID50 687 90 9% 13%
Methylmercury MeHg NDT 0.025 uM ID50 618 0.48 uM ID50 605 33 5% 5%
Monoethylhexylphthalate MEHP Teratogen 100 uM ID50 16 680 uM ID50 844 4 25% 0%
Penicillin G PenG Non-Teratogen 1000 uM Max conc 1 1100 uM Max conc 536 0 0% 0%
Valproic acid VPA Teratogen / NDT 1000 uM ID50 1925 800 uM ID50 4133 919 48% 22%
NDT: Neurodevelopmental Toxicant
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Gene expression differences between ESTn and the ESTc were further 
characterized using principal component analysis (PCA) to visualize them as a 
differentiation track, as was described earlier [187]. In this analysis, a principal 
component is defined as a mathematically derived combination of genes and 
their expression characteristics which can be used to depict part of the process 
observed. A number of principal components that are mutually independent 
can be derived which in combination describe the process under study. For the 
differentiation track comparison was based on those identified to be 
significantly differentially expressed in all three ESTn experiments or both 
ESTc experiments during differentiation over time sampled at days 3, 4 and 5 
(FDR < 0.01, FC > 1.5). PCA analysis was performed with these genes, resulting 
in two curves describing the differentiation track for either ESTn or ESTc. 
A network with gene, protein and compound interactions was built in 
Cytoscape using data obtained from the STITCH database [239] (http://stitch.
embl.de/). We used the gene symbols enriched in clusters B and G as input, to 
let the STITCH search tool determine mutual interactions among the input 
genes as well as proteins and chemicals that the STITCH search tool finds 
associated with them. This query was performed using the mouse as organism, 
a confidence score of 0.300 and otherwise default settings. STITCH output 
files were reformatted for input and visualization in Cytoscape [240].
Results
Selection of genes regulated over time in ESTn and ESTc
Genes significantly regulated over time (day 3, day 4 and day 5 of the protocols; 
FDR < 0.01; FC > 1.5) in the ESTn and ESTc were determined for three and 
two separate experiments, respectively (Figure 1A). In the three ESTn 
experiments, 3297, 3903 and 3977 genes were regulated over time, of which 
2453 were commonly regulated over three experiments. In the two ESTc 
experiments, 3509 and 3754 genes were regulated time-dependently, of which 
2675 were commonly regulated in both experiments. The 2675 and 2453 genes 
commonly regulated in the ESTc and ESTn, respectively, were used for further 
analysis, leading up to a combined total of 3648 genes to be further analyzed. 
In total, 1480 genes were commonly significantly regulated over time in both 
models, comprising 60% of ESTn and 55% of ESTc temporally regulated 
genes, respectively.
mbni.med.umich.edu/Brainarray/Database/CustomCDF) [161] and 4648 
additional probe sets defined by Affymetrix chip annotation 26 were used in 
further analyses, giving a total of 20,979 probe sets. Probe sets for Affymetrix 
internal controls or probe sets that did not correspond to an Entrez Gene ID were 
not used in further analyses. For each gene, maximal fold change (FC) in gene 
expression between the experimental groups were determined by comparing the 
average normalized signal values per group and were calculated as the maximum/
minimum ratio. For gene expression over time, samples were compared to the 
mean expression of all time samples. For compound toxicity effects, the treated 
samples were compared to the time matched day 4 controls. Genes differentially 
expressed between any of the experimental groups were identified by a one-way 
ANOVA. A significance threshold with a false discovery rate (FDR) of FDR < 0.01 
and FC > 1.5 was used to select genes significantly differentially expressed over 
time. Genes expressed over time in all three ESTn and/or both ESTc experiments 
were used for further analysis (Figure 1A). Genes regulated over time were ranked 
using hierarchal clustering and definition of gene expression clusters with a similar 
expression profile over time was performed using a hierarchal clustering branching 
cutoff at 10 branches. A significance threshold of FDR < 0.05 and p < 0.001 was 
used to select genes significantly differentially expressed due to compound 
exposure compared to the day-matched control. For further analysis of gene 
expression changes by specific compounds (FLU, MeHg and VPA) all genes 
significantly regulated by the compound were included (FDR < 0.05 and p < 
0.001), without the additional time criteria. Hierarchical clustering of changes to 
control for all significantly differentially expressed genes was performed in 
GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium), using Euclidean 
distance and Ward linkage. Venn diagrams describing relations of significant gene 
expression were created using Venny [214].
Functional annotation and enrichment for Gene Ontology biological processes 
(GOBP) were studied using DAVID (http://david.abcc.ncifcrf.gov/) [92]. 
Significantly enriched GOBP categories were based on a set criteria of p-value (p < 
0.01), and genes changed within each specific gene ontology category (> 5). In 
order to visualize GOBP enrichment, GOBP were separated into the following 
groups: “general development” (including broad developmental terms not 
describing specific organs or cell types), “neural development”, “cardiac/
vasculature and mesenchymal development”, “other development” (including 
development and differentiation related to organs and cell types other than neural 
or cardiac), “transcription”, “metabolic, biosynthetic and catabolic processes” 
and “other” GOBP (including all GOBP not involved in the earlier defined criteria). 
Involvement of individual genes in these pathways was determined at GeneCards 
(www.genecards.org) [90]. 
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Cdx2) and other organ/cellular development (9 genes) (GATA6, Foxc1, Foxc2, 
Igf2). In addition, 8 genes were involved in neural development, of which 4 
genes were also involved in cardiac development (Cfc1, Snai2, Gpr124 and 
Hey2). Furthermore, in cluster B, all 77 genes were significantly regulated over 
time in ESTc and 46 of these genes were also significantly regulated in ESTn. 
Genes regulated over time in ESTn showed a much lower FC compared to FC 
in ESTc. Genes in cluster G were mainly homeobox genes (24 genes) (e.g. 
Hoxb, Hoxc and Hoxd family genes, Pax3, Pax6, Mnx1), involved in neural 
development (10 genes) (e.g. Col2a1, Foxd1) and retinoic acid signaling (9 
genes) ( e.g. Crabp1, Cyp26b1, Nr2f1, Rarb). In cluster G, all 70 genes were 
significantly regulated over time in ESTn and 49 of these genes were also 
significantly regulated in ESTc. Genes regulated over time in ESTc showed a 
much lower FC compared to that in the ESTn. Furthermore, genes significantly 
regulated by both ESTn and ESTc were upregulated from day 4 onwards in 
ESTn, but only upregulated on day 5 in ESTc.
In order to investigate functional connections between the genes within clusters 
B and G, interaction maps were constructed using STITCH and Cytoscape. 
Approximately 70% of the genes in both clusters were involved in the 
interaction mapping. For cluster B, genes involved with Wnt-, BMP- and TGFβ-
signalling pathways clustered together, with cardiac, vasculature and mesoderm 
differentiation related genes mainly connected to these genes. In cluster G, 
genes were mainly connected to RA, which was added by STITCH as a highly 
associated compound, and consisted mainly of RA signaling and homeobox 
genes, whereas genes related to neural development were connected at the rim 
of the network (Figure 1G and figure 1H).
Common and unique gene expression changes between ESTn 
and ESTc
Common and model-specific global gene expression changes over time in ESTn 
and ESTc were investigated. Changes of time-dependent gene expression were 
visualized using PCA (Figure 1B). The first and second principal components 
(PC1 and PC2) together were responsible for 71% of gene expression variation. 
Day 3 samples of all experiments, both ESTn and ESTc, clustered together. 
Day 4 and day 5 samples followed distinct separate paths corresponding to 
differences in the ESTn versus ESTc differentiation culture conditions. For 
each time-point in both models, samples clustered together, demonstrating 
limited variation within and among experiments in both models. Hierarchal 
clustering of the 3648 genes regulated by either ESTn and/or ESTc is shown in 
figure 1C. Ten gene clusters were identified, each describing distinct patterns of 
gene expression changes over time in both ESTn and ESTc. For instance, 
clusters B, D and E were mainly regulated over time in ESTc (17% of all 
time-regulated genes), while clusters F and G were mainly regulated over time 
in the ESTn (12% of all time-regulated genes). Furthermore, clusters A, C, H, 
I and J showed similar gene expression responses over time for both models, 
indicating these genes are involved in processes regulated in both models, 
independent of different culture conditions. Number of genes and number of 
GOBP regulated varied between clusters. GOBP enrichment analysis of genes 
regulated within the clusters showed that in all clusters a substantial part of 
enriched GOBP was involved in General Development, Transcription and 
Metabolic Processes (Figure 1D). In addition, GOBP in cluster H were enriched 
for cell death and apoptosis. Specifically, the number of GOBP related to neural 
development were enriched in clusters A-G, and most prominently in cluster F, 
whereas GOBP related to cardiac, vasculature and/or mesenchyme development 
were enriched in clusters A-F, most prominently in clusters B and D. The 
increased amount of enriched GOBP related to neural (cluster G) and cardiac 
(clusters B and D) related development was in correspondence with the gene 
expression profiles in these clusters as observed in figure 1C. 
Further analysis of the two most responsive clusters B and G was performed at 
the gene expression level (Figures 1E and 1F). These clusters contained the 
fewest genes regulated as compared to other clusters, but were enriched for a 
relatively large number of GOBP (86 and 47). Genes in cluster B were involved 
in cardiac, vasculature or mesenchymal development (23 genes) (e.g. Myl7, 
Mesp2 and Nrp1), development related signaling pathways (15 genes), including 
the TGFβ-signaling pathway (e.g. Bmp2, Bmp7, Fgf3, Fgfb2), Wnt-signaling 
pathway (Wnt2, Wnt5a, Frzb) and homeobox gene expression (Lhx1, Msx2, 
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Figure 1  Time-related gene expression changes in ESTn and ESTc. A) number of genes 
regulated over time (day 3, 4 and 5) in three ESTn experiments and two ESTc experiments 
(FDR < 0.01; FC > 1.5). Genes (3648) expressed in all three ESTn experiments and in 
both ESTc experiments were used for further analysis. B) PCA of samples taken at days 
3, 4 and 5 in ESTn and ESTc, comprising 3648 genes regulated by ESTn and/or ESTc, 
describing the differentiation tracks for ESTn and ESTc experiments. C) Hierarchal 
clustering of the 3648 genes regulated over time in either model. The average gene 
expression of the top ten clusters (A-J) is provided for each experiment. Number of 
genes per cluster and GOBP regulated by these clusters are provided. D) Number of 
GOBP regulated in each cluster related to general development, neural development, 
cardiac/vasculature/mesodermal development, other organ/cell development, cell death 
and apoptosis, transcription, metabolic/biosynthetic/catabolic processes or other 
processes. E) Genes regulated in clusters B and G. Gene order is based on hierarchal 
clustering in figure 1C. Gene expression, function and significance (ESTn = grey, ESTc 
= black) are shown.
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Figure 1  Molecular interaction network based on STITCH interactions for genes in 
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not in ESTn (FDR 0.07 and 0.23, respectively). Further analysis showed that 
all significantly regulated genes within the GOBP Mesoderm Formation (20 
genes) were part of the Gastrulation GOBP (data not shown). Four GOBP 
related to transcription, including the GOBP Transcription itself, were more 
significantly enriched in the ESTn (FDR 4.1*10-13) compared to the ESTc (FDR 
1.0*10-4). 
Compound- and time induced gene expression changes in ESTn 
and ESTc
In total, seven compounds previously studied for developmental toxicity in the 
ESTn and ESTc using a comparable transcriptomic approach were included in 
the analysis (Table 1) [83, 155, 177, 203, 263]. Ideally, concentrations at which 
compound effects were compared between assays were equipotent (ID50) in 
terms of morphological end point of ESTn and ESTc, respectively. For all 
compounds equipotent concentrations were within the same order of magnitude 
in both assays, except for MeHg, which appeared over an order of magnitude 
more potent in ESTn as compared to ESTc. For flusilazole and hexaconazole, 
in ESTn cytotoxicity occurred at concentrations lower than those at which 
effects on differentiation were observed. Therefore, for these two compounds, 
the IC20 in ESTn was used for comparison with ESTc to compare similar 
effective concentrations in both assays and to avoid the analysis being 
dominated by cell viability-related genes rather than differentiation-related 
genes. The number of genes regulated by a compound in (48% of genes 
regulated in ESTn and 22% of those regulated in ESTc). MeHg induced gene 
expression showed a low overlap, with only 33 genes regulated by both models 
(5% of genes regulated in both ESTc and ESTn), despite a similar number of 
genes regulated in both models. In total, 6748 and 9380 genes (FDR < 0.05) 
were significantly regulated by any compound in ESTn or ESTc, respectively. 
Furthermore, of these compound-regulated genes, 1718 and 1808 genes were 
additionally regulated over time in ESTn or ESTc, respectively (Figure 3A). 
Genes in these sets were therefore involved in differentiation in either model 
and regulated by at least one compound. In total, 2720 genes were regulated 
time-dependently and by at least one compound in both ESTn and ESTc. Gene 
expression profiles of these 2720 genes are shown as a hierarchal clustering 
plot in figure 3B. 
To further illustrate differences in compound induced gene expression changes 
between the two models, compound specific effects of MeHg, FLU and VPA 
on gene expression in ESTn and ESTc are shown (Figure 4). MeHg and FLU 
both induced dissimilar gene expression profiles in ESTn and ESTc, with only 
limited overlap in significantly altered genes between models (Table 1). When 
GOBP enrichment over time in ESTn and ESTc
Differences in significance of GOBP enrichment between the two models was 
examined in a clustering plot (-log(FDR)) (Figure 2A). In general, GOBP 
involved in cardiac development were more significantly enriched in the ESTc, 
including the GOBPs Heart Development (ESTn FDR 7.8*10-7; ESTc FDR 
9.5*10-11), Striated Muscle Development (ESTn FDR 0.07; ESTc FDR 8.5*10-5) 
and Mesoderm Development (ESTn FDR 2.4 ; ESTc FDR:8.0*10-6). GOBP 
involved in neural development were more significantly enriched in the ESTn, 
including GOBP Regulation of Neuron Differentiation (ESTn FDR 2.3*10-8 ; 
ESTc FDR 0.006). GOBP involved in general development were more evenly 
regulated between the ESTn and ESTc. Overall, GOBP enriched related to 
general development were significantly enriched at a comparable level, such as 
Embryonic Morphogenesis (ESTn FDR 5.0*10-22 ; ESTc FDR 1.0*10-23). 
However, the GOBP Gastrulation and Formation of Primary Germ Layer were 
significantly regulated in ESTc (FDR 1.2*10-6 and 4.8*10-6, respectively) but 
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Figure 2  Clustering of GO biological process enrichment significance (FDR < 0.05 in 
one of the models) over time (days 3, 4 and 5) between ESTn and ESTc
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genes were regulated up or down in one model by MeHg or FLU, FC regulation 
in the other model was either in the opposite direction or completely absent 
(Figure 4A, Figure 4C). VPA-regulated genes in general showed similar 
direction of gene expression in both models, in addition to genes significantly 
regulated in only one of the models (Figure 4E). 
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Figure 4  Compound related gene expression profiles in ESTn and ESTc. Hierarchal 
clustering of the genes regulated by MeHg (A), FLU (C) and VPA (E) in either ESTn 
and/or ESTc (FDR < 0.05). Hierarchal clustering of the genes regulated by VPA in 
either ESTn and/or ESTc (FDR < 0.05; FC > 1.1, dark grey = significant in ESTn, black 
= significant in ESTc). Number of GOBP significantly enriched (p < 0.001, number 
genes regulated within GOBP > 5) after 24h exposure to B) MeHg, D) FLU and F) VPA. 
Enrichment for each compound is shown based on all genes regulated, up-regulated 
genes and down-regulated genes; number of genes per group is indicated on top of each 
bar. GOBP function is depicted in each bar. 
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Figure 3  Time and compound related gene expression in ESTn and ESTc. A) Venn 
diagrams of genes regulated over time (day 3, 4 and 5; FDR<0.01; FC>1.5) and by any 
compound (compared to day-matched control; FDR<0.05) for both ESTn and ESTc 
experiments. 1718 and 1808 genes were regulated over time and by any compound in 
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significantly regulated by any of the seven compounds in ESTn or ESTc, respectively).
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Compound induced GOBP enrichment in ESTn and ESTc
Analysis of GOBP enrichment by compounds and assays is shown in figures 
4B, 4D and 4F. In each figure the number of enriched GOBP is shown for all 
genes regulated by the compound, as well as separately for either upregulated 
or downregulated genes. Within each bar, a subdivision of GOBP in relation to 
specific themes is shown. Due to the statistical algorithms used for calculating 
enrichment, the number of enriched GOBP will depend on the number of genes 
used as input as well as the functional coherency of the input gene set. 
Therefore, the number of enriched GOBP can vary between the “larger” set of 
all regulated genes versus the “more focused” set of up- or downregulated 
genes.
In the ESTn, MeHg upregulated genes were specifically enriched for neural 
and cardiac development related GOBP and downregulated genes were 
enriched for general development GOBP (Figure 4B). In ESTc, MeHg 
upregulated genes were enriched for GOBP related to general development and 
other development (including mainly specific organ and cell differentiation 
GOBP) (Figure 4B). Furthermore in the ESTc, a large group of GOBP related 
to transcription and metabolism (macromolecule and nitrogen related) were 
enriched by MeHg upregulated genes. 
GOBP enriched by FLU exposure in ESTn showed enrichment in both up- and 
down-regulated genes of general development related GOBP and other 
developmental GOBP (skeletal and epithelium development related GOBP) 
(Figure 4D). Furthermore, FLU up-regulated GOBP involved in metabolism 
were related to sterol- and cholesterol metabolism, whereas downregulated 
GOBP were involved in glucose- and hexose metabolism. FLU exposure in 
ESTc had a large effect on development related GOBP, specifically cardiac, 
vasculature and mesenchyme related developmental processes, which were 
mainly enriched by down-regulated genes (Figure 4D). GOBP related to FLU 
up-regulated genes were involved in sterol- and cholesterol metabolism, 
whereas down-regulated genes were involved in transcription and metabolism 
related to transcription. 
VPA exposure in ESTn enriched many processes involved in development, 
including neural and cardiac development (Figure 4F). GOBP enriched by VPA 
up-regulated genes were involved in neural development, cellular morphogenesis 
related GOBP (other development) and transport related processes (other). 
GOBP enriched by VPA down-regulated genes were involved in general 
development, cardiac development, skeletal development (“other development” 
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Figure 4   Continued.
Figure 4  GOBP enriched by genes regulated both over time (FDR < 0.01 FC > 1.5) 
and by VPA (FDR < 0.05 p<0.001) in ESTn (885 genes) and ESTc (1525 genes). (GOBP 
 p < 0.001, number genes regulated within GOBP > 5)
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group) and cell proliferation (“other” group). Changes in gene expression 
induced by VPA in ESTc regulated processes involved in transcription and 
metabolic processes. GOBP enriched by VPA up-regulated genes were involved 
in cellular transport, whereas GOBP enriched by VPA down-regulated genes 
were involved in mitosis, stress, DNA repair, transcription and metabolic 
processes mainly involved in transcription. Transcription related terms 
included a large group of GOBP related to epigenetics, including histone 
modification, methylation and chromosome reorganization. 
In order to specifically investigate VPA effects on genes related to development, 
an additional gene selection was used by which genes had to be regulated both 
by VPA (FDR < 0.05) and over time (the 3648 genes defined earlier in Figure 
1A). This resulted in 1599 genes (enriching 95 GOBP) and 885 genes (enriching 
90 GOBP) regulated in ESTc and ESTn, respectively. Using this approach, for 
both models approximately 60 GOBP were involved in developmental related 
processes. In addition, more cardiac development and transcription related 
GOBP were enriched in ESTc whereas more neural- and “other” development 
related GOBP were enriched in ESTn (Figure 4G).
Discussion
T he development and implementation of predictive alternative assays in developmental toxicology has been hampered by the complexity of 
embryo-fetal development. The multitude of mechanisms in development and 
their spatial and time-dependent relevance do not allow a single in vitro assay 
to contain all developmental mechanisms. Therefore, a combination of in vitro 
assays in a battery and/or tiered approach will be needed to achieve an 
acceptable level of prediction of in vivo developmental toxicity of tested 
chemicals. Various studies have addressed this issue, for instance by applying 
a group of available assays showing improved prediction of the combination 
over individual assays [175, 264], This study used a variety of assays based on 
receptor binding, cell differentiation, and whole embryo culture methods. The 
much larger ToxCast initiative used several hundreds of high throughput 
assays, primarily based on enzyme activity and receptor binding assays [265, 
266]. This battery is being extended with more complex assays such as the EST 
and the zebrafish embryotoxicity assay to enhance predictivity [267, 268]. 
Although it should be realized that the entire developmental programme is 
more than the sum of its constituents, a battery approach containing the most 
crucial mechanisms of development may be able to detect most embryotoxi-
cants. In addition, such a battery should be used within an integrated testing 
strategy which also employs non-testing information such as physico-chemical 
properties and structure-activity relationships [11, 269]. 
The ESTc is one of the most extensively studied in vitro assays for developmental 
toxicity [18]. It has a rich history of validation efforts that have shown its 
possibilities and limitations [17, 36, 37, 264]. One limitation relates to the 
readout of spontaneously contracting cardiomyocytes only. We hypothesized 
that the addition of alternative differentiation pathways might improve 
detection of developmental toxicants both in terms of numbers of compounds 
detected as well as to mechanistic information gained about tested compounds. 
Therefore, we developed the ESTn as a complementary assay to the ESTc [142]. 
We have performed a series of transcriptomics experiments in both models, 
studying time- and compound-perturbed gene expression effects, in order to 
enhance information about compound-mediated effects at the molecular level, 
and to possibly increase predictivity [83, 155, 177, 203, 263]. The basic 
difference between the ESTn and ESTc differentiation protocols in the current 
observation period is the supplementation with RA. RA, an active metabolite 
of vitamin A, is an essential regulator for instance in the physiology of vision 
and brain function, with blood serum levels in human adults of approximately 
2 ng/ml (approximately 7 nM) [270]. RA is also known to play an essential role 
as a morphogen in normal embryogenesis. Subtle gradients of RA direct 
morphogenesis throughout the embryo, including limb development [271] and 
neural development [272, 273]) through specific receptor interactions with the 
retinoic acid receptor family [274]. During early organogenesis in vivo, RA 
levels are observed to be highest in the neural tube [272]. This morphogen is 
employed to induce neural differentiation in ESTn.  Other investigators have 
used similar or higher concentrations to induce neural differentiation in stem 
cell differentiation assays [52, 275]. The extensive differences in differentiation 
pathways between the cardiac and neural differentiation assays is especially 
exemplified in the present study by the detailed analysis of clusters B and G, 
with development related signaling pathways (e.g. FGF, Wnt and BMP) and 
cardiac genes dominating in ESTc and homeobox gene and neural pathways 
dominating in ESTn (Figure 1). Reduced expression of cardiac development 
and Wnt- and TGFβ-signaling pathways by RA has been demonstrated before 
in differentiating mouse ESC in a comparable setting, where neural to 
mesodermal fate change occurred when RA signaling was inhibited, dependent 
on induction of Nodal-, Wnt- and FGF-signaling pathways [262]. Furthermore, 
in zebrafish it has been shown that early neural patterning is mediated by the 
Wnt-, FGF- and RA-signaling pathways. Wnt and FGF suppressed the Cyp26 
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gene important in RA metabolism, whereas induced Cyp26 gene expression 
suppressed Wnt and FGF related genes [276].  
The current comparison between existing data of ESTc and ESTn was 
performed using tested concentrations that were equipotent on the differentia-
tion end point in the assays wherever possible. Therefore, the effective 
concentrations of a given compound analyzed might differ somewhat between 
tests, resulting in comparisons between different tested concentrations. 
However, given that the qualitative nature of the gene expression response was 
studied rather than its magnitude, such a comparison is justified. Differences 
in effective concentrations between assays were especially apparent with 
MeHg, which showed a 20-fold difference in ID50 between tests (Table 1). In 
addition, for FLU and HEX, cytotoxicity overruled effects on differentiation 
in ESTn but not ESTc. Therefore, from a pragmatic point of view, we decided 
to use IC20 concentrations in ESTn, which matched with ID50 concentrations 
in ESTc and allowed useful comparisons of differentiation related gene 
expression signatures in both assays without domination of cell viability 
related genes only.
The added value of both tests combined over the use of a single assay was 
confirmed in the present study in several aspects. The well-known specific 
effect of MeHg on neurodevelopment [109] was mimicked both in its higher 
potency in ESTn as well as in the related gene expression pattern. For example, 
neurodevelopmental GOBP were uniquely affected in ESTn as compared to the 
more general transcription and metabolic processes but not cardiac GOBP 
dominating in ESTc. This is reminiscent of the reliable prediction of MeHg in 
ESTn as compared to its variable prediction in ESTc in the past [17, 155, 277]. 
As to FLU and HEX showing cytotoxicity at concentrations inhibiting neural 
differentiation in ESTn, the detailed analysis of FLU (Figure 4CD) indicates a 
similar effect on the gene expression level, with only few neural specific gene 
sets regulated in ESTn whereas in ESTc multiple cardiac gene sets appear 
affected.
VPA induced by far the highest number of genes among the compounds 
analyzed in the present study. In both assays specific differentiation inhibition 
was observed in the absence of reduced cell viability. However, whereas in 
ESTn neural gene sets appeared to be regulated in the overall analysis as 
expected, ESTc failed to reveal effects on cardiac gene sets (Figure 4F). 
Restriction of the analysis of VPA induced gene expression changes to genes 
regulated during the differentiation process revealed both cardiac and neural 
gene sets regulated in both assays, with neural gene sets dominating in ESTn 
and cardiac gene sets dominating in ESTc (figure 4G). The relatively large 
number of genes regulated by this compound as compared to other test 
compounds may have caused the less specific gene expression response 
observed. This analysis shows the advantage of restricting the gene expression 
analysis to the subset of genes that change their expression with the differen-
tiation process. These differentiation-related genes determine the “differentia-
tion track” as defined in earlier studies [187]. This selection of genes can be 
used to reveal more specific information of compound effects on gene pathways 
related to differentiation in the assays.   
In summary, we showed that combining ESTn and ESTc provided added value 
over individual assays by revealing complementary information on test 
compounds. These observations serve to both improve the detection of differ-
entiation-modulating compounds as well as show underlying gene expression 
changes indicating mechanisms of action. Such underlying knowledge will 
assist extrapolation from in vitro to in vivo as well as between species. The 
latter is ultimately important as the entire testing paradigm is focused towards 
risk assessment for man. The current interest in defining adverse outcome 
pathways (AOP) as the basis of hazard assessment [226, 278] is served by this 
approach in view of its detailed assessment of gene expression pathways 
underlying differentiation modulation. An inclusive combination of in vitro 
assays, each of which incorporating one of the critical AOP, could provide a 
strong basis for a comprehensive pre-screen of in vitro prediction of human 
hazard. These findings exemplify the usefulness of combining complementary 
in vitro assays in in vitro tiered/battery approaches with the aim to improve 
overall detection of compounds potentially affecting embryo-fetal development. 
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Introduction
D ue to the implementation of the European REACH legislation for chemical safety and additional global pressures, a reduction in animal usage for 
toxicology studies is in high demand.  The majority of toxicological testing is 
devoted to assess developmental health risks [12].  In vitro models, such as the 
rodent whole embryo culture (WEC) and embryonic stem cells (ESC), which 
can be induced into multiple lineages of cell types, such as neural (ESTn) and 
cardiomyocyte (ESTc), serve as potential replacements for current in vivo-based 
approaches to predict the potential for chemical compounds to induce 
developmental toxicity [175].  While less complex than whole animal models, 
in vitro developmental models possess characteristics (e.g. structure, 
mechanistic pathways) which are believed to allow partial representation of 
the whole organism developing in vivo.  Multiple research groups are currently 
working on determining the applicability domain for these tests while trying 
to improve aspects of each methodology (e.g. duration, stability) to enable 
implementation into the risk assessment framework [14].
The integration of toxicogenomic evaluations may improve the prediction of 
developmental toxicity in vitro. Recent studies suggest toxicogenomics assessments 
assist in identifying 1) unique and common mechanisms of toxicity across 
multiple developmental toxicants [82, 155], 2) dose- [230, 279] and time- 
response [40, 177], and 3) potential gene lists predictive of in vitro toxicity [83, 
84, 187, 230].  Furthermore, in vitro toxicogenomic assessments provide 
mechanistic markers linked with developmental toxicity which can be identified 
across both in vivo and in vitro developmental models.  Initial studies in either 
ESC or WEC evaluating compound effects of retinoic acid [280], methylmercury 
[82, 177], phthalates [40, 81, 82] triazoles [81, 230] and glycol ethers [82] 
suggest specific transcriptomic responses to be relevant for developmental 
toxicity in vivo. These and future toxicogenomic studies conducted in develop-
mentally-related models will produce valuable datasets to examine and link 
specific responses in vitro with in vivo developmental toxicity.
Although the identification of common responses across in vivo and in vitro 
models seems straightforward in principle, many factors exist in comparing 
across toxicogenomic studies due to inherent biological complexity of each 
model and each study. Recent gene expression studies completed in vivo and/
or in vitro suggest many factors to play a role in response, including model 
[281], dose [152, 230], time [151, 282, 283], strain [151, 282], species [284, 
285], gender [286], organ [287] and developmental time.  As well, technical 
Abstract
T oxicogenomic evaluations may improve toxicity prediction of in vitro- based developmental models, such as whole embryo culture (WEC) and 
embryonic stem cells (ESC), by providing a robust mechanistic marker which 
can be linked with responses associated with developmental toxicity in vivo. 
While promising in theory, toxicogenomic comparisons between in vivo and in 
vitro models are complex due to inherent differences in model characteristics 
and experimental design. Determining factors which influence these global 
comparisons are critical in the identification of reliable mechanistic-based 
markers of developmental toxicity. In this study, we compared available 
toxicogenomic data assessing the impact of the known teratogen, methylmercury 
(MeHg) across a diverse set of in vitro and in vivo models to investigate the 
impact of experimental variables (i.e. model, dose, time) on our comparative 
assessments. We evaluated common and unique aspects at both the functional 
(Gene Ontology) and gene level of MeHg-induced response. At the functional 
level, we observed stronger similarity in MeHg-response between mouse 
embryos exposed in utero (2 studies), ESC, and WEC as compared to liver, 
brain and mouse embryonic fibroblast MeHg studies. These findings were 
strongly correlated to the presence of a MeHg-induced developmentally-relat-
ed gene signature. In addition, we identified specific MeHg-induced gene 
expression alterations associated with developmental signaling and heart 
development across WEC, ESC and in vivo systems. However, the significance 
of overlap between studies was highly dependent on traditional experimental 
variables (i.e. dose, time). In summary, we identify promising examples of 
unique gene expression responses which show in vitro–in vivo similarities 
supporting the relevance of in vitro developmental models for predicting in 
vivo developmental toxicity.
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Methods
Acquisition of Datasets Associated with Gene Expression 
Analysis of MeHg Effects
Retrieved toxicogenomic datasets regarding MeHg exposure were generated at 
different research institutions.  Investigations concerning MeHg impacts in 
mouse embryos undergoing early gestational development [151, 152] and 
mouse embryonic fibroblasts (MEF) [292] were performed at the University of 
Washington (US) under supervision by Dr. Elaine M. Faustman.  Toxicogenomic 
studies regarding MeHg exposure in the WEC [82] and ESTn and ESTc systems 
(neural and cardiomyocytes) [155, 177] were conducted at the National 
Institute for Public Health and the Environment, (The Netherlands) under 
supervision by Dr. Aldert H. Piersma.  The dataset concerning MeHg gene 
expression alterations in mouse brain in gestational/postpartum-exposed mice 
[291] was accessed with permission from Dr. Chris N. Glover and Dr. Christer 
Hogstrand (National Institute of Nutrition and Seafood Research, Norway; 
University of Canterbury, New Zealand).  The dataset investigating sub 
chronic MeHg effects in rat (kidney) was identified using ArrayExpress at EBI 
(E-TOXM-30, TNO Quality of Life, The Netherlands) [287].
All datasets were initially processed separately.  Methodologies regarding 
statistical analysis of initial processing of each dataset were conducted as 
previously described when possible [82, 151, 152, 155, 177, 287, 291, 292].  A 
complete summary of processing steps (array type, normalization) are 
described in Supplementary Table 1 (see supplementary data original article), 
including modifications to previous methodologies.  A general framework to 
investigate MeHg-toxicogenomic responses across in vivo and in vitro datasets 
is illustrated in Supplemental Figure 1 (see supplementary data original article). 
Identification of Differentially Expressed Genes due to MeHg 
Exposure
Normalized data were log transformed and imported into BRBarraytools 
(NCI) [293]. ANOVA was used to determine significantly altered genes by 
MeHg within each dataset across all experimental conditions (i.e. time, dose). 
P-values were corrected for multiple testing by calculating the False Discovery 
Rate (FDR) according to Benjamini and Hochberg [85].  All redundant probes 
(multiple probes for the same gene) within each study were eliminated; only 
the most significant (p-value) probe to be altered by MeHg was included for 
the following comparative analyses.
differences, such as RNA preparation, platform [68, 288], experimental 
practices [289], and differing statistical approaches may add obstacles in 
identifying common biomarkers across studies.  In the area of carcinogenesis, 
initial comparative toxicogenomic assessments across multiple compounds 
have shown promise in identifying responses which distinguish genotoxicants 
from non-genotoxicants [290], however, these approaches may be too crude to 
examine the complexity of developmental toxicants due to vast mechanisms of 
toxicity and the specificity and comparability of common windows of sensitivity 
for particular toxicants. Initial comparisons examining responses across 
smaller sets of compounds and development models may assist in guiding 
which variables may factor in these comparative assessments. 
Due to the public health relevancy surrounding exposure and inherent neuro-
developmental and teratogenic toxic properties [144], methylmercury (MeHg) 
is one of the most studied developmental toxicants.  In the recent decade, 
toxicogenomic evaluations of MeHg have been conducted across a diverse set 
of conditions in both in vivo and in vitro developmental models.  Therefore, 
using the unique availability of MeHg data, in this study, we investigated 
factors which influence comparisons of toxicogenomic response. We included 
currently available published datasets assessing MeHg in in vivo and in vitro 
models representative of early rodent embryonic development (five total) [82, 
151, 152, 155, 177].  Also, we selected two in vivo studies assessing long term 
effects in brain [291] and kidney [287, 292] and one in vitro study (mouse 
embryonic fibroblasts) [292] for comparisons. We compared variables of interest, 
including model, dose, and time which may influence toxicogenomic comparisons 
across these studies which represented a variety of experimental conditions 
and toxicity outcomes. We conducted global comparative assessments across 
all eight studies, examining MeHg-induced functional changes (GO Biological 
Processes) as well as specific gene expression alterations associated with 
development via model by model comparisons between in vitro and in vivo 
developmental models. In general, these initial comparisons suggest that 
common toxicogenomic responses are able to be identified across in vitro and 
in vivo developmental models, however, many factors influence these comparative 
assessments. Moreover, this study provides insight into the specificity of models 
in response; specific developmental models may compliment other models 
better when assessing common toxicological responses across in vivo and in 
vitro models. These types of genomic based-analyses may guide in defining 
applicability domains of developmental models in terms of windows of sensitivity 
and chemical response.
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comparing each dose/time group to its relative control using the average 
intensity.  Cross-scatter plots were employed to visually compare the effect of 
MeHg across multiple conditions in vivo with WEC.  Genes identified to be 
significantly altered in vivo at each particular condition (dose/time) were 
evaluated for significance using a post-hoc test (T-test, p<0.05).
Comparison of Developmental Genes Commonly Altered 
between In Vivo and ESC systems
Additionally, we assessed commonly MeHg-altered genes related to the GO 
biological process, developmental process between mouse whole embryos 
[152], ESTn [177] and ESTc [155]. As described above [152], the in vivo dataset 
used for these assessments investigated the impact of MeHg on gene expression 
in C57 mouse embryos (GD8 + 0, 8, 12h) across three dose groups (1, 4, 6mg/
kg BW).  The ESTn study [8] examined gene expression changes at 24, 48, 72, 
96h in MeHg exposed (25nM) cultures.  MeHg-induced alterations were 
assessed in ESTc at 24h following MeHg exposure (480nM).  Commonly 
represented genes across the three studies (17315 genes) were determined using 
Official Gene Symbol (OGS) annotation.  Genes were identified to be 
significantly altered by MeHg across two of the three studies irrespective of 
dose or time (ANOVA, p<0.05).  Employing DAVID [294], we identified genes 
to be related to the GO Biological Process, developmental process.  In total, 
163, 281 and 181 developmentally-related genes were identified to be 
significantly altered between ESTn and ESTc; whole mouse embryos and ESTn; 
and whole mouse embryos and ESTn, respectively. The relative fold change 
(log2 scale) was determined comparing each dose/time group to its relative 
control using the average intensity.  Cross-scatter plots were created between 
all three studies.  Selected comparisons are shown between the three model 
systems.  Genes identified to be significantly altered in vivo/in vitro for each 
particular condition (dose/time) were evaluated for significance using a 
post-hoc test (T-test, p<0.05), when necessary.
Overlapping MeHg-induced Alterations in Developmental  
In Vivo / In Vitro models
To investigate the overlap in MeHg response between developmental in vitro 
and in vivo models, we identified genes commonly significantly altered 
(ANOVA, p<0.05) in at least four of the five available studies [82, 151, 152, 
155, 177].  Datasets were merged by OGS annotation.  Fold change values for 
all 53 genes identified to be significantly altered in four of the five studies 
(ANOVA, p<0.05) were examined for response to MeHg (in comparison with 
comparative control) using hierarchical clustering (TIGR MEV, mean average). 
Functional Analysis of Differentially Expressed Genes across 
Developmental Models
Due to differences in distribution of significance and the complexity of using 
differing sizes of gene lists for later analyses, a ranking approach was 
implemented to make comparisons regarding common gene expression 
responses and assessing functional changes in gene expression (gene ontology 
analysis).  The top 1000 genes were determined using ANOVA to develop a 
ranking value for each gene within each study.  This approach translated into 
different criteria in terms of p-value cutoff for each one of the studies (see 
supplementary data original article, table 1). Enrichment of significantly 
enriched gene ontology (GO) Biological Processes was conducted using DAVID 
[294].  Enriched GO Biological Processes were determined to contain ≥5 genes 
and a p<0.05. Similar results were observed with assessments conducted using 
the top 500 (not shown) in terms of broad functional changes, however, less 
categories of genes were enriched. Hierarchical clustering (Manhattan, Average 
Linkage) was performed using the p-value associated with enrichment of GO 
Biological Processes across all eight studies to determine similarities in over-
representation at the functional level for all significantly enriched GO Biological 
Processes and more specifically, developmentally-related terms (children terms 
of the GO Biological Process, developmental process) (TIGR MEV) [295, 296].
Comparison of Developmental Genes Commonly Altered 
between In Vivo and WEC
Due to common enrichment of GO developmentally-related processes in MeHg 
altered genes across multiple models and prior investigations suggesting these 
related genes to be critical for development of the organism, we further 
examined these related responses at the gene level to identify common 
biomarkers in the context of factors which influence our comparisons (model, 
dose, time).  We assessed MeHg commonly altered genes related to the GO 
biological process, Developmental Process between mouse embryos [152] and 
rat WEC [82].  As described [152], the in vivo dataset used for these assessments 
investigated the impact of MeHg on gene expression in C57 mouse embryos 
(GD8 + 0, 8, 12h) across three dose groups (1, 4, 6mg/kg BW).  The WEC 
study [82] examined gene expression changes at 4h in MeHg exposed (6µg/ml) 
embryos.  Commonly represented genes in both studies (9166 genes) were 
determined using Official Gene Symbol (OGS) annotation.  In total, 267 genes 
were identified to be significantly altered by MeHg in both studies irrespective 
of dose or time (ANOVA, p<0.05).  Employing DAVID, we identified 28% of 
these genes (76 genes) to be related to the GO biological process, developmental 
process.  For these 76 genes, the relative fold change (log2 scale) was determined 
CHAPTER 8 TRANSCRIPTOMIC COMPARISON OF METHYLMERCURY EFFECTS IN VITRO AND IN VIVO
178 179
the 136 developmentally-related GO Biological Processes suggested greater 
similarity in functional response between datasets, A and E and B, F, G as 
compared to C, D and H (Figure 2B). A selection of specific GO Biological 
Processes associated with Developmental Process, Heart Development, 
Anterior/Posterior Pattern Formation, and Regulation of Neurogenesis were 
significantly enriched (p<0.05), dependent on model (Figure 2C). For example, 
we observed enrichment of the most general developmentally-related GO 
Biological Process, Developmental Process, across models, A, B, E, F, G. 
Enrichment of genes related to Heart Development were only observed in 
models A, B, E and G.
Classification of developmental- and apoptosis-related genes was conducted 
using DAVID. In addition, genes previously identified to be critical for neurulation 
in mouse models [297, 298] were labeled.
Results
Microarray Datasets Investigating MeHg-induced 
Developmental Toxicity
We examined the comparative relationship of MeHg-induced gene expression 
response across eight transcriptomics studies (labeled A-H) (Table 1). 
Specifically, we obtained four in vivo studies assessing MeHg effects on gene 
expression in mouse embryos exposed in utero (A, B), young mice (brain) 
exposed in utero and during postnatal period (C) and adult rats (kidney) 
chronically exposed to MeHg (D).  We compared responses in these in vivo 
models with studies conducted in four alternative (in vitro)-based assays WEC 
(E), ESTn (F), ESTc (G), and MEF (H).  Different parameters were observed 
across all eight studies regarding, model, dose, time (exposure duration), and 
linked toxicity endpoint.
Overlapping Enrichment of MeHg-induced Impacts across  
In Vivo and In Vitro Developmental Models
As shown in figure 1A, we identified overlapping and non-overlapping enrichment 
of GO Biological Processes within the most prominent MeHg-induced gene 
expression alterations (top 1000 in each dataset) across the eight datasets 
examined. In total, 537 GO Biological Processes were identified to be 
significantly enriched in at least one of the eight datasets (≥5 genes changed, p 
< 0.05).  Twenty-five percent of enriched GO Biological Processes were related 
to Developmental Process terms (Figure 1B).  Other general themes previously 
linked with MeHg-toxicity were identified such as Cell Differentiation (6%) 
and Stress-related (6%) (e.g. cell death, cell cycle arrest, oxidative stress, DNA 
damage).  Hierarchical clustering of the degree of enrichment (p-value) of the 
537 GO Biological Processes indicated similarity between datasets A and B 
(mouse embryos) and in vitro models (E, F, G) as compared to datasets C, D, 
and H (Figure 1C).
Overlap in enrichment of developmentally-specific GO Biological Processes 
were apparent between datasets, in particular, between A, B, E, F, and G 
(Figure 2A). Hierarchical clustering of the degree of enrichment (p-value) of 
Table 1   In Vivo and In Vitro Study Comparisons:  MeHg-induced 
Toxicogenomic Changes in Gene Expression 
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Early  
Organogenesis
1, 4, 6mg/kg (ip),  
GD8
8, 12h BW, growth, 
reproductive, 
structural defects 
(≥4mg/kg)
B M Embryo Neurulation
Early  
Organogenesis
4mg/kg (ip),  
GD8
12, 24h Neural tube closure 
delay reproductive 
and growth effects
C M Brain Gestation
Post-partum
1.5, 4.5mg/kg  
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(≥1.5mg/kg)
D R Kidney Adult 0.25, 0.75mg/kg 
(gavage)
(14 days)
NA NOAEL (0.75mg/kg)
E R Embryo Neurulation
Early  
Organogenesis
6µg/mL  
(GD10)
4h Reduction in total 
morphological score
F M ESCn Neural  
Differentiation
25nM  
(d3)
24, 48, 
72, 96h
Inhibition of 
differentiation
G M ESCc Cardiomyocyte 
Differentiation
480nM  
(d3)
24h Inhibition of 
differentiation
H M MEFs Normal Culture 5mM 24h Increased cell death
Coding (A-H) signifies study label throughout the manuscript and for shorthand notation of select 
figures. Toxicogenomic studies were completed in rat (R) or mouse (M).
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Comparison of MeHg-induced Developmental Gene Expression 
Alterations in the ESC Model  and Mouse Embryo
In comparisons between models A (mouse embryo), F (ESTn) and G (ESTc), we 
observed 165 (a), 281 (b), 181 (c) genes commonly altered between G and F; F 
and A; and G and A, respectively (Figure 4A). Comparing across all three 
studies, 67 genes were identified to be commonly significantly altered by MeHg 
in all three models (Figure 4A).  
In figure 4Ca, 165 genes identified to be significantly altered in both ESTn and 
ESTc model systems are plotted using a cross-scatter plot.  At 24h, in both 
ESTc and ESTn, 84 genes (blue triangles) were identified to be commonly 
MeHg-induced Developmental Gene Expression Alterations in 
Mouse Embryo and WEC: The influence of dose and time
Developmental genes commonly significantly altered by MeHg (76 total) in 
mouse embryo (A) and WEC (E) were examined for comparative expression 
changes between models in association with dose- and time-dependent effects 
(in vivo) (Figure 3).  In general, we observed an overrepresentation of common 
up-regulated gene expression responses (quadrant I) in the 76 genes related to 
development between both studies across all conditions in vivo (Figure 3B, 
a-e).  We observed a dose-dependent effect in the number of genes commonly 
altered between studies with increasing dose (in vivo) in our 8h (a-c) and 12h 
(d, e) comparisons with the WEC (Figure 3B).  For example, 54/76 genes were 
significantly altered between in vivo (6mg/kg, 8h) and WEC (6µg/ml, 4h). 
Seventy-four percent of the 54 genes were observed to be commonly upregulated 
(quadrant I) in this comparison.  Common directionality was observed for 
>60% of all commonly altered genes dependent on comparison.  Up-regulation 
of specific targets was observed for genes such as Celsr1, Chd7, Frem2, Cdx2, 
and Smarcc1 in both models (Figure 3C).
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Figure 1  GO Enrichment of MeHg-induced Gene Expression Alterations across In 
Vivo and In Vitro Models. Enrichment of GO Biological Processes within the most 
prominent MeHg-induced responses (top 1000 genes in each study) across eight in vitro 
and in vivo studies (Figure 1A).  Species (mouse or rat) and examined tissue/cell type are 
located to the left of the hierarchical clustering plot depicting the enrichment score 
(p-value) of GO biological processes identified using DAVID.  In total, 537 GO Biological 
Processes identified to be significantly enriched in one of the eight datasets (p<0.05, genes 
changed >5) are depicted by color intensity (columns).  GO Biological Processes related 
to development, cell differentiation and stress are labeled by color bar corresponding 
with the columns above (Figure 1B).  Hierarchical clustering by study using the enrichment 
score (p-value) of all 537 GO Biological Processes (Figure 1C).  Coding (A-H) corresponds 
with coding in Figure 1A.
Figure 2  Enrichment of Developmentally-related GO Biological Processes across In 
Vivo and In Vitro Models. Enrichment of GO Biological Processes related to 
development within the most prominent MeHg-induced responses (top 1000 genes in 
each study) across eight in vitro and in vivo studies (Figure 2A).  Species (mouse or rat) 
and examined tissue/cell type are located to the left of the hierarchical clustering plot 
depicting the enrichment score (p-value) of GO Biological Processes identified using 
DAVID.  In total, 157 GO Biological Processes related to development identified to be 
significantly enriched in one of the eight datasets (p<0.05, genes changed >5) are 
depicted by color intensity (columns).  Hierarchical clustering by study using the 
enrichment score (p-value) of all 157 GO Biological Processes (Figure 2B). Examples of 
model dependent enrichment of select developmentally-related GO Biological Processes 
(Figure 2C).
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disrupted in expression (Figure 4B). Within these 84 genes, 56% showed 
common directionality (Quadrant I and III). Common alterations include 
genes such as Gata3 (↑) and Ndrg2 (↓).  In general, strong correlation in the 
directionality of response of all significantly altered genes was not observed 
between the two systems.
In ESTn (24h, 25 nM) and mouse embryos 8h (6 mg/kg), 83/281 altered genes, 
showed common significance in this particular comparison (Figure 4Cb). Of 
the 83 genes, 45% were observed to be altered in the same direction, including 
Celsr1 (↑), Hoxb4 (↑), Sall3 (↑) and Dnmt3b (↓) (Figure 4B). Fifty-one percent 
of the 83 genes were specifically down-regulated in mouse embryos and 
up-regulated in the ESTn (quadrant III).
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Figure 3  MeHg-induced Develo mental Gene Expression Alterations in Mouse 
Embryo and WEC. Common developmentally-related MeHg-induced gene expression 
alterations in in vivo (whole mouse embryo) and WEC models across different dose and 
time conditions (in vivo) (Figure 3A, a-e).  In total, 76 genes were identified to be 
commonly altered across all conditions tested in the two studies.  Post-hoc analysis 
(T-test) was used to determine significance in particular dose/time groups (p<0.05, 
dark diamonds).  Figure 3B describes relationships observed in Figure 3A.  The 
percentage of the 76 genes showing common directionality between the two models in 
the degree of response (% common direction).  The percentage of the 76 genes identified 
to be commonly upregulated (Quadrant I) (% common direction, Quadrant I).  The 
total number of commonly altered developmentally-related genes, significant in both 
models in particular conditions (# commonly altered).  The percentage of commonly 
altered genes showing similar directionality between the two models in the degree of 
response (% common direction).  The percentage of the commonly altered genes 
identified to be commonly upregulated (Quadrant I).  Comparison of fold change 
response in MeHg-induced developmentally-related gene expression alterations in 
mouse embryos (GD8, 6 mg/kg, 8h) and rat WEC (GD10, 6 µg/ml, 4h) (Figure 3C).
Figure 3   Continued
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In comparisons between ESTc (24h, 480 nM) and mouse embryos (6 mg/kg, 
8h), 102/181 genes were identified to be significantly altered (Figure 4Cc). 
Sixty one percent of the 102 genes showed common up/down-regulation 
(Tgfb2, Tbx3, Msx1, Gata3) between the two models (Figure 4B).  Improved 
correlation in terms of common directionality of response (86%) was observed 
within the subset of developmental genes related to heart development (Figure 
4Cd).  Commonly upregulated genes related to heart development included 
Tbx3, Tgfb2, Msx1, Tbx20, Nrp1, and Nrp2.
Biomarkers of MeHg developmental toxicity applicable across 
developmental in vitro and in vivo models
Overlapping MeHg-induced gene expression alterations were determined 
across developmental models (A, B, E, F and G).  In total, 53 genes were 
identified to be altered by MeHg (ANOVA, p < 0.05) in 4/5 studies (Figure 5). 
Enrichment of developmentally- and cell death-related GO Biological Processes 
was observed within the 53 genes (data not shown).  In total, 34% (18 genes) 
of the 53 genes were identified to be developmentally related, including five 
previously identified as neural tube defect (NTD) candidate genes in mouse 
models (i.e. Frem2, Gja1, Piga, Cycs, Apaf1). 
Embryo (in vivo)
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c & d b
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Figure 4  MeHg-induced Developmental Gene Expression Alterations in Mouse 
Embryo and ESC Model Systems. The overlap in significant developmentally-related 
gene expression alterations in MeHg exposed mouse embryos, ESTn and ESTc (Figure 
4A). Figure 4B describes relationships observed in Figure 4C. Cross scatter plots 
comparing common MeHg-developmentally related gene expression alterations in ESTn 
and ESTc (Figure 4Ca), mouse embryo and ESTn (Figure 4Cb), and mouse embryo and 
ESTc (Figure 4Cc). Cross scatter plot comparing common MeHg-heart developmentally- 
related gene expression alterations in mouse embryo and ESTc (Figure 4Cd). Post-hoc 
analysis (T-test) was used to determine significance in particular dose/time groups (p < 
0.05, dark diamonds).
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Discussion
A lternative models, such as the WEC and ESC systems are being developed as potential replacements for in vivo-based approaches to determine the 
potential for chemicals to induce developmental toxicity [14].  Established 
protocols for these alternative models use morphological criteria to classify 
chemical toxic properties [142, 299].  The integration of toxicogenomic 
evaluations may improve the capability of in vitro-based models by providing 
robust mechanistic markers used for classification and prediction [187, 280, 
300]. Toxicogenomic responses identified in vitro provide a subjective endpoint 
which can be correlated with responses across other models, in particular, in 
vivo models assessing the relationship between exposure and developmental 
disease.  Therefore, toxicogenomic evaluations enable a linkage between in 
vitro and developmental toxicity outcomes in vivo.  In theory, the identification 
of these biomarkers or “phenotypic anchors” associated with developmental 
toxicity in vivo that are also identified to be altered in vitro due to chemical 
exposure should provide a more reliable, mechanistic-based objective endpoint 
to classify and predict developmental toxicity potential.  The comparability of 
toxicogenomic data across models may also provide a robust measure to 
determine the applicability domain of a particular test in terms of chemical, 
organ and developmental window specificity.  Due to the complexity of the 
developing organism and the wide diversity of mechanisms of developmental 
toxicants, the generation of toxicogenomic data assessing multiple variables is 
crucial in understanding the potential use of toxicogenomic data in making 
these types of comparisons across in vitro and in vivo developmental models.
Toxicogenomic comparisons across studies are complex because of inherent 
differences in experimental design and model.  Determining factors which 
influence these global comparisons are critical in the identification of reliable 
mechanistic based markers of developmental toxicity. Here, as a proof of 
principal, we examined eight in vivo and in vitro datasets examining the 
impact of the known developmental neurotoxicant and teratogen, MeHg, 
across a wide set of diverse study designs (Table 1). MeHg-induced gene 
expression alterations across the eight studies were assessed from the functional 
and gene level.  At the functional level (GO biological process), we provide 
evidence of specific in vitro models to share response similarities with early 
developmental models (i.e. neurulation, mouse) as we observe better 
correlations with enrichment of MeHg-GO responses as compared to other 
study designs in vivo (kidney, brain) and in vitro (MEFs) (Figure 1).  Differences 
at the functional level between early developmental models (A, B, E, F, G) and 
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Figure 5  Overlapping MeHg–induced Transcriptional Alterations across Developmental 
Models. Hierarchical clustering of all 53 genes identified to be altered by MeHg in 4/5 
developmental in vivo/in vitro models (A, B, E, F, G) (ANOVA, p < 0.05).  Fold change 
values (log2 ratios) are presented in color.  Genes related to GO Biological Processes, 
developmental process and apoptosis are labeled (right).  In addition, genes previously 
identified to be linked with neural tube defects in mouse models are labeled (right).
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In the two ESC systems (F, G), at the functional level, we observed strong 
similarities in MeHg-response for enriched GO Biological Processes as well as 
developmentally specific categories (Figure 1, 2).  Despite these observations, 
only 56% of commonly altered developmental genes were observed to correlate 
in the same direction in response to MeHg in the two systems at 24h following 
day 3 of culture (p < 0.05) (Figure 4Ca).  Interestingly, the ESC models were 
derived from the same blastocyst-derived cell line (ES-D3, ATCC) and studies 
were conducted in the same laboratory suggesting possible similarities. 
However, stark differences in culturing procedures between the ESTn and 
ESTc occur after culture day 3 with the addition of growth factors (e.g. retinoic 
acid on day 3) which induce neural versus cardiomyocyte differentiation [40, 
142].  Our results support commonalities in MeHg effects between the two 
systems at the gene level (e.g. Msx1, Ndrg2), but also point out major differences 
in terms of the directionality of response (e.g. Tbx3, Prdm14) in genes 
significantly disrupted in both systems (p < 0.05).  Differences in response 
between these two studies may be explained by the addition of retinoic acid on 
day 3 of culturing, as well as differing concentrations (ESTn , 25 nM and ESTc, 
480 nM) and sensitivity of the two systems (neural more sensitive on a 
concentration basis).   
As observed in comparisons between the WEC and mouse embryo (A) study, 
we observed similarities in MeHg response at the functional level (Figure 2) for 
developmentally-related GO Biological Processes between both ESC systems 
(F, G) and mouse embryos (A, B).  Cross comparisons of commonly altered 
developmental genes between ESTn (F) and whole embryos (A) indicated 
common targets such as Celsr1, Sall1, however, the majority of responses were 
not concordant in directionality (55%) between the two systems (Figure 4Cb). 
Likewise, we observed genes which correlated directionally (up/down) in 
comparisons between ESTc and mouse embryo (A) with MeHg (e.g. Gata3, 
Tbx3), but also genes differentially expressed in terms of direction (39%) 
(Figure 4Cc).   Interestingly, in both comparisons (Figure 4Cb, c), we observed 
a high representation of downregulated genes in the ESC model systems which 
were upregulated in the whole embryo study (Quadrant III).  With these broad 
assessments of all commonly MeHg-altered developmental genes, it is not 
surprising to observe imperfect correlations due to the character of the 
underlying model comparison. ESC systems, in theory, possess characteristics 
which may mimic partial representation of the whole organism developing in 
vivo. For example, the ESTc model represents a subtype of progenitor cell on 
the track of differentiating into beating cardiomyocytes.  However, we may 
not necessarily expect to see precise correlations at the gene level in comparing 
chronic organ models (C, D)/cultured MEFs (H) included the presence (or 
absence) of a robust MeHg-induced developmental-gene signature (Figure 2A, 
B).   Furthermore, gene categories (GO Biological Processes) related to specific 
processes were only observed in select models (Figure 2C).  For example, while 
the most general developmental term, developmental process, was observed to 
be enriched across models A, B, E, F, G, children terms of the parent term 
developmental process were also only observed to be enriched in particular 
models.  While we hesitate to make strong conclusions without further analyses 
and more representative datasets assessing across dose and time for the selected 
study designs, our results give a preliminary assessment of the comparative 
signature specificity across these particular in vivo and in vitro models and 
highlight the specificity of select in vitro models to present (functionally) 
similar gene expression signatures as early developing embryos exposed to 
MeHg.
Due to the specificity of developmental signatures from the functional level in 
select developmental models (A, B, E, F, G), we assessed whether commonly 
altered developmentally-related genes were regulated similarly between these 
models in terms of significance and directionality.  Moreover, we examined 
differences in our comparative assessments due to factors which influence the 
comparability of response, including model, dose and time.  
In comparisons between mouse embryos (A) and WEC (E) we observed 
correlations (in terms of common directionality) in gene expression response 
influenced by dose and time (in vivo).  Better correlations (# of genes commonly 
altered, directionality), in general, were observed with the highest dose tested 
(6 mg/kg, 8h and 12h) in the mouse embryo study (A) and WEC (6 µg/ml, 
24h), including multiple genes critical for embryonic development (e.g. Celsr1, 
Chd7) [301, 302].  These simple comparisons indicate the complexity of 
aligning in vitro and in vivo responses.  Careful consideration must be assessed 
for dose and time-dependent factors when determining if an overlap in response 
exists between two systems.  In these comparisons, dose levels (≥4 mg/kg) of 
MeHg in utero and the concentration used in the WEC (6 µg/ml) are comparable 
in their ability to induce teratogenic effects, including effects on neural tube 
closure and reduced growth (i.e. body weight, somites, size) [82, 151, 152, 
173, 303].  While these models hold inherent similarities in terms of the 
exposure window (GD8
mouse ≈ GD10rat), multiple differences in study designs 
could explain differences in observed responses, including, species differences, 
maternal environment versus culturing conditions, concentration, time point, 
MeHg-kinetics, probe specificity, and other experimental considerations.
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a cell line to whole embryo due to the complexity of what is being assessed at 
the embryo level (multiple tissues, dilution of response, etc.).  Interestingly 
though, comparisons between ESTc and mouse embryo (A) were greatly 
improved when only comparing the subset of developmental genes related to 
heart development (Figure 4Cd).  These results suggest that specific pathway(s) 
or a specific process may be impacted similarly between the two models, 
enabling the identification of a subset of genes in which MeHg targets in both 
systems.  Again, due to the limitation of these comparisons, our conclusions 
need further verification, but form a basis for future comparative analyses. 
Gene expression alterations associated with developmental signaling and heart 
development across ESC and in vivo-based models may serve as possible 
predictors to assess developmental toxicity in the ESC model system.  Specific 
pathways (or genes) may correlate, in terms of response, in both these 
representative simple and complex (in vivo) systems in connection with adverse 
developmental outcomes.
In total, we identified 53 genes to be commonly altered (4/5 studies) across 
developmental models (A, B, E, F, G) (Figure 6).  In general, directionality in 
MeHg response was not necessarily agreeable across all conditions across all 
five studies.  The response associated with MeHg in these 53 genes indicates 
the promise of identifying overlapping targets across multiple in vivo and in 
vitro developmental models and the potential ability to derive predictive gene 
sets across in vitro and in vivo models, but also illustrates the true complexity 
due to the influence of multiple factors on response (e.g. dose, time, model, 
platform).  Comparisons between neuroblastoma (P19) cells and mouse 
embryos exposed to valproic acid support the ability to identify common 
toxicogenomic responses across in vivo and in vitro developmental models 
[76].  Studies like these, which evaluate compound-induced response across in 
vivo and in vitro developmental models may greatly assist in determining the 
applicability domain of in vitro models in their ability to correlate with in vivo 
model hazard identification and toxicity prediction.  
In this study, we did not focus on overlapping single gene changes across all 
eight studies due to limited common response (see supplementary data original 
article, table 2).  From the GO level, MeHg-induced developmentally related 
genes were not enriched within the brain (C), kidneys (D) and MEF (G) studies. 
These results do not necessarily translate into developmentally-related genes 
not being impacted in these systems.  In fact, many developmental genes are 
impacted in these systems.  However, the strength of signature is weaker in 
these designs/models in terms of the proportion of genes impacted by MeHg 
related to development as compared to other processes.  Studies assessing 
expression profiles across models under exposure and control conditions may 
provide insight into differences in toxicant-induced developmental-related 
signatures.
Also, in this study, we did not attempt to focus on comparisons at the gene 
level between different platforms (Affymetrix, Codelink, Operon) due to the 
added complexity of platform specificity [68, 288].  Differences in MeHg 
response were apparent at the gene level even between similar studies A 
(Affymetrix) and B (Codelink), both assessing MeHg response in C57 mouse 
embryos undergoing neurulation (not shown).  Close examination of Figure 5 
reveals some of these differences in the directionality of expression in 
overlapping genes between mouse embryo studies (A, B). Despite these 
observations, strong similarities were observed between these two studies at 
the functional level (Figure 1A, C), supporting the use of programs which 
identify gene expression changes at a higher functional level (pathway, 
GO-level) as previously observed in comparisons between non-developmental 
models [304, 305].
Conclusion
T oxicogenomic studies conducted in developmentally-related models produce valuable datasets which allow comparison of specific responses across in 
vitro and in vivo developmental models.  Mechanistic-based markers (e.g. 
RNA, proteins, etc) may improve assessment of potential toxicity by providing 
an objective measure which can be associated with developmental anomalies. 
As with all toxicological models, response and toxicity is dependent on multiple 
factors such as dose and time.  Here, in this study, using MeHg as an example 
developmental toxicant, we show promise of these types of toxicogenomic 
comparisons, but also the complexity in evaluating transcriptional responses 
across models.  More intelligent design is needed for future studies which 
consider for comparable factors related to dose, time, kinetics, developmental 
time, microarray platform, species and other experimental variables to make 
proper comparisons across developmental models.  
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Summary of main findings
I n this thesis the development of the neural embryonic stem cell test (ESTn) as a high throughput system for detection of compound induced neurode-
velopmental toxicity is described: from developing  and characterizing the 
model to implementation of transcriptomics techniques in the testing strategy 
and finally the formation of a biomarker gene set for neurodevelopmental 
toxicity in this test system. In addition, the time-related and compound induced 
gene expression changes across ESTn and other in vitro and in vivo models are 
compared. A schematic summary of the main findings is provided in Figure 1.
Development and molecular characterization of the ESTn is described in 
chapter 2. A 20-day neural differentiation protocol was designed based on two 
existing protocols published by Okabe et al. and Bibel et al. [52, 103]. The 
main steps in the protocol are embryoid body (EB) formation using the hanging 
drop method, exposure of the EB to the morphogen retinoic acid (RA) at a 
physiological concentration in a suspension culture, step-wise reduction of the 
serum percentage from 20% to 0% in the medium and addition of an 
extra-cellular matrix and growth factors stimulating neural differentiation. At 
the end-stage of the differentiation culture, EB were for 75-100% surrounded 
by neural outgrowth (Figure 2). 
In order to increase the high-throughput of the test system, two additional 
shorter variants of the protocol (13 and 17 days), with a reduced ‘serum-free’ 
phase were designed and the three protocols were characterized morphologi-
cally and at the molecular level for development related protein and mRNA 
markers using immunocytochemistry, gene expression and flow-cytometry. 
Early in the protocols, which are identical the first seven days, markers for all 
three primary germ layers are expressed and in addition, an increase in 
ectodermal and specific neuron type differentiation was observed, whereas 
pluripotency markers were decreased over time. This demonstrates neural dif-
ferentiation was induced early in the protocols. Furthermore, at the end-stage 
of the three protocols, expression level of specific neuron type markers was 
comparable between the three protocol variants, except for GFAP, a marker 
for astrocytes, for which gene expression was lower but still significantly 
present in the shortest protocol. Due to the shared morphological and molecular 
characteristics of the three protocols, further experiments to test compound 
induced effects on neural differentiation were performed in the shortest 
protocol. 
As a proof-of-principle, perturbation of neural differentiation by the model 
neurodevelopmental toxicant methylmercury (MeHg) was assessed at multiple 
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concentrations. Neurite outgrowth was assessed by morphologically scoring 
the percentage of the EB surrounded by neural outgrowth and by measuring 
the amount cells positive for the pluripotency marker SSEA1, neural precursor 
marker nestin and neuronal marker βIII-tubulin. Due to the possible binding 
of MeHg to proteins in the serum, three different MeHg exposure designs were 
performed: exposure only during the serum containing period (days 3-5), only 
during the serum-free period (days 6-13) or a complete exposure (days 3-13). 
MeHg exposure effects on morphological neural outgrowth at the serum-only 
and complete exposures showed a similar concentration response, whereas the 
serum-free exposure was more sensitive. An explanation may be that at start 
of the serum-free exposure, the cell population in culture is different compared 
to the population with exposure from day 3 onwards. Furthermore, a complete 
absence of neural outgrowth observed exclusively after late exposure 
(serum-free and complete exposure) to the highest concentration tested, may 
be related to cytotoxicity of the compound at this concentration, which may be 
more pronounced under serum-free conditions. Due to the similar concentra-
tion-response observed after serum-containing and complete exposure and 
possible effects of lack of protein binding in the serum-free phase of the 
method, exposure for following experiments was performed from day 3-5. A 
scheme of the final version of the ESTn is depicted in chapter 2, figure 1.
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Figure 2  Example of an embryoid body (EB) completely surrounded by neural 
outgrowth.
Figure 1  A Schematic summary of the main findings
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General and specific effects on development could be discriminated between 
compounds. For example, concentration-dependent gene expression for the 
biological process embryonic morphogenesis was enriched for all compounds, 
indicating an effect on general development. However, cyproconazole and 
VPA (both neurodevelopmental toxicants) but not hexaconazole (developmental 
toxicant) significantly enriched the neuron development process. In addition, 
compound class specific mechanisms could be detected, including sterol 
biosynthetic process enriched by the triazoles. Implementation of transcrip-
tomics in this study was shown to precede morphological changes and provided 
a more sensitive measure to assess possible developmental toxicity.
In order to increase knowledge on the applicability domain of the test system, 
effects on gene expression of six additional compounds with a different 
mechanism of action was assessed at equipotent and non-toxic concentrations 
in chapter 5. Five compounds tested were known (neuro)developmental 
toxicants (acetaldehyde, carbamazepine, flusilazole, monoethylhexyl phthalate 
(MEHP), and phenytoin) and penicillin G was tested as a negative control. 
Compounds induced transcriptomic profiles were assessed at two concentrations 
for gene expression profiling; a toxic concentration inhibiting differentiation 
by approximately 50% or a concentration at which 80% of the cells was still 
viable and a non-toxic concentration thirty times lower. Both compound-spe-
cific and common gene expression changes were observed between subsets of 
tested compounds, in terms of significance, magnitude of regulation and 
functionality. However, overlap between the compounds was very low, 
indicating the specific mechanisms behind each of the compound’s 
developmental toxicity. In addition, gene expression and GOBP enrichment 
showed concentration dependence, allowing discrimination of non-toxic 
versus toxic concentrations on the basis of transcriptomics. This information 
may be used to define adaptive versus toxic responses at the transcriptome 
level. 
In chapter 6, transcriptomics data from chapters 3, 4 and 5 is used to identify 
a biomarker gene set to predict neurodevelopmental toxicity in the ESTn. Gene 
expression responses were distinguished using the differentiation track 
algorithm with data from ten compounds and nineteen exposures. Using 
classification feature selection in combination with a leave-one-out cross-vali-
dation, a set of 29 genes was obtained consisting of genes mainly involved in 
neural development. This set allowed for 84% prediction accuracy and may 
contribute to further improve ESTn transcriptomics studies aimed at compound 
risk assessment.
The ESTn was developed as a companion test system to the ESTc, therefore 
differences and similarities in transcriptomics responses between the two 
In chapter 3 the ESTn is further characterized by monitoring temporal gene 
expression changes related to differentiation. Cultures were sampled at days 0, 
3, 4, 5, 6 and 7 of the ESTn protocol and whole genome mRNA expression was 
assessed. Temporal regulated genes could be subdivided into eight separate 
clusters, each describing a distinct gene expression pattern over time. Multiple 
analysis techniques (including hierarchical clustering, DAVID and Tox-profiler) 
showed that early up-regulated gene clusters were involved in processes related 
to transcription and pluripotency and that late up-regulated gene clusters were 
related to processes involved in neural development. Furthermore, using 
principal component analysis (PCA) a differentiation track describing differen-
tiation over time could be constructed with all genes regulated over time, as 
was shown before for cardiac differentiation in the cardiac stem cell test (ESTc) 
[187]. The differentiation track showed that for each time-point, samples 
clustered together, but that variation between samples increased over time, 
indicating cells in culture differentiated to become more heterogeneous in gene 
expression profile. 
MeHg induced effects on gene expression over time were studied after 24, 48, 
72 and 96h exposure, starting from day 3 of culture onwards. MeHg was 
observed to up-regulate neural development related processes and 
down-regulate general development related processes and to a lesser extent, 
endoderm and mesoderm related processes. In addition, the PCA-based dif-
ferentiation track method was used to study temporal MeHg effects on gene 
expression after 24, 48 and 72h exposure. In this approach, a differentiation 
track is set up using the genes regulated by the time-matched control and the 
two control days surrounding the day of interest (e.g. for 24h exposure, 
controls days 3, 4 and 5 are used to setup the track). Then the exposed samples 
are compared to its day-matched control and significant deviation from the 
track is calculated. MeHg induced samples were most significantly deviating 
from the differentiation track after 24h exposure. Based on these results, for 
following transcriptomics experiments a 24h compound exposure with 
controls on day 3, 4 and 5 was performed.
Compound induced concentration-dependent effects on gene expression 
during embryonic stem cell (ESC) differentiation were studied in chapter 4. 
Three known (neuro)developmental toxic compounds were selected as test 
compounds; the triazoles cyproconazole and hexaconazole and the 
anticonvulsant valproic acid (VPA). Compound-mediated effects on gene 
expression were identified after 24h exposure in relation to morphological 
changes on day 11 of culture. All three compounds showed a concentration-
dependent effect in gene expression and biological processes, providing 
information on mechanisms and concentration-response characteristics. 
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the ESC default differentiation pathway is induced, mainly differentiating cells 
towards mesodermal and endodermal lineages, resulting in approximately 
40% cardiomyocytes at end of culture. Due to the relatively weak prediction 
of the ESTc for neurodevelopmental toxicants such as MeHg, the need for 
addition of a neural differentiation based EST was recognized [17, 36, 37]. 
As was described in chapter 2, we developed the ESTn as a companion model 
to the ESTc, leaving as many as possible characteristics of the original ESTc 
differentiation model intact. This approach introduced advantages, but also 
some minor disadvantages of the ESTn protocol compared to other possible 
methods. Similarly as the ESTc, standardized embryoid body (EB) formation 
using the hanging drop method is implemented in the ESTn, decreasing 
variation in EB size compared to spontaneous EB formation [21]. Three-di-
mensional EB formation furthermore allowed differentiation to mimic the in 
vivo developmental process in a more complete manner compared to monolayer 
differentiation, due to the presence of all three germ layers [307]. However, in 
the EB no physical structures such as formation of a  neural tube or blood 
vessels is observed. The three-dimensional induced multi-lineage character of 
the assay may allow improved detection of developmental toxicity in the assay. 
On the other hand, this three-dimensional complexity can be a disadvantage 
when a relatively simple morphological readout for compound effects on dif-
ferentiation is preferred. EB structure is maintained throughout the complete 
protocol, from EB formation to the morphological readout, supporting stable 
culture conditions. In previously described ESC neural differentiation methods 
for neurodevelopmental toxicity, ESC monolayer culture was used [106], or EB 
were dissociated to single cells during the protocol [41], ensuing a less stable 
protocol. Further similarities between the ESTn and ESTc, the suspension 
phase after the hanging drop phase and plating of the EB on day 5, are 
maintained to keep comparability between protocols. 
In order to induce neural differentiation, three distinct steps are implemented 
in the protocol, which were earlier described in neural differentiation protocols 
by Okabe et al. and Bibel et al. [52, 103]. The first being addition of the 
morphogen all-trans retinoic acid (RA) to the culture at the suspension phase 
at a physiological concentration during neural development in vivo [308]). The 
first developed ESC neural differentiation models already used RA as a 
morphogen to induce differentiation [52]. RA, an active metabolite of vitamin 
A, is known to play an important role in normal embryogenesis. Subtle 
gradients of RA direct morphogenesis throughout the embryo, including limb 
development and neural development [271-273]. In addition, during early 
systems are discussed in chapter 7. Gene expression profiles of both ESTn and 
ESTc over time early in both methods (days 3, 4 and 5) and changes induced 
by seven compounds, including six in vivo developmental toxicants and one 
negative control, are compared. Although temporal gene expression responses 
were generally comparable between models, a relatively small group of genes 
could be identified behaving differently in each model. These genes were 
mainly related to cardiac development and early developmental signaling 
pathways in ESTc and neural development and retinoic acid signaling in ESTn. 
Compound induced gene expression changes were generally different in either 
model, predicting mechanism behind compound developmental toxicity better 
in one model or in the other (e.g. MeHg in ESTn and FLU in ESTc). However, 
VPA induced gene expression changes were comparable in both ESTn and 
ESTc, but varied at the process level. A comparison between the two models 
shows that a tiered approach of compound screening in ESTc and ESTn may 
improve prediction and understanding of the compound mechanism of action.
A transcriptomic based in vivo versus in vitro comparison is performed in 
chapter 8 in order to obtain insight on differences in prediction and mechanism 
of action in different models. The impact of MeHg on a diverse set of in vitro 
and in vivo models was assessed. Models predicting developmental toxicity 
were the in vitro rat whole embryo culture (WEC), ESTc and ESTn and two 
mouse-embryo developmental toxicity studies. Models predicting general 
toxicity were an embryonic fibroblast system, adult rat liver brain studies. 
Evaluation of common and unique aspects at the functional and gene level 
showed stronger similarities in MeHg response between the development 
related studies compared to the general toxicity studies. This comparison 
shows in vitro / in vivo similarities supporting the relevance of in vitro 
developmental models for predicting in vivo developmental toxicity.
General discussion
Development of a neural differentiation cell culture
ESC differentiation models are currently very promising as alternative and 
animal-free models for developmental toxicity [306]. Due to the pluripotent 
nature of ESC, in theory the effect of compounds on any differentiation route 
of the three germ layers can be studied, which is not possible in primary cell 
lines, immortalized cell lines, or cells already in a more advanced stage of dif-
ferentiation, such as neural progenitor cells (NPC) [19, 130-132]. In the ESTc, 
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was performed on very distinct morphological stages during ESC differentia-
tion with relatively much time between time-points studied, by which especially 
during early ESC differentiation, subtle short changes in gene expression were 
not identified. More recently, early temporal gene expression changes over a 
relatively small time-span (one day or less) were studied in a number of ESC 
differentiation protocols, including the ESTn and ESTc, as described in chapter 
3  and chapter 7  [177, 187, 235]. In these studies, it was shown that the 
continuous developmental changes occurring in various mouse and human 
ESC differentiation models could be visualized using PCA to describe a ‘dif-
ferentiation track’ [177, 187, 235, 316]. This approach makes it possible to 
visualize and quantify differentiation status and developmental potency status 
of cells cultures. In the ESTn, the differentiation track over time showed that 
all time-points clustered together and separate time-points were ordered 
chronologically. However, over time, variation between samples increased, 
probably due to increased heterogeneity of the cell culture. Studies on ESC dif-
ferentiation have been instrumental in describing differentiation processes, 
showing a reduction of pluripotency and an induction of neural differentia-
tion-related gene sets over time [177, 187, 235]. In addition, these studies 
showed that early ESC differentiation in diverse differentiation protocols is 
characterized by a cascade of time-dependent early-, mid- and late-regulated 
gene expression profiles and processes. For instance, in ESTn, ESTc and other 
ESC differentiation models, genes and processes involved in pluripotency 
(including Pou5f1, Nodal and Eomes) and proliferation (including Ccnd1 and 
Ccne1) were up-regulated early and down-regulated over time, genes 
up-regulated for a short duration during the midterm of the protocol related to 
early differentiation (T, Cyp26a1, Frzb, Lhx1) and genes and process 
up-regulation of (end-stage) differentiation as a late response (including Tubb3, 
Pax6, Gata6 among others). These ‘coordinated waves’ of differentiation have 
also been observed in vivo during the gastrula stage in multiple species, 
including the mouse [317]. 
Comparing temporal gene expression profiles in ESTn and ESTc
In order to further characterize early ESC differentiation, in chapter 7 early 
temporal gene expression signatures (days 3, 4 and 5) for neural differentiation 
in ESTn and cardiomyocyte differentiation in ESTc were compared. This 
analysis showed for a large part (71% of genes regulated in either model) early 
gene expression profiles in the two models were regulated similarly, illustrating 
that temporal differentiation related genes are conserved in both models. In 
addition, genes regulated early specifically in ESTn (12%) could be related to 
connected processes involved in patterning (mainly homeobox related), RA 
organogenesis in vivo, RA levels are observed to be highest in the neural tube 
[272]. The second critical step in the ESTn is gradual serum deprivation of the 
medium as an induction and selection for neural cell types. Serum deprivation 
is currently widely used to induce ESC neural differentiation and was first 
described in an ECC cell line [56, 309]. In ECC, serum deprivation was 
described to induce neural differentiation and in addition induce apoptosis in 
other cell types which depend on serum for growth [309, 310]. However, 
specific mechanisms behind the effects of serum deprivation on neural differ-
entiation remain unclear. The last critical step in the ESTn is facilitating neural 
growth by offering a an extracellular matrix (laminin and poly-L-ornithine) 
and addition of growth factors to the medium [311]. These growth factors 
include progesterone, sodium selenite, transferrin and bFGF and are used in 
serum free primary neuron cultures to create a viable environment for neural 
cell types [308]. Together RA supplementation, serum deprivation, the 
extracellular matrix and  addition of growth factors create the environment 
for ESC to differentiate into neural cell types in ESTn.
Molecular characterization of ESC neural differentiation
Characterization at the single gene level
Characterization of differentiation over time in ESC differentiation cultures 
has been performed using distinguished gene expression markers for differen-
tiation of all three germ layers, as was also performed in ESTn in chapter 2 
[19]. Using this approach, differentiation can be studied in broad terms with 
markers for pluripotency (e.g. Pou5f1 and SSEA1), markers for progenitor cells 
of the three germ layers (e.g. T, nestin, Nkx2-5) and markers for mature cell 
types (e.g. Myh6, Tubb3, GFAP), which has shown characteristics reminiscent 
of germ layer development and specific lineage differentiation in ESTn and 
other models [19, 312]. Although this approach can provide information on 
general temporal regulation of predetermined differentiation routes, obtained 
information remains limited due to the pre-selection of genes. 
Characterization at the whole genome level
In recent years, transcriptomics analysis have provided a more complete view 
of ESC differentiation dynamics. A number of studies published described a 
range of differentiation routes, including cardiac, neural and pancreatic dif-
ferentiation [80, 169, 313-315]. In these studies it was confirmed that gene 
expression profiles of specialized cellular differentiation protocols were 
concurrent with functional processes observed for specific regions of the 
embryo during development. However, in these studies transcriptome profiling 
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genes [41, 321]. In order to perform quick readout screens, a relatively fast 
readout system was required for ESTn. Due to the complexity of the neural 
outgrowth at the end of culture, fast measurement of functional parameters 
was not possible. Therefore, initially a combination of a morphological and 
molecular approach was chosen, assessing neural outgrowth from EB micro-
scopically and compound effects on protein markers using flow cytometry, as 
was described in chapter 2. Morphology of neural outgrowth was scored as 
the percentage of neural corona surrounding each EB, irrespective of the 
distance of outgrowth from the EB. A scoring was performed for 100, 75, 50, 
25, <10 and 0% neural outgrowth surrounding the EB (Figure 3). For scoring 
compound effects on neurite outgrowth, a cutoff was chosen at ≥75% neural 
outgrowth around the EB, based on historical control data. Thus, when more 
than 75% of the corona around an EB contained microscopically observable 
neural outgrowth, the EB was scored positive, whereas below 75% it was 
scored negative. Using a concentration-response curve, the concentration by 
which a 50% inhibition of differentiation (ID50) (EB with >75% neural 
outgrowth) was observed, could be identified. This ID50 method has also been 
used to define developmental toxicity in the EST [17]. 
Next to morphology, initially flow cytometry was used to count the number of 
cells positive for the pluripotency marker SSEA1, neural precursor marker 
nestin and neuron marker βIII-tubulin. Flow cytometry has been successfully 
implemented in the validated EST using the cardiomyocyte marker MYH as 
readout parameter [322]. As a proof-of-principle, effects of the model neurode-
velopmental toxicant MeHg were assessed using the morphology and 
flowcytometry readouts. A strong concentration-response was observed in the 
morphological readout, but only limited prediction was observed by the flow 
cytometry method. Therefore, for further experiments, morphological scoring 
metabolism and neural development, whereas genes regulated specifically in 
ESTc (17%) were related highly connected to Wnt-, Tgfβ- and BMP signalling 
and cardiac development, showing early gene expression responses are highly 
related to the morphological phenotype later in the protocols. 
Temporal gene expression profiles in ESC differentiation in context 
of in vivo organogenesis
A useful in vitro model should to a certain extent be comparable to the in vivo 
situation [318]. Mouse ESC are collected in vivo from the inner cell mass of the 
blastocyst, approximately 4 days after fertilization [19]. Therefore, the first 
week of ESC differentiation is expected to be correlated to day 4 - 10, during 
gastrulation of the developing embryo [19]. Mitiku and Baker performed a 
very detailed genomic profiling of gastrulation and organogenesis in the mouse 
embryo from day 6.5 through 9.0 post conception, which was compared to our 
data in the discussion in chapter 3 [171]. Seven gene clusters were identified, 
describing specific processes during development, including two clusters 
involved in neurogenesis and cardio-vasculature development, which were 
up-regulated from day 8.0 onwards, in a comparable manner to late responses 
observed in ESTn and ESTc [171, 177, 187]. Interestingly, another cluster 
involved in blood vessel development and neurogenesis consisted of genes with 
a peak up-regulation at day 8, which was again down-regulated at day 9.0, 
similar to the observation in ESTn and ESTc. Comparisons of gene clusters 
with late expression profiles in ESTn with the in vivo data were performed and 
corresponding genes, and GO terms were observed.  Although evidence is 
limited, this similar gene signature provides an additional indication that 
processes involved in ESTn and ESTc are comparable to the in vivo situation.  
 
 
ESTn as a test system for assessment of neurodevelopmental 
toxicity
Developing an endpoint for neurodevelopmental toxicity in ESTn
For detection and prediction of adverse effects on neural differentiation in the 
ESTn, a readout method was needed. In earlier described models for 
neurotoxicity and neurodevelopmental toxicity, a number of readouts have 
been proposed [319], including cell morphology by assessing neural outgrowth, 
axonal and dendritic morphology, cytotoxicity/viability and migration in 
monolayer or neurosphere cultures [149, 150], functional parameters 
determined by electric potential or calcium homeostasis [147, 320] or assessing 
neural differentiation using mRNA transcripts of a small selected number of 
100% 75% 50% 25% <10% 0%
Positive Negative
Figure 3  Schematic overview of Morphological Scoring criteria for determining the 
percentage of neural outgrowth around the EB.
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morphological outgrowth, however, this method does not take into account 
effects on the variety of cell types in culture, such as shifts in ectodermal 
versus other germ layer type cells or even differences in neuron types or neurons 
versus astrocytes [319]. In addition, as stated before, neuron functionality 
cannot be taken into account using this model. Furthermore, morphological 
scoring provides insight on the ultimate effect of a compound on neurite 
outgrowth, while the adverse compound effect might have occurred much 
earlier in the differentiation process, as was observed in ESTc [155]. Although 
the morphological readout in ESTn and other readouts in previous test systems 
show promise in being used for the prediction of neurodevelopmental toxicity, 
the complexity of the developing nervous system warrants a more comprehensive 
assessment at the molecular level of exposure effects by neurodevelopmental 
toxicants [60].
Implementation of transcriptomic techniques in ESTn for 
prediction of neurodevelopmental toxicity 
The usefulness of transcriptomics as a mechanistic approach for prediction of 
(neuro)developmental toxicity has been shown in vivo and in vitro [79, 80, 82, 
151]. The use of molecular screens for toxicity testing is furthermore predicted 
to play an important role in near-future risk assessment [217]. The aim of 
transcriptomics implementation in the ESTn was to increase test throughput 
by measuring compound toxicity at an earlier stage, gain additional mechanistic 
insight in compound specific toxicity and to find biomarkers for (neuro)
developmental toxicity [177, 263]. Performing a time-response transcriptomics 
study to determine most robust gene expression changes over time has been 
proven useful before in mouse developmental toxicity studies [152]. In order to 
determine the most informative exposure duration, MeHg exposure effects at 
the morphological ID50 concentration after 24, 48, 72 and 96h exposure were 
assessed in chapter 3. Using multiple analysis tools, from the single gene level 
to process enrichment, MeHg was observed to increase neurectodermal related 
genes and decrease mesodermal, endodermal and early differentiation genes 
over all time-points. Similar observations made in the WEC and in vivo in 
mice confirmed that transcriptomics in the ESTn can provide additional 
information on compound mechanism of action [82, 152]. In vivo mechanism 
of action was later also verified in ESTn for multiple other compounds in 
chapter 4 and chapter 5, including VPA, cyproconazole and flusilazole [203, 
263].
In order to make a statistical prediction for compound induced neurodevelop-
mental toxicity in ESTn, the differentiation track approach was used in chapter 
3 determining best exposure timing, chapter 5 to explain differences in 
of neurite outgrowth was used as a parameter to define compound effects on 
neural differentiation and outgrowth. 
Exposure strategy: Selection of exposure duration and 
concentration ranges
Due to the complexity of the ESTn, including changes of serum percentage in 
culture medium and the differentiating character of the culture cell types, 
effects of compound exposure duration and concentration ranges should be 
taken into consideration, in order to obtain an optimum exposure strategy for 
assessing compound perturbation on neural differentiation in ESTn (chapter 
2). The ESTn was designed to detect compound induced effects specifically on 
neural development. In an optimal setting, a compound has an effect on neural 
differentiation, but not on cell viability or cytotoxicity [17]. Therefore, a 
viability assay (the Resazurin assay) on ESC was performed to determine the 
cytotoxic effects of a compound, and to determine a concentration-range to be 
tested in ESTn [323]. Furthermore, previous studies performed in our 
laboratory showed that proliferation and differentiation of ESC in the ESTc 
are highly intertwined processes [137]. It was recommended that, to largely 
limit exposure to the proliferation phase of the assay, it would be advantageous 
that EB be exposed to compounds from day 3 in the assay onwards [137]. Up 
to day 3, the ESTc and ESTn are identical. Therefore, compound exposure was 
performed from day 3 onward in all studies. Another variable influence on 
exposure in culture was serum deprivation of the culture medium [324]. Effects 
of MeHg exposure only during the serum-containing period (days 3-5), only 
during the serum-free period (days 6-13) or a complete exposure (days 3-13) 
was assessed. Due to the similar concentration-response observed after serum-
containing and complete exposure and possible differences in exposure due to 
compound binding to protein between the serum-containing and serum-free 
phase of the method, exposure for following experiments was performed from 
day 3-5. In addition, temporal transcriptomics profiling of ESTn differentia-
tion described in chapter 3 showed that greatest changes in gene expression are 
observed early in the ESTn (day 3-5) compared to later (days 6 and 7), indicating 
greatest compound effects can be expected during this stage of culture [177].  
Limitations of scoring of neural outgrowth as a readout for neuro-
developmental toxicity
Although the morphological readout in ESTn was successful in predicting neu-
rodevelopmental toxicity for a number of compounds, including MeHg, 
valproic acid, carbamazepine and phenytoin (chapters 3, 4 and 5), there are 
limitations to this readout. The scoring only takes into account the 
CHAPTER 9 SUMMARY AND GENERAL DISCUSSION
208 209
Implementation of transcriptomic concentration-response in ESTn 
to identify adaptive and adverse responses
The value of taking into account concentration-response in combination with 
transcriptomics to identify compound toxic properties has been shown in 
various fields of toxicological research [151, 229, 230, 305, 325]. In the field of 
reproductive toxicology, Naciff and Daston performed a range of studies in the 
male and female reproductive tract, showing individual endocrine disruptor 
induced gene expression changes followed a dose-response relationship [73, 
325-327]. Comparable findings were observed in developmental toxicity 
studies by Robinson et al., where exposure to the metals MeHg, cadmium and 
arsenic showed a dose-dependent effect on development related gene expression 
and process enrichment during gestational development in the mouse [152, 
279]. Furthermore, a study in the ESTc described flusilazole concentration-
dependent mechanisms of action at the transcriptome level [230]. Effects on 
processes related to development were observed at lower concentrations than 
those related to sterol metabolism, followed by enrichment of cell cycle gene 
expression at even higher cytotoxic concentrations. Similar findings were 
observed in chapter 4 where exposure to VPA, cyproconazole and hexaconazole 
in the ESTn showed a concentration-dependent effect on individual gene 
expression, fold change and process enrichment. Using a concentration-re-
sponse approach, mechanistic effects on development related processes could 
be identified at concentrations below observed effects on morphology, 
providing a more sensitive measure of concentration-dependent effects. 
Furthermore, compound specific process enrichment could be identified, 
enabling discrimination between the neurodevelopmental- (e.g. VPA and 
cyproconazole) and more general developmental toxicants (e.g. hexaconazole). 
In addition, compound class specific responses on sterol metabolism could be 
identified, discerning the triazoles from VPA.    
Although using transcriptomics enables to detect compound induced effects on 
gene expression with greater sensitivity, a definition is required to discriminate 
adaptive from adverse gene expression changes. This definition should identify 
the level of regulation of a functional process representing an adverse response, 
in order to discern compound adverse effects exclusively with gene expression. 
This distinction has gained importance in view of interpreting gene-expression 
findings for risk assessment [226]. Until adverse and adaptive responses are 
identified, application of toxicogenomics for risk assessment remains dependent 
on traditional toxicology parameters [328]. Based on available human data, it 
has been proposed that reproductive and developmental toxicants have a 
threshold of adversity [329]. Current in vivo developmental toxicity testing 
paradigms are also build upon this hypothesis [10, 11]. In order to discern 
mechanism of action between compounds and for biomarker discovery in 
chapter 6. The differentiation track approach was first described by van Dartel 
et al. [187]. Using this technique, differentiation over time can be visualized by 
PCA and compound induced deviation from the track can be statistically 
defined [187]. Earlier we observed an increase in variation of late time-point 
samples for differentiation over time, indicating an increased heterogeneity 
between samples of one time-point [177]. Furthermore, greatest dynamics in 
gene expression changes were observed at day 4 (which is the same time-point 
as a 24h exposure) on the differentiation track compared to the remaining 
time-points, as was also observed in ESTc [177, 187]. Compound induced 
effects on the differentiation track were further studied on a 24, 48 and 72 
hour exposure differentiation track. The 24 hour MeHg exposure provided the 
most significant deviation from the differentiation track, whereas 48 and 72 
hour exposure samples did not deviate significantly from the track, due to 
increased time- and compound-induced sample variance. Furthermore, a 
shorter exposure of 6 and 12 hours with monobutyl phthalate in the ESTc did 
not induce any significant gene expression changes [40]. Therefore, based on 
the least variance, greatest observed dynamics in temporal gene expression 
and most significant compound deviation from the track, a 24 hour exposure 
was chosen for following experiments. Use of the differentiation track in 
chapter 5 was furthermore instrumental to visualize compound induced 
changes on differentiation [263].
In chapter 6, the differentiation track was further used to obtain a biomarker 
set for prediction of neurodevelopmental toxicity in the ESTn. Using a de novo 
analysis, including a leave-one-exposure-out approach, a gene set consisting of 
29 genes was developed using data from chapters 3, 4 and 5. This gene set 
described both ESC differentiation and predicted neurodevelopmental toxicity. 
Evaluating the performance of this gene set in combination with the differen-
tiation track algorithm showed that developmental toxicity of 10 compounds 
and 19 toxic and non-toxic exposures could be correctly predicted with an 
accuracy of 84%. These genes were mainly involved in processes related to 
neural development and general development. A similar approach was 
successfully performed for the ESTc for 15 compounds, resulting in a set of 52 
genes with an accuracy of 83% [84]. In contrast to the prediction accuracy of 
78% under the original ECVAM validated EST, the results for both ESTn and 
ESTc are promising [17]. However, additional compounds have to be evaluated, 
including negative controls and pharmacological active compounds which are 
not developmental toxic, to further confirm prediction of these differentiation 
track-based novel identified gene sets. 
CHAPTER 9 SUMMARY AND GENERAL DISCUSSION
210 211
information is followed by non-testing information such as read-across and 
(Quantitative) Structure-Activity Relationships ((Q)SAR). Simple in vitro 
screening assays, such as receptor binding assays, will provide more mechanistic 
data and as a next step, more complex (multi)cellular in vitro models such as 
the ESTn, can be studied. In this phase, multiple test systems each describing a 
part of development could be combined to provide a more complete indication 
of possible untoward effects on embryogenesis, functioning as a prioritizing 
tool for determining whether in vivo developmental toxicity studies are 
necessary. An initiative combining multiple in vitro models in an effort to 
determine compound induced toxicity in humans is the US Environmental 
Protection Agency (EPA) ToxCast program [332]. In this project 650 in vitro 
assays, including a variant on the ESTc, are combined to obtain a chemical 
fingerprint of currently more than 2000 chemicals. Using computational 
technology, it is thought a prediction model can be constructed for 
developmental toxicity based on high- throughput systems [266]. The optimal 
place of ESTn within an intelligent testing strategy is dependent on a clear 
definition of its applicability domain, in terms of the biological processes 
represented in the assay. The term applicability domain was defined by 
European Centre of Validation of Alternative Methods (ECVAM) as: Definition 
of the chemical classes and/or ranges of test method endpoints for which the 
model makes reliable predictions [35]. According to this definition, the 
predictive value of the method for different compound classes should assist in 
determining its applicability domain. Furthermore, the biological mechanisms 
incorporated within the system need to be characterized, to define the scope 
and limitations of the assay. 
Defining the applicability domain
Developmental toxicants are structurally diverse and induce a broad range of 
developmental defects [333]. Furthermore, it has been shown that compounds 
inducing comparable birth defects, can do this through multiple mechanisms 
of action. For instance, in the WEC it was observed that four compounds 
inducing spina bifida in vivo showed limited overlap in toxicogenomic 
responses [82]. In chapter 5 a similar finding is observed in the ESTn, where 
five compounds inducing neural tube defects in vivo showed no overlap in gene 
expression responses. To deal with this issue, a compound category approach 
may be useful. This strategy allows the assessment of specific chemical classes 
and their biological mechanisms for which the ESTn can make accurate 
prediction. A category approach could lead to a substantial reduction in animal 
use for developmental toxicity testing. When a chemical class has been correctly 
adverse from adaptive effects on gene expression, Daston and Naciff proposed 
an approach for validation of in vitro alternatives, in which not the compound 
per se but an “exposure”, defined as a compound concentration or dose, is 
classified as a developmental toxicant, enabling the use of a compound 
exposure as both a  ‘positive’ and a ‘negative’ toxicant [101].  In line with this 
approach ESTn gene expression responses between a non-developmental toxic 
and a developmental toxic exposure concentration were compared in chapter 
5. The study design was aimed at distinguishing between adaptive and adverse 
responses at the gene expression level. The developmental toxicants 
carbamazepine and flusilazole were observed to enriched pathways involved in 
transcription and compound metabolism at the low concentrations, whereas 
development related processes were enriched only at the high concentration. 
Additionally, the low concentration carbamazepine enriched histone 
methylation related processes which represent a known pharmacological 
mechanism of action of carbamazepine [227]. Taken together current evidence 
in literature suggests that up to a certain level of induction, general physiological 
pathways such as related to transcription and metabolism may indicate 
adaptive responses, whereas the induction of developmental pathways may be 
more specifically indicating adverse responses [151, 203, 229, 230, 305, 325]. 
In addition, the magnitude of induction should be considered. More detailed 
studies and development of additional concentration-response modeling tools 
will be needed to define the thresholds between adaptive and adverse responses 
in in vitro assays, in the interest of their interpretation and in view of hazard 
and risk assessment [217]. 
ESTn in risk assessment
Risk assessment determines the risks of human exposure to a compound or 
pharmaceutical [330]. Regulatory risk assessment is currently based on animal 
toxicity studies [9, 11]. Intelligent testing strategies are used to assess 
toxicological profiles, using decision schemes to determine the requirements of 
animal studies needed for hazard assessment [331]. Intelligent testing strategies 
use a stepwise approach (battery or tiered) with tests of increasing complexity 
to gather information on compound toxicity, weighing the information to 
determine further testing after each test performed, with the aim of limiting 
the number of animals needed. To further reduce the number of animals and 
decrease the time consuming process of toxicity testing, enhancing the use of 
in vitro developmental toxicity testing methods within intelligent testing 
strategies is desirable. In an intelligent testing strategy, such as the OECD 
conceptual framework [11], initial prioritization based upon all existing 
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profiles of both ESTn and ESTc over time early on days 3, 4 and 5 are compared. 
Although temporal gene expression responses were generally comparable 
between models, a relatively small group of genes could be identified behaving 
differently in each model. These genes were mainly related to cardiac 
development in ESTc and neural development in ESTn. Gene expression 
changes induced by seven compounds, including six in vivo developmental 
toxicants and one negative control were assessed further. Compound induced 
gene expression changes were generally different in either model, predicting 
better in one model or in the other. For instance, the neurodevelopmental 
toxicant MeHg, which was misclassified in the validated EST [17], specifically 
induced gene expression changes related to neural development in ESTn, and 
only general development in ESTc. Furthermore, the tested concentration in 
ESTn was 200 fold lower compared to ESTc, indicating a higher sensitivity of 
neural differentiating cells to MeHg. On the other hand, specific effects of 
flusilazole on cardiac differentiation were observed in ESTc, whereas at a 
comparable concentration, no specific effects on neural differentiation were 
observed in ESTn. Furthermore, VPA induced gene expression changes were 
comparable in both ESTn and ESTc, but varied at the process level. Testing of 
developmental toxicants in both ESTc and ESTn in a tiered approach can 
provide additional information for in vitro developmental toxicity prediction 
screens, especially when a compound is suspected to be a neurodevelopmental 
toxicant, as shown with MeHg.
Interspecies- and in vitro / in vivo extrapolations using 
 transcriptomics
Transcriptomics assessments provide a sensitive, robust and common endpoint 
that can be compared across in vivo and in vitro models, which usually use a 
variety of model-specific morphological endpoints to determine developmental 
toxicity. Additionally, cross-comparisons across in vitro and in vivo models 
may facilitate the identification of relevant biomarkers associated with compound 
exposure and developmental toxicity, and increase our understanding in 
determining how systems correlate in terms of response to compounds. 
For extrapolation between species in vivo, there is recent transcriptomics 
evidence that the phylotypic stage plays a critical role in development [339]. 
Irie and Kuratani performed a quantitative comparative transcriptome analysis 
of four model vertebrate embryo models (mouse, chick, zebrafish and frog) and 
showed that the phylotypic stage is the most conserved phase in development 
across vertebrates (e.g. GD8.5 in mouse and 24hpf in zebrafish) [339]. During 
this stage, forming of the blastula, gastrulation and neurulation occur. In 
addition, at earlier (cleavage and morula) and later stages (somitogenesis and 
predicted in vitro, chemicals belonging to the same class but with unknown 
embryotoxic properties could reliably be tested in the ESTn. In addition, using 
a read-across approach a prediction can be made as to the embryotoxic potency 
of that compound. Implementing a compound category approach and relative-
potency ranking within a compound class have proven to be reliable methods 
for determining relative toxic properties in various models for developmental 
toxicity [15, 78, 81, 277, 334-336]. In the ESTc, de Jong et al. were able to rank 
relative potency of a series of homologous compounds, glycol ether alkoxy acid 
metabolites, valproic acid analogs and triazoles, matching the potency ranking 
to in vivo ranking [15, 334, 335]. In addition, using transcriptomics, 
categorization of phthalates and triazoles was performed in the ESTc, using 
gene sets of class specific differentiation modulation [81, 337]. Furthermore, 
within classes, known in vivo developmental toxicants and non-developmental 
toxic compounds could be distinguished using gene expression profiling [81]. 
In line with these studies, in chapter 4 a transcriptomic comparison between 
gene expression profiles induced by two triazoles, the neurodevelopmental 
toxicant cyproconazole and developmental toxicant hexaconazole, was 
performed in ESTn. For both compounds, effects on general embryonic 
development terms could be identified, however, only for cyproconazole effects 
on neuron development were observed. Although further research is needed to 
determine the applicability domain of the ESTn, these results provide promising 
insight. To further increase knowledge on the applicability domain, a proposed 
method is identification of perturbations in pathways of toxicity in a model 
[217]. In the National Research Council’s proposed 21st century toxicity testing 
strategy, these pathways of toxicity are identified as the biological signaling 
pathways important in compound perturbation [217]. In their vision, a systems 
approach can be used to describe the fundamental biologic events involved in 
toxicity pathways and to provide evolving biologic modeling tools that describe 
cellular circuits and their perturbations by compounds [338]. When the specific 
pathways of toxicity are identified for the ESTn, the applicability domain of 
the test system will be better understood.
Extrapolating transcriptional profiling in the ESTn to other 
test systems and species
Transcriptomic ESTn and ESTc comparisons
The ESTn was developed as a companion test system to the ESTc, and in both 
models transcriptomics studies have been performed to determine 
developmental toxicity. In chapter 7 differences and similarities in transcrip-
tomics responses between the two systems are discussed. Gene expression 
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organogenesis) transcriptomic profiles between vertebrates is less conserved. 
Extrapolation of compound induced developmental toxicity between species at 
the phylotypic stage may be more relevant than at earlier or later stages. 
Current transcriptomic tests performed in vivo, and in the WEC, zebrafish, 
ESTn and ESTc are performed during this stage, increasing the probability of 
finding effects which can be extrapolated to the human situation [77, 82, 84, 
177, 215].
Although limited, initial comparative studies across models have shown the 
ability to match gene alterations linked with developmental toxicity in vivo 
with biomarkers in vitro. In a study by Kultima et al. [340], targets of valproic 
acid associated with effects on neural tube development in vivo were identified 
to be commonly altered in P19 neuroblastoma cells due to valproic acid.  Genes 
commonly altered between the two models represented known neural tube 
defect candidate genes and pathways critical for early embryogenesis (e.g. 
retinoic acid).  In a parallel transcriptomic comparison study between 
unexposed cultured whole embryos (WEC) and embryos in vivo, high 
similarities in gene expression changes over time were identified between the 
two model systems, including significance of gene expression changes, direction 
in regulation (increase or decrease) and corresponding functionality [341], 
suggesting the WEC to be a good representation of this particular window of 
in vivo development at the molecular level. Similarly, in response to all-trans-
retinoic acid exposure, high similarity in gene expression changes were 
observed between WEC and embryos in vivo despite both common and unique 
developmental toxicity endpoints [77].
In chapter 8, a larger comparison study between in vivo model systems and in 
vitro systems, including the ESTn and ESTc, MeHg-induced transcriptomic 
response was compared to identify commonalities and dissimilarities in 
response [342]. Greater similarity were observed in terms of response between 
mouse embryos exposed in utero (2 studies), differentiating ESC in the ESTc 
and ESTn and WEC as compared to adult mouse liver, juvenile mouse brain 
and mouse embryonic fibroblast MeHg-studies. MeHg was observed to impact 
developmentally-related signatures in the early development model systems (in 
vivo or in vitro) versus the non-traditional developmental model systems. 
Future comparisons between ESTn and in vivo (as well as other alternative 
systems) using the emerging rich toxicogenomic databases should increase the 
mechanistic understanding of the relevancy of compound induced response in 
the ESTn, and therefore, the applicability domain of the ESTn for developmental 
toxicity testing. 
Conclusion 
In this thesis the development of the ESTn and implementation of transcrip-
tomics into the ESTn testing strategy have been described, ultimately resulting 
in a biomarker gene set for prediction of neurodevelopmental toxicity. 
Compound effects on gene expression have been studied both over time and 
concentrations, comparing mechanism of action of a range of neurodevelop-
mental toxicants. Furthermore, comparisons between ESTn, ESTc and other 
developmental toxicity models show the ESTn can add mechanistic insight and 
increased prediction to the developmental toxicity testing strategy. In order 
increase the prediction of the ESTn, the applicability domain of the ESTn 
should be further defined by defining the pathways of toxicity important in 
ESTn neural differentiation and compound perturbation.
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Inleiding
D e wetenschap van de ontwikkelingstoxicogie houdt zich bezig met het onderzoeken van de giftige effecten van stoffen op de ontwikkeling van de 
ongeboren vrucht. Om geboorteafwijkingen door giftigheid van stoffen te 
voorkomen, verplicht huidige internationale wetgeving fabrikanten om stoffen 
en medicijnen te testen op ontwikkelingstoxiciteit. De bepaling van toxiciteit van 
een stof wordt uitgevoerd op proefdieren. Van alle proefdieren die tegenwoordig 
gebruikt worden voor toxicologische testen, wordt ongeveer 65% gebruikt voor 
fertiliteit- en ontwikkelingstoxicologie. Dit komt doordat in deze studies het 
effect van stoffen over meerdere generaties dieren wordt bestudeerd. Omdat het 
gebruik van proefdieren ethisch ongewenst is, is het belangrijk om nieuwe 
alternatieve testsystemen te ontwikkelen voor het voorspellen van ontwikke-
lingstoxiciteit, waarbij minder of zelfs géén proefdieren gebruikt hoeven te 
worden. Daarnaast zijn de huidige testen te arbeidsintensief om voorspellingen 
te kunnen doen over de giftigheid van een groot aantal stoffen in een korte tijd. 
Een veelbelovend alternatief model voor het voorspellen van ontwikkelings-
toxiciteit is de embryonale stamcel test (EST). Deze test maakt gebruik van de 
pluripotente eigenschap van embryonale stamcellen (ESC), waardoor deze cellen 
kunnen differentiëren tot elk celtype in het lichaam. In deze test worden 
stamcellen gedifferentieerd tot hartspiercellen (cariomyocyten), welke onder de 
microscoop waarneembaar zijn doordat deze cellen contraheren. Het verstoren 
van deze differentiatie ten gevolge van blootstelling aan ontwikkelingstoxische 
stoffen wordt gezien als een maat voor ontwikkelingstoxiciteit. Dit wordt gemeten 
door met behulp van de microscoop 'handmatig' het aantal celculturen met 
kloppende gebieden te tellen. Uit validatie van de EST bleek dat de test een redelijk 
goede voorspelling gaf voor ontwikkelingstoxiciteit, maar niet voor stoffen welke 
een nadelig effect hebben op de ontwikkeling van het zenuwstelsel. Om de voor-
spelbaarheid van de EST te verbeteren, werden daarom een aantal voorstellen 
gedaan. Een van deze verbeteringen was het ontwikkelen van een neurale variant 
van de EST, om de giftigheid van neuraal ontwikkelingstoxische stoffen toch goed 
te kunnen voorspellen. Een ander voorstel was om de subjectieve handmatige 
scorings methode van de EST te vervangen door een objectievere maat. Een methode 
om dit te doen is met behulp van transcriptomics, een relatief nieuwe techniek 
waarmee de expressie van tienduizenden genen in één experiment gemeten kan 
worden. Wanneer met deze techniek het verschil in genexpressie tussen blootgestelde 
en niet blootgestelde cellen gemeten wordt, kan een profiel ontwikkeld worden 
welke stof geïnduceerde effecten op ontwikkeling in een testsysteem beschrijft. 
Daarnaast kan deze methode opheldering geven over de vele moleculaire 
mechanismen die ten grondslag liggen aan  ontwikkelingstoxiciteit. 
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over de tijd verhoogd waren en markers voor pluripotentie over de tijd verlaagd 
werden. Hiermee werd aangetoond dat neurale differentiatie al vanaf vroeg in 
het protocol geïnduceerd werd. Vergelijking van de eindstadia van de drie 
protocollen laat zien dat de mate van genexpressie voor verschillende neuronen 
typen vergelijkbaar is. Uit dezelfde analyse blijkt dat het genexpressie niveau 
voor een marker voor astrocyten lager, maar nog steeds significant verhoogd is 
in het korte protocol ten opzichte van de andere twee langere protocollen. 
Aangezien de drie protocollen wat betreft morfologie en moleculaire expressie 
vergelijkbaar zijn, werd voor de volgende experimenten gebruik gemaakt van 
het kortste protocol, wat we vanaf nu de ESTn zullen noemen.
Om te bepalen of het mogelijk was om specifieke neurale ontwikkelingstoxici-
teit te kunnen voorspellen in de ESTn, stelden we de cellen bloot aan methylkwik 
(MeHg) op verschillende concentraties. We bepaalden het effect van MeHg op 
de neurale differentiatie door bij verschillende EB de mate van neurale uitgroei 
rond de EB te bepalen. Daarnaast gebruikten we de flow-cytometrie methode 
om het percentage cellen te tellen dat positief was voor de volgende drie 
markers: SSEA1, een marker voor pluripotentie; nestin, een marker voor 
neurale voorlopercellen; en βIII-tubuline, een marker voor neuronen. Doordat 
MeHg aan bestanddelen van het serum in het medium kan binden, kan de 
effectieve concentratie en daarmee de blootstelling aan de cellen dalen. 
Aangezien in de ESTn het serum percentage in het medium verlaagd wordt van 
20% naar 0%, voerden we drie verschillende blootstellingen uit: blootstelling 
tijdens de serum periode (dag 3-5), tijdens de serum vrije periode (dag 6-13) of 
tijdens de gehele periode (dag 3-13). Effecten van MeHg op de neurale uitgroei 
waren vergelijkbaar voor blootstellingen tijdens de serum periode en gehele 
periode, terwijl de serum vrije periode gevoeliger was. Daarnaast was bij de 
hoogst geteste concentratie nog steeds neurale uitroei waargenomen bij de 
serum periode blootstelling, terwijl bij de twee andere blootstellingen geen 
neurale uitgroei meer was. Dit komt waarschijnlijk doordat tijdens de serum 
vrije periode meer MeHg vrij beschikbaar is in het medium waardoor de 
effectieve concentratie toeneemt. Door de vergelijkbare concentratierespons 
tijdens de serum periode en complete blootstelling werd voor de toekomstige 
experimenten gebruik gemaakt van de blootstelling van dag 3 tot dag 5. 
In hoofdstuk 3 wordt de ESTn verder gekarakteriseerd door genexpressie over 
de tijd te bestuderen met behulp van transcriptomics. We namen monsters van 
celkweken op dag 0 van de kweek (pluripotente ESC) en op de dagen 3, 4, 5, 6 
en 7 tijdens de neurale differentiatie. Genen die gereguleerd waren over de tijd 
konden, op basis van hun genexpressie profiel, onderverdeeld worden in acht 
Samenvatting
I n dit proefschrift wordt de ontwikkeling van de neurale embryonale stam- cel test (ESTn) beschreven. De ESTn is ontwikkeld als een snel, of ‘high- 
throughput’, test systeem voor het detecteren van neuraal-ontwikkelings toxische 
stoffen. Alle stappen, van ontwikkeling en het karakteriseren van het model, 
naar implementatie van transcriptomics technieken in het test systeem tot het 
ontwikkelen van een biomarker genen set voor neuraal-ontwikkelings toxiciteit 
worden besproken in dit proefschrift. Daarnaast worden de genexpressie 
profielen, welke de differentiatie over de tijd en effecten van stoffen beschrijven 
in de ESTn, vergeleken genexpressie profielen in andere in vitro en in vivo 
modellen.
De ontwikkeling en het karakteriseren van de ESTn is beschreven in hoofdstuk 2. 
Een 20 dagen lang neuraal differentiatie protocol was ontworpen, gebaseerd 
op twee eerder beschreven protocollen door Okabe et al. en Bibel et al. De 
belangrijkste stappen om stamcellen te laten differentiëren tot neurale cellen in 
deze methode zijn de volgende: Ten eerste de vorming van embryoid bodies 
(EB) door middel van de ‘hanging drop’ methode. Een EB is een agglomeratie 
van cellen die de karaktereigenschappen heeft van een zeer vroeg stadium 
embryo. Ten tweede worden deze EB bloot gesteld aan retinolzuur (RA), een 
actieve metaboliet van vitamine A. Deze metaboliet heeft tijdens de 
ontwikkeling onder andere een belangrijke functie in de vroege vorming van 
het zenuwstelsel. Ten derde wordt het serum percentage in het medium in twee 
stappen verlaagd van 20% naar 0% en worden groeifactoren toegevoegd aan 
het medium, beiden om ESC differentiatie richting neurale cellen te stimuleren. 
Aan het einde van de kweek worden de EB compleet omringd door neurale 
uitgroei, die bestaat uit neuronen en glia cellen (Hoofdstuk 9, Figuur 2). 
Omdat dit protocol voor neurale differentiatie redelijk lang is voor een snelle 
screening van stoffen, ontwikkelden we twee kortere varianten, een 13 dagen 
en een 17 dagen lange methode. Dit deden we door de fase waarin het medium 
geen serum bevat te verkorten. De drie protocollen werden vergeleken wat 
betreft morfologie van de neurale uitgroei en op moleculair niveau, waarbij we 
keken naar RNA en eiwit markers welke belangrijk zijn tijdens de vroege 
ontwikkeling. Dit gebeurde met behulp van immunocytochemie, genexpressie 
bepalingen en flow-cytometrie. Tijdens de eerste zeven dagen zijn de drie 
protocollen identiek aan elkaar. Tijdens deze fase zagen we dat markers voor 
de drie primaire kiemlagen (ectoderm, mesoderm en endoderm) aanwezig 
waren in de kweek. Daarnaast werd gezien dat neurale en ectodermale markers 
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centratierespons karakteristieken. Algemene en specifieke effecten van de 
verschillende stoffen konden zichtbaar gemaakt worden. Het biologische 
proces 'embryonic morphogenesis' werd bijvoorbeeld door elk van de stoffen 
beïnvloed, wat aangeeft dat deze stoffen een effect op 'standaard' ontwikkeling 
hebben. Verder werden voor cyproconazole en valproaat specifieke effecten op 
neurale ontwikkeling gevonden, terwijl deze niet gevonden werden voor 
hexaconazole. Dit komt overeen met de literatuur, aangezien cyproconazole en 
valproaat neuraal ontwikkelingstoxisch zijn en hexaconazole dat niet is. Verder 
konden klasse specifieke effecten worden gevonden voor de triazolen, aangezien 
zij het sterol biosynthese proces beïnvloedden, een belangrijk mechanisme in 
de antischimmel werking van deze stoffen. Het gebruik van transcriptomics in 
deze studie toonde verder aan dat effecten op genexpressie eerder waarneembaar 
waren dan effecten op morfologie, waardoor dit een meer gevoeligere methode 
kan zijn om ontwikkelingstoxiciteit te meten.
In de volgende transcriptomics studie in hoofdstuk 5 werden effecten op 
genexpressie van zes stoffen met verschillende werkingsmechanismen 
bestudeerd, om het toepassingsdomein van het testsysteem te bepalen. Vijf van 
deze stoffen zijn bekende ontwikkelingstoxische stoffen en één stof was 
meegenomen als een negatieve controle. De stoffen werden getest op een 
toxische concentratie waarop het effect op morfologie vergelijkbaar was tussen 
de stoffen én een concentratie die 30 keer lager, en dus niet toxisch, was. Stof 
specifieke en algemene genexpressie veranderingen werden waargenomen 
tussen de verschillende stoffen. Er werden echter geen processen gevonden die 
door alle ontwikkelingstoxische stoffen aangedaan waren. Dit toont aan dat 
effecten op neurale differentiatie via meerdere mechanismen geïnduceerd 
kunnen worden. Ook konden genexpressie profielen en proces verrijking 
gebruikt worden om de verschillen in genexpressie in een niet toxische en ont-
wikkelingstoxische concentratie te vergelijken. Deze informatie kan gebruikt 
worden om verschillen in genexpressie veranderingen ten opzichte van 
adaptieve of ongunstige effecten te verklaren.
In hoofdstuk 6 zijn de transcriptomics data van hoofdstukken 3, 4 en 5 
gecombineerd om een biomarker genen set te verkrijgen om neurale ontwik-
kelingstoxiciteit in de ESTn te voorspellen. Genexpressie veranderingen werden 
vergeleken met behulp van de ‘differentiatie track’ waarbij data van 10 stoffen 
en 19 blootstellingen werd gebruikt. Met behulp van een genen set evaluatie 
gekoppeld aan een ‘leave-one-out cross-validatie’ kon een set van 29 genen 
gevonden worden die vooral te maken hadden met neurale ontwikkeling. Met 
deze genen set kon neurale ontwikkelingstoxiciteit in de ESTn voor 84% van 
clusters, elk met een specifiek genexpressie patroon over de tijd. Met 
verscheidene analyse technieken kon aangetoond worden dat genen met een 
vroeg verhoogde genexpressie gerelateerd waren aan pluripotentie en 
transcriptie en dat laattijdig gereguleerde genen te maken hadden met neurale 
ontwikkeling. Daarnaast kon differentiatie over de tijd beschreven worden met 
behulp van de ‘differentiatie track’, waarbij door ‘principal component analysis’ 
het patroon van genexpressie van alle genen over de tijd weergegeven kan 
worden per monster. De ‘differentiatie track’ liet zien dat voor elk getest 
tijdspunt de monsters samen clusterden en dat deze groepjes chronologisch 
over de track verdeeld lagen. Daarnaast werd de variatie tussen monsters 
binnen een tijdsmeting groter bij monsters genomen op een later tijdspunt. Dit 
geeft aan dat cellen in de kweek differentieerden en ten opzichte van elkaar 
steeds meer verschillend werden. 
Op eenzelfde manier werd ook het effect van MeHg bestudeerd met behulp 
van transcriptomics. Cellen werden blootgesteld aan MeHg vanaf dag 3, 
waarna monsters werden genomen na 24, 48, 72 en 96 uur blootstelling. Deze 
data lieten zien dat op elk tijdspunt MeHg de genexpressie verhoogde van 
neuraal gerelateerde genen en genexpressie verlaagde van genen gerelateerd 
aan algemene en vroege ontwikkeling. De ‘differentiation track’ techniek werd 
gebruikt om veranderingen van MeHg op de genexpressie aan te tonen na 24, 
48 en 72 uur blootstelling. MeHg monsters verschilden het meest van de ‘dif-
ferentiation track’ na 24 uur blootstelling. Op 48 en 72 uur blootstelling was 
de variatie binnen de tijd en blootgestelde monsters te groot om een significant 
verschil op te kunnen pikken. Op basis van deze gegevens werden monsters 
voor de volgende transcriptomics experimenten blootgesteld voor 24 uur en, 
namen we controles mee van dag 3, 4 en 5 om de ‘differentiatie track’ op te 
kunnen zetten.
Een belangrijk gegeven in de toxicologie is dat giftigheid toeneemt met de 
concentratie van de blootstelling en dat er dus een concentratie hoort te zijn 
waarbij een stof niet giftig is. In hoofdstuk 4 gebruiken we transcriptomics om 
het effect van de blootstelling van een stof te bestuderen bij verschillende 
concentraties. Hiervoor gebruikten we drie stoffen waarvan bekend is dat ze 
ontwikkelingstoxisch zijn: de twee triazolen cyproconazole en hexaconazole 
en valproaat. Triazolen worden normaal gebruikt als antischimmel middelen 
en valproaat is een medicijn dat gebruikt wordt tegen epilepsie. Effecten van 
deze stoffen werden gemeten op genexpressie niveau na 24 uur blootstelling en 
vergeleken met de uitkomst van de morfologische score op dag 11. Alle drie de 
stoffen lieten een concentratie gemedieerd effect zien op genexpressie en 
biologische processen, wat informatie verschafte over mechanismen en con-
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Conclusie
I n dit proefschrift wordt de ontwikkeling van de ESTn en implementatie van transcriptomics in de ESTn test strategie beschreven. Dit leidde uiteindelijk 
tot een biomarker genen set voor het voorspellen van neurale ontwikke-
lingstoxiciteit in de ESTn. Stof effecten op genexpressie over tijd en concentratie 
zijn beschreven en bestudeerd, waardoor een vergelijking tussen mechanismen 
van verschillende neuraal ontwikkelingstoxische stoffen gemaakt kan worden. 
Verder is er een vergelijking gemaakt tussen de ESTn, ESTc en andere in vitro 
en in vivo modellen waaruit blijkt dat de ESTn een bijdrage kan leveren aan 
mechanistisch inzicht en een verhoging van de predictie in ontwikkelingstoxi-
citeit test strategieën. Om de predictie van de ESTn verder te verhogen is het 
nodig om het toepassingsdomein van de ESTn verder te definiëren, waarbij het 
belangrijk is om de mechanismen achter toxiciteit in de ESTn in kaart te 
brengen. 
de blootstellingen goed voorspeld worden. Deze set verbetert de predictie van 
de ESTn en kan in de toekomst eventueel gebruikt worden voor risico evaluaties.
De ESTn was ontwikkeld om gebruikt te worden in combinatie met de originele 
ESTc. De overeenkomsten en verschillen tussen de twee modellen op 
genexpressie niveau worden beschreven in hoofdstuk 7. Tijd gereguleerde 
genexpressie profielen van ESTn en ESTc op dag 3, 4 en 5 en blootstelling aan 
zeven stoffen werden tussen de modellen vergeleken. Hoewel genexpressie 
verschillen over de tijd tussen de twee protocollen voor een groot deel 
vergelijkbaar waren, was er een kleinere groep genen die zeer specifiek 
gereguleerd werd door één van beide modellen en niet in het andere model. 
Deze genen waren gerelateerd aan hartspierdifferentiatie in de ESTc en neurale 
differentiatie in ESTn. Stof geïnduceerde genexpressie veranderingen waren 
over het algemeen zeer verschillend tussen de modellen, waardoor de ontwik-
kelingstoxiciteit óf in de ESTc (bijvoorbeeld flusilazole) óf in de ESTn 
(bijvoorbeeld MeHg) goed werd voorspeld. Een uitzondering hierop was 
valproaat, waarbij genexpressie veranderingen in beide modellen vergelijkbaar 
waren, hoewel er op het proces niveau grote verschillen waren. Een vergelijking 
op genexpressie niveau tussen ESTn en ESTc laat zien dat beide modellen een 
eigen specifieke bijdrage kunnen leveren aan voorspelling van ontwikke-
lingstoxiciteit.
Een vergelijking tussen ESTn en andere in vitro en in vivo modellen op trans-
criptomics niveau is uitgevoerd in hoofdstuk 8, om inzicht te krijgen in 
overeenkomsten en verschillen van mechanismen in deze modellen. Het effect 
van MeHg op genexpressie in verschillende in vitro en in vivo modellen was 
bestudeerd. Modellen voor ontwikkelingstoxiciteit waren de in vitro rat ‘whole 
embryo culture’, ESTc en ESTn en twee in vivo embryotoxiciteitstesten. 
Daarnaast waren modellen vergeleken welke acute toxiciteit voorspellen zoals 
een embryonale fibroblast cellijn en het jong-volwassen brein en de nier. 
Evaluatie van vergelijkbare en unieke aspecten op het functionele en 
genexpressie niveau toonden aan dat deze een vergelijkbaar patroon lieten zien 
in de ontwikkelingstoxiciteit modellen, maar niet in de andere modellen. Deze 
vergelijking laat zien dat extrapolatie van in vitro naar in vivo modellen 
relevant is en dat genexpressie veranderingen over modellen heen voor een 
groot deel overeen komen. 
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